0001564590-23-002041 | 20-F/A | XBRL Viewer

Print Document View Excel Document

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2021 shares
Document Information [Line Items]
Document Type	20-F/A
Amendment Flag	true
Amendment Description	Legend Biotech Corporation ( “Legend Biotech”, “Legend”, “we”, “our”, “ours”, “us”, or the “Company”) is filing this Amendment No. 1 on Form 20-F/A (the “Form 20-F/A”, “Amendment No. 1”, or “Amended Annual Report”) to the Annual Report on Form 20-F for the fiscal year ended December 31, 2021, which was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2022 (the “Original 20-F”) to (i) address comments from the staff of the Division of Corporation Finance of the SEC on the Original 20-F and (ii) to amend and restate (the “Restatement”) its audited financial statements as at December 31, 2021 and 2020 and for the years ended December 31, 2021, December 31, 2020 and December 31, 2019 (the “Audited Affected Financials”). Background of the Restatement As previously reported, on October 19, 2022, the audit committee (the “Audit Committee”) of Legend Biotech, based on the recommendation of, and after consultation with, the Company’s management, concluded that the Company’s previously issued Audited Affected Financials and the Company’s financial statements for the interim period ended March 31, 2022 should no longer be relied upon. The Company determined that the original valuation of the commercial license for cilta-cel (the “Commercial License”) pursuant to its worldwide collaboration and license agreement with Janssen Biotech, Inc. (“Janssen”) was understated and was a single performance obligation and, as a result, the accounting for revenue recognition in the Audited Affected Financials was materially incorrect. As a result of the Restatement, the Company has concluded there was a material weakness in its internal control over financial reporting as of December 31, 2021, and its disclosure controls and procedures were not effective. See additional discussion included in Part II, Item 15 of this Amended Annual Report. The Restatement adjustments also affect periods prior to the Original 20-F and such adjustments have been reflected in the restated opening stockholders’ equity balances as of January 1, 2019. Also, as previously disclosed, management determined that its report regarding the effectiveness of the Company’s internal controls over financial reporting (“ICFR”) contained in the Original 20-F, and Ernst & Young Hua Ming LLP (“EYHM”), the Company’s independent registered accounting firm as of December 31, 2021, has determined its opinion relating to the effectiveness of the Company’s ICFR as of December 31, 2021 included in the Original 20-F, should not be relied upon. The impact of the Restatement is more fully described in Note 2.2 to the Company’s restated consolidated financial statements included in Part III, Item 18 of this Amended Annual Report. Items Amended This Form 20-F/A includes changes to: (1) Part I, Item 3 – Key Information, including Item 3D – Risk Factors, (2) Part I, Item 4 – Information on the Company, (3) Part I, Item 5 – Operating and Financial Review and Prospects, (4) Part II, Item 15 – Controls and Procedures, (5) Part III, Item 18 – Financial Statements and (6) Part III, Item 19 – Exhibits. See below and 2.2 Restatement of Previously Issued Consolidated Financial Statements of the Notes to Consolidated Financial Statements in Part III, Item 18 of this Form 20-F/A for a detailed discussion of the changes made as a result of the Restatement. As required by Rule 12b-15 under the Securities and Exchange Act, as amended, Part III Item 19 of the Original 20-F has been amended to include updated certifications from Legend Biotech’s principal executive officer and principal financial officer pursuant to Sections 906 and 302 of the Sarbanes-Oxley Act of 2002, which are attached to this Form 20-F/A as Exhibits 12.1, 12.2, 13.1 and 13.2, respectively. Except as otherwise noted, this Amendment No. 1 does not amend, update or change any other disclosures in the Original 20-F and does not reflect events occurring after the filing of the Original 20-F. Among other things, forward-looking statements made in the Original 20-F have not been revised to reflect events, results or developments that occurred or facts that became known to us after the date of the Original 20-F, other than with respect to the Restatement, and such forward-looking statements should be read in conjunction with our filings with the SEC, including those subsequent to the filing of the Original 20-F. Substantially concurrently with the filing of this Amendment No. 1, the Company is filing an amendment to its Form 6-K related to the Company’s interim financial information for the three months ended March 31, 2022.
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	LEGEND BIOTECH CORPORATION
Entity Central Index Key	0001801198
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	308,456,852
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Title of 12(b) Security	Ordinary shares, par value $0.0001 per share
Trading Symbol	LEGN
Security Exchange Name	NASDAQ
Entity File Number	001-39307
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	Legend Biotech Corporation
Entity Address, Address Line Two	2101 Cottontail Lane
Entity Address, City or Town	Somerset
Entity Address, Country	KY
Entity Address, Postal Zip Code	NJ 08873
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1408
Auditor Name	Ernst & Young Hua Ming LLP
Auditor Location	Shanghai, the People’s Republic of China
American Depositary Shares
Document Information [Line Items]
Title of 12(b) Security	American depositary shares, each representing two ordinary shares, par value $0.0001 per share
Trading Symbol	LEGN
Security Exchange Name	NASDAQ
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	Legend Biotech Corporation
Entity Address, Address Line Two	2101 Cottontail Lane
Entity Address, City or Town	Somerset
Entity Address, Postal Zip Code	08873
Contact Personnel Name	Ying Huang
Entity Address, State or Province	NJ
City Area Code	737
Local Phone Number	317-5050

CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement Of Profit Or Loss And Other Comprehensive Income [Abstract]
REVENUE	$ 68,826	$ 75,000	$ 59,980
Other income and gains	3,059	6,119	7,459
Research and development expenses	(313,346)	(232,160)	(161,943)
Administrative expenses	(46,961)	(23,134)	(6,751)
Selling and distribution expenses	(102,542)	(49,571)	(25,620)
Other expenses	(9,132)	(346)	(221)
Fair value loss of warrant liability	(6,200)
Fair value loss of convertible redeemable preferred shares		(79,984)
Finance costs	(900)	(4,209)	(223)
LOSS BEFORE TAX	(407,196)	(308,285)	(127,319)
Income tax credit	3,614	41,912	25,729
LOSS FOR THE YEAR	(403,582)	(266,373)	(101,590)
Attributable to:
Ordinary equity holders of the parent	$ (403,582)	$ (266,373)	$ (101,590)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
Basic	$ (1.43)	$ (1.13)	$ (0.51)
Diluted	$ (1.43)	$ (1.13)	$ (0.51)
Exchange differences:
Exchange differences on translation of foreign operations	$ 5,215	$ 4,078	$ (1,268)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	5,215	4,078	(1,268)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX	5,215	4,078	(1,268)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(398,367)	(262,295)	(102,858)
Attributable to:
Ordinary equity holders of the parent	$ (398,367)	$ (262,295)	$ (102,858)

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
NON-CURRENT ASSETS
Property, plant and equipment	$ 102,506	$ 72,342	$ 45,188	$ 45,188
Advance payments for property, plant and equipment	2,168	224	665
Right-of-use assets	38,283	39,542	27,790	27,790
Time deposits	4,705
Intangible assets	4,684	2,852	519
Other non-current assets	17,269	13,189	6,449
Total non-current assets	169,615	128,149	80,611
CURRENT ASSETS
Inventories	1,749	1,800	1,157
Trade receivables	50,410	75,000	30,000
Prepayments, other receivables and other assets	13,758	10,452	21,671
Financial assets measured at amortized cost	29,937
Lease receivables	94	619
Pledged deposits	1,444	384	256
Time deposits	163,520	50,000	75,559
Cash and cash equivalents	688,938	455,689	83,364	83,364	$ 210,166
Total current assets	949,850	593,944	212,007
Total assets	1,119,465	722,093	292,618
CURRENT LIABILITIES
Trade and notes payables	7,043	5,238	9,586
Other payables and accruals	123,558	99,787	70,854
Government grants	304	283
Lease liabilities	911	1,464	1,027
Tax payable	9,488	8,795	12,782
Warrant liability	87,900
Total current liabilities	229,204	115,567	94,249
NON-CURRENT LIABILITIES
Interest-bearing loans and borrowings	120,462
Lease liabilities	1,593	1,909	5,058
Government grants	1,866	2,051
Deferred tax liabilities		4,241	41,988
Other non-current liabilities	396	554
Total non-current liabilities	124,317	8,755	47,046
Total liabilities	353,521	124,322	141,295
EQUITY
Share capital	31	27	20
Reserves	765,913	597,744	151,303	151,300
Total ordinary shareholders’ equity	765,944	597,771	151,323
Total equity	765,944	597,771	151,323	$ 151,323	$ 252,909
Total liabilities and equity	$ 1,119,465	$ 722,093	$ 292,618

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands

Total

Initial Public Offering

Private Placement by Genscript

Follow-On Public Offering

Share Capital

Initial Public Offering

Share Capital

Follow-On Public Offering

Share Premium

Initial Public Offering

Share Premium

Private Placement by Genscript

Share Premium

Follow-On Public Offering

Share-based Compensation Reserves

Foreign Currency Translation Reserve

Retained Earnings/(Accumulated Losses)

Beginning balance at Dec. 31, 2018

$ 252,909

$ 20

$ 3,908

^[1]

$ 704

^[1]

$ (3,161)

^[1]

$ 251,438

^[1]

Loss for the year

(101,590)

Other comprehensive income/ loss:

Exchange differences on translation of foreign operations

(1,268)

TOTAL COMPREHENSIVE LOSS FOR THE YEAR

(102,858)

(1,268)

(101,590)

Equity-settled share-based compensation expense

1,272

Ending balance at Dec. 31, 2019

151,323

3,908

^[1]

1,976

^[1]

(4,429)

^[1]

149,848

^[1]

Loss for the year

(266,373)

Other comprehensive income/ loss:

Exchange differences on translation of foreign operations

4,078

TOTAL COMPREHENSIVE LOSS FOR THE YEAR

(262,295)

4,078

(266,373)

Conversion of convertible redeemable preferred shares to ordinary shares

240,434

240,432

Issuance of ordinary shares

$ 450,085

$ 12,000

$ 4

$ 450,081

$ 12,000

Exercise of share options

1,464

1,885

(422)

Equity-settled share-based compensation expense

4,760

Ending balance at Dec. 31, 2020

597,771

708,306

^[1]

6,314

^[1]

(351)

^[1]

(116,525)

^[1]

Loss for the year

(403,582)

Other comprehensive income/ loss:

Exchange differences on translation of foreign operations

5,215

TOTAL COMPREHENSIVE LOSS FOR THE YEAR

(398,367)

5,215

(403,582)

Issuance of ordinary shares

$ 323,440

$ 2

$ 323,438

Issuance of ordinary shares relating to private placement for an institutional investor

218,300

218,298

Exercise of share options

4,642

6,089

(1,447)

Reclassification of vested restricted stock units

5,323

(5,323)

Equity-settled share-based compensation expense

20,158

Ending balance at Dec. 31, 2021

$ 765,944

$ 31

$ 1,261,454

^[1]

$ 19,702

^[1]

$ 4,864

^[1]

$ (520,107)

^[1]

[1]	These reserve accounts comprise the consolidated reserves of US$765.9 million, US$597.7 million and US$151.3 million in the consolidated statements of financial position as at December 31, 2021, 2020 and 2019, respectively.

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019
Statement Of Changes In Equity [Abstract]
Reserves	$ 765,913	$ 597,744	$ 151,303	$ 151,300

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax	$ (407,196)	$ (308,285)
Adjustments for:
Finance income	(971)	(2,930)
Finance costs	900	4,209
Depreciation of property, plant and equipment	8,139	6,234
Loss on disposal of property, plant and equipment	974	55
Amortization of intangible assets	1,379	192
Depreciation of right-of-use assets	4,399	3,507
Fair value loss of warrant liability	6,200
Fair value loss of convertible redeemable preferred shares		79,984
Fair value gains on financial assets measured at fair value change through profit or loss		(47)
Foreign currency exchange loss/(gain), net	4,867	(66)
Equity-settled share-based compensation expense	20,158	4,760
Deferred government grant	(295)	(114)
Cash flows from (used in) operations before changes in working capital	(361,446)	(212,501)
Decrease/(increase) in trade receivables	24,590	(45,000)
(Increase)/decrease in prepayments, other receivables and other assets	(2,966)	3,366
Increase in other non-current assets	(1,175)	(3,973)
Decrease/(increase) in inventories	51	(643)
Government grant received	80	2,452
Increase/(decrease) in trade and notes payables	1,805	(4,348)
Increase in other payables and accruals	140,747	26,932
(Decrease)/increase in other non-current liabilities	(158)	554
Increase in pledged deposits, net	(1,060)	(128)
Cash used in operations	(199,532)	(233,289)
Income tax paid		(278)
Finance income received	652	3,366
Income tax received	557	7,391
Interest on lease payments	(142)	(195)
Net cash flow used in operating activities	(198,465)	(223,005)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(42,197)	(26,254)
Purchase of intangible assets	(3,207)	(4,029)
Prepayment to collaborator for collaboration right- of-use assets	(1,708)	(19,493)
Purchase of financial assets measured at fair value through profit or loss	(50,000)	(22,682)
Cash received from withdrawal of financial assets measured at fair value through profit or loss	50,081	22,682
Cash receipts of investment income		47
Proceeds from disposal of property, plant and equipment	4	1
Addition in time deposits	(298,107)	(50,000)
Decrease in time deposits	180,000	75,559
Purchase of financial assets measured at amortized cost	(29,849)
Net cash flows used in investing activities	(194,983)	(24,169)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of cash advances from related parties		(4)
Proceeds from convertible redeemable preferred shares		160,450
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs		450,085
Proceeds from issuance of ordinary shares relating to private placement by GenScript		12,000
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs	323,440
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor	300,000
Proceeds from exercise of share options	4,642	1,464
Payments of expenses for issuance of convertible redeemable preferred shares		(2,514)
Principal portion of lease payments	(1,419)	(2,602)
Net cash flows from financing activities	626,663	618,879
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	233,215	371,705
Effect of foreign exchange rate changes, net	34	620
Cash and cash equivalents at beginning of year	455,689	83,364
CASH AND CASH EQUIVALENTS AT END OF YEAR	688,938	455,689
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances	858,607	506,073
Less: Pledged deposits	1,444	384
Time deposits	168,225	50,000
Cash and cash equivalents as stated in the statement of financial position	688,938	455,689
Cash and cash equivalents as stated in the statement of cash flows	$ 688,938	$ 455,689

Corporate Information

12 Months Ended

Dec. 31, 2021

Disclosure Of Significant Investments In Subsidiaries [Abstract]

Corporate Information

LEGEND BIOTECH CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2021, 2020 AND 2019

1. CORPORATE INFORMATION

Legend Biotech Corporation (the “Company”) was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Law of the Cayman Islands. The registered office address of the Company is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grant Cayman KY1-1002, Cayman Islands.

The Company is an investment holding company. The Company’s subsidiaries are principally engaged in research and development of biological products.

In the opinion of the Directors, the ultimate holding company of the Company is Genscript Corporation (“Genscript Corp”), which was incorporated in the United States of America.

Information about subsidiaries

Company

Place and date

incorporation

Issued ordinary

shares/paid-up

capital

Percentage of equity

interest attributable

to the Company

Principal

activities

Direct %

Indirect %

Legend Biotech Limited (“Legend

BVI”)

The British Virgin

Islands

June 2, 2015

US$

80,000,000

100

—

Investment holding

Legend Biotech HK Limited

(“Legend HK”)

Hong Kong

June 3, 2015

US$

80,000,000

—

100

Investment holding

Nanjing Legend Biotechnology Co.,

Ltd. (“Legend Nanjing”)

PRC*

November 17, 2014

US$

162,500,000

—

100

Manufacture and

sale of life science

research products

and services

Legend Biotech USA Incorporated

(“Legend USA”)

United States of

America

August 31, 2017

—

100

Manufacture and

sale of life science

research products

and services

Legend Biotech Ireland Limited

(“Legend Ireland”)

Ireland

November 13, 2017

—

100

Manufacture and

sale of life science

research products

and services

Legend Biotech Belgium B.V.

(“Legend Belgium”)

Belgium

June 23, 2021

US$

2,423,693

—

100

Manufacture and

sale of life science

research products

and services

Hainan Chuanji Biotechnology Co.,

Ltd. (“Hainan Chuanji”)

PRC

October 25, 2021

—

100

Life science

research and

development

Basis of Preparation

12 Months Ended

Dec. 31, 2021

Basis Of Preparation [Abstract]

Basis of Preparation

2.1 BASIS OF PREPARATION

The consolidated financial statements of the Company and its subsidiaries (collectively referred to as the “Group”) have been prepared in accordance with International Financial Reporting Standards (“IFRSs”) as issued by the International Accounting Standards Board (the “IASB”), which comprise all standards and interpretations.

The consolidated financial statements have been prepared on a historical cost basis, except for financial assets and financial liabilities, which have been measured at fair value. The consolidated financial statements are presented in US dollars (“US$”) and all values are rounded to the nearest thousand except when otherwise indicated.

Basis of consolidation

The consolidated financial statements include the financial statements of the Group for each of the three years ended December 31, 2021. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

(a)

the contractual arrangement with the other vote holders of the investee;

(b)

rights arising from other contractual arrangements; and

(c)

the Group’s voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income or loss are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above.

Restatement of Previously Issued Consolidated Financial Statements

12 Months Ended

Dec. 31, 2021

Restatement Of Previously Issued Consolidated Financial Statements [Abstract]

Restatement of Previously Issued Consolidated Financial Statements

2.2 RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS

The Group has restated its Consolidated Statements of Financial Position at December 31, 2021 and 2020, Consolidated Statements of Profit or Loss and Other Comprehensive Income, Changes in Equity and Cash Flows for each of the fiscal years ended December 31, 2021, 2020 and 2019, included in the Annual Report on Form 20-F for the fiscal year ended December 31, 2021, which was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2022 (the “Original 20-F”).

The individual restatement matters that underlie the restatement adjustments are described below. The restatement adjustments also affect periods prior to the Original 20-F and such adjustments have been reflected in the restated opening stockholders’ equity balances as of January 1, 2019.

Revenue Recognition Adjustments

As previously disclosed, in December 2017, the Group entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. (“Janssen”) for the worldwide development and commercialization of cilta-cel (the “Janssen Agreement”). Historically, the Group has recognized revenue under the Janssen Agreement pursuant to two performance obligations: (i) the sale of the commercial license for cilta-cel (the “Commercial License”) and (ii) service on the Joint Steering Committee (the “JSC”) under the collaboration. The sale of the Commercial License was recognized as revenue at the time of sale and the revenue the Group recognized as a result of its service on the JSC was recognized over the term of the clinical development plan under the Janssen Agreement. The Group concluded that the transaction price, at inception of the Janssen Agreement, includes the fixed upfront fee of $350 million and $50 million of milestone payments that were highly probable of being achieved. All other potential milestone payments were considered variable consideration.

The Group has since determined the Janssen Agreement contains a contract with a customer (Janssen) in the scope of IFRS 15 for a right to use our intellectual property (in the form of a license) and technology transfer service that form a single performance obligation. These elements of the Janssen Agreement are representative of a

vendor-customer relationship as Janssen contracted with Legend to obtain a license of its intellectual property for LCAR-B38M and related technology transfer, which are an output of Legend’s ordinary activities, in exchange for consideration. Janssen is not a customer for collaborative activities, including participation on the JSC, which are in the scope of other IFRS standards. Also, the Group determined that the original stand-alone selling price of the Commercial License performance obligation was understated.

The Group has revised its accounting treatment to recognize revenue for the $350 million upfront fee and $50 million milestone license revenue in 2018, the year in which the single performance obligation to deliver the license of intellectual property, including a technology transfer service, was satisfied. Subsequent development, manufacturing and regulatory milestones will be recognized in full in the period in which it is highly probable a significant reversal of the cumulative revenue recognized for the IFRS 15 contract will not occur, as they are associated with the performance obligation to deliver the license of intellectual property that was satisfied in 2018. The Group recognized revenue of $65 million, $75 million and $60 million for development milestones achieved in 2021, 2020 and 2019, respectively. The Group will recognize revenue for sales-based milestones when the milestone is achieved pursuant to the royalty recognition constraint.

In connection with the restatement, the Group has also corrected the corresponding contract liabilities of previously deferred license and collaboration revenue as a result of the change in performance obligations identified.

Collaboration Assets Adjustments

The Group has identified and corrected errors related to the accounting treatment of assets purchased by the Group or Janssen that are solely to be used by the collaboration and subject to the cost sharing terms and conditions in the Janssen Agreement (“Collaboration Assets”). Historically, the Group recorded Collaboration Assets it purchased from third party vendors, net of Janssen’s share of these costs, as well as its share of the cost of Collaboration Assets purchased by Janssen as property, plant and equipment.

The Group has revised its accounting treatment to record its share of Collaborations Assets that are leased to and by the collaboration in accordance with IFRS 16, Leases to correctly reflect the assets associated with the collaboration.

If the Group’s collaboration partner owns the asset, and on the basis of the terms and conditions of the collaboration agreement, there is a lease from the Group’s collaboration partner to the collaboration, the Group recognises a right-of-use asset and lease liability for its share of the asset leased from the collaboration partner to the collaboration. This is usually the case when the collaboration, through the JSC and other governance committees, has the right to direct the use and obtains substantially all of the economic benefits from using the asset. Lease payments the Group makes prior to lease commencement are recorded as prepaid rent within other non-current assets and will be reclassified to a right-of-use asset upon lease commencement.

If the Group owns the asset, and on the basis of the terms and conditions of the collaboration agreement, there is a lease from the Group to the collaboration, the Group recognises a finance lease for the asset it leases to the collaboration. In such cases, the Group’s share of the asset that is jointly controlled by the collaboration is recorded in property, plant and equipment, and a lease receivable is recognized for the collaboration partner’s share of the asset.

Income Taxes

The Company recorded adjustments to income taxes to reflect the impact of the restatement adjustments, as well as additional income tax adjustments related to the accounting for the Janssen Agreement.

The tables below present the impact of the restatement on the Company’s Consolidated Statements of Financial Position at December 31, 2021 and 2020, Consolidated Statements of Profit or Loss and Other Comprehensive Income for the years ended December 31, 2021, 2020 and 2019, the Company’s Consolidated Statements of Changes in Equity for the years ended December 31, 2021, 2020, and 2019 and the Company’s Consolidated Statement of Cash Flows for the years ended December 31, 2021, 2020, and 2019.

	Consolidated statement of profit or loss and other comprehensive income for the year ended December 31, 2021
				Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets		Tax impacts		Total Adjustments			As Restated
	US$’000			US$’000			US$’000		US$’000		US$’000			US$’000
Revenue		89,792			(20,966	)		—		—		(20,966	)		68,826
Other income and gains		3,059			—			—		—		—			3,059
Research and development expenses		(313,346	)		—			—		—		—			(313,346	)
Administrative expenses		(46,939	)		(22	)		—		—		(22	)		(46,961	)
Selling and distribution expenses		(102,542	)		—			—		—		—			(102,542	)
Other expenses		(9,132	)		—			—		—		—			(9,132	)
Fair value loss of warrant liability		(6,200	)		—			—		—		—			(6,200	)
Finance costs		(900	)		—			—		—		—			(900	)
Loss before tax		(386,208	)		(20,988	)		—		—		(20,988	)		(407,196	)
Income tax (expense)/credit		(1	)		—			—		3,615		3,615			3,614
Loss for the year		(386,209	)		(20,988	)		—		3,615		(17,373	)		(403,582	)
Attributable to: ordinary equity holders of the parent		(386,209	)		(20,988	)		—		3,615		(17,373	)		(403,582	)
Loss per share attributable to ordinary equity holders of the parent
Basic		(1.37	)		(0.07	)		—	0.01			(0.06	)		(1.43	)
Diluted		(1.37	)		(0.07	)		—	0.01			(0.06	)		(1.43	)
Exchange differences:
Exchange differences on translation of foreign operations		10,620			(5,897	)		—	492			(5,405	)		5,215
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods		10,620			(5,897	)		—	492			(5,405	)		5,215
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX		10,620			(5,897	)		—	492			(5,405	)		5,215
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(375,589	)		(26,885	)		—		4,107		(22,778	)		(398,367	)
Attributable to:
Ordinary equity holders of the parent		(375,589	)		(26,885	)		—		4,107		(22,778	)		(398,367	)

	Consolidated statements of financial position as at December 31, 2021
			Adjustments by category
	As Previously Reported		Revenue Recognition			Collaboration assets			Tax impacts			Total Adjustments			As Restated
	US$’000		US$’000			US$’000			US$’000			US$’000			US$’000
NON-CURRENT ASSETS
Property, plant and equipment		145,724		—			(43,218	)		—			(43,218	)		102,506
Advance payments for property, plant and equipment		2,168		—			—			—			—			2,168
Right-of-use assets		7,186		—			31,097			—			31,097			38,283
Time deposits		4,705		—			—			—			—			4,705
Intangible assets		4,684		—			—			—			—			4,684
Other non-current assets		5,148		—			12,121			—			12,121			17,269
Total non-current assets		169,615		—			—			—			—			169,615
CURRENT ASSETS
Inventories		1,749		—			—			—			—			1,749
Trade receivables		50,410		—			—			—			—			50,410
Prepayments, other receivables and other assets		12,754		—			—			1,004			1,004			13,758
Financial assets measured at amortized cost		29,937		—			—			—			—			29,937
Lease receivables		—		—			94						94			94
Pledged deposits		1,444		—			—			—			—			1,444
Time deposits		163,520		—			—			—			—			163,520
Cash and cash equivalents		688,938		—			—			—			—			688,938
Total current assets		948,752		—			94			1,004			1,098			949,850
Total assets		1,118,367		—			94			1,004			1,098			1,119,465
CURRENT LIABILITIES
Trade and notes payables		7,043		—			—			—			—			7,043
Other payables and accruals		123,464		—			94			—			94			123,558
Government grants		304		—			—			—			—			304
Lease liabilities		911		—			—			—			—			911
Tax payable		—		—			—			9,488			9,488			9,488
Warrant liability		87,900		—			—			—			—			87,900
Contract liabilities, current		60,644		(60,644	)		—			—			(60,644	)		—
Total current liabilities		280,266		(60,644	)		94			9,488			(51,062	)		229,204
NON-CURRENT LIABILITIES
Interest-bearing loans and borrowings		120,462		—			—			—			—			120,462
Contract liabilities, non-current		242,578		(242,578	)		—			—			(242,578	)		—
Lease liabilities		1,593		—			—			—			—			1,593
Government grants		1,866		—			—			—			—			1,866
Other non-current liabilities		396		—			—			—			—			396
Total non-current liabilities		366,895		(242,578	)		—			—			(242,578	)		124,317
Total liabilities		647,161		(303,222	)		94			9,488			(293,640	)		353,521
EQUITY
Share capital		31		—			—			—			—			31
Reserves		471,175		303,222			—			(8,484	)		294,738			765,913
Total ordinary shareholders’ equity		471,206		303,222			—			(8,484	)		294,738			765,944
Total equity		471,206		303,222			—			(8,484	)		294,738			765,944
Total liabilities and equity		1,118,367		—			94			1,004			1,098			1,119,465

	Consolidated Statements of Changes in Equity as at December 31, 2021
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
As at December 31, 2021
Share capital		31			—			31
Share premium		1,261,454			—			1,261,454
Share-based compensation reserves		19,702			—			19,702
Foreign currency translation reserve		6,987			(2,123	)		4,864
Accumulated losses		(816,968	)		296,861			(520,107	)
Total equity		471,206			294,738			765,944

	Consolidated statements of cash flows during the year ended December 31, 2021
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax		(386,208	)		(20,988	)		(407,196	)
Adjustments for:
Finance income		(971	)		—			(971	)
Finance costs		900			—			900
(Reversal of)/provision for the impairment of trade receivables		(22	)		22			—
Depreciation of property, plant and equipment		11,046			(2,907	)		8,139
Loss on disposal of property, plant and equipment		974			—			974
Amortization of intangible assets		1,379			—			1,379
Depreciation of right-of-use assets		1,492			2,907			4,399
Fair value loss of warrant liability		6,200			—			6,200
Foreign currency exchange loss, net		4,867			—			4,867
Equity-settled share-based compensation expense		20,158			—			20,158
Deferred government grant		(295	)		—			(295	)
		(340,480	)		(20,966	)		(361,446	)
Decrease in trade receivables		24,590			—			24,590
Increase in prepayments, other receivables and other assets		(2,966	)		—			(2,966	)
Increase in other non-current assets		(1,175	)		—			(1,175	)
Decrease in inventories		51			—			51
Government grant received		80			—			80
Increase in trade and notes payables		1,805			—			1,805
Increase/(decrease) in other payables and accruals		142,091			(1,344	)		140,747
Decrease in other non-current liabilities		(158	)		—			(158	)
(Decrease)/increase in contract liabilities		(22,310	)		22,310			—
Increase in pledged deposits, net		(1,060	)		—			(1,060	)
Cash used in operations		(199,532	)		—			(199,532	)
Finance income received		652			—			652
Income tax received		557			—			557
Interest on lease payments		(142	)		—			(142	)
Net cash flow used in operating activities		(198,465	)		—			(198,465	)

	Consolidated statements of cash flows during the year ended December 31, 2021
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(43,905	)		1,708			(42,197	)
Purchase of intangible assets		(3,207	)		—			(3,207	)
Prepayment to collaborator for collaboration right-of-use assets		—			(1,708	)		(1,708	)
Purchase of financial assets measured at fair value through profit or loss		(50,000	)		—			(50,000	)
Cash received from withdrawal of financial assets measured at fair value through profit or loss		50,081			—			50,081
Proceeds from disposal of property, plant and equipment		4			—			4
Addition in time deposits		(298,107	)		—			(298,107	)
Decrease in time deposits		180,000			—			180,000
Purchase of financial assets measured at amortized cost		(29,849	)		—			(29,849	)
Net cash flows used in investing activities		(194,983	)		—			(194,983	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs		323,440			—			323,440
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor		300,000			—			300,000
Proceeds from exercise of share options		4,642			—			4,642
Principal portion of lease payments		(1,419	)		—			(1,419	)
Net cash flows from financing activities		626,663			—			626,663
NET INCREASE IN CASH AND CASH EQUIVALENTS		233,215			—			233,215
Effect of foreign exchange rate changes, net		34			—			34
Cash and cash equivalents at beginning of year		455,689			—			455,689
CASH AND CASH EQUIVALENTS AT END OF YEAR		688,938			—			688,938
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		858,607			—			858,607
Less: Pledged deposits		1,444			—			1,444
Time deposits		168,225			—			168,225
Cash and cash equivalents as stated in the statement of financial position		688,938			—			688,938
Cash and cash equivalents as stated in the statement of cash flows		688,938			—			688,938

	Consolidated Statement of profit or loss and other comprehensive income for the year ended December 31, 2020
				Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets		Tax impacts			Total Adjustments			As Restated
	US$’000			US$’000			US$’000		US$’000			US$’000			US$’000
Revenue		75,676			(676	)		—		—			(676	)		75,000
Other income and gains		6,119			—			—		—			—			6,119
Research and development expenses		(232,160	)		—			—		—			—			(232,160	)
Administrative expenses		(23,147	)		13			—		—			13			(23,134	)
Selling and distribution expenses		(49,571	)		—			—		—			—			(49,571	)
Other expenses		(346	)		—			—		—			—			(346	)
Fair value loss of convertible redeemable preferred shares		(79,984	)		—			—		—			—			(79,984	)
Finance costs		(4,209	)		—			—		—			—			(4,209	)
Loss before tax		(307,622	)		(663	)		—		—			(663	)		(308,285	)
Income tax credit		4,145			—			—		37,767			37,767			41,912
Loss for the year		(303,477	)		(663	)		—		37,767			37,104			(266,373	)
Attributable to: ordinary equity holders of the parent		(303,477	)		(663	)		—		37,767			37,104			(266,373	)
Loss per share attributable to ordinary equity holders of the parent
Basic		(1.28	)		—			—		0.15			0.15			(1.13	)
Diluted		(1.28	)		—			—		0.15			0.15			(1.13	)
Exchange differences:
Exchange differences on translation of foreign operations		(2,142	)		6,702			—		(482	)		6,220			4,078
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods		(2,142	)		6,702			—		(482	)		6,220			4,078
OTHER COMPREHENSIVE (LOSS)/ INCOME FOR THE YEAR, NET OF TAX		(2,142	)		6,702			—		(482	)		6,220			4,078
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(305,619	)		6,039			—		37,285			43,324			(262,295	)
Attributable to:
Ordinary equity holders of the parent		(305,619	)		6,039			—		37,285			43,324			(262,295	)

	Consolidated Statements of Financial Position as at December 31, 2020
			Adjustments by category
	As Previously Reported		Revenue Recognition			Collaboration assets			Tax impacts			Total Adjustments			As Restated
	US$’000		US$’000			US$’000			US$’000			US$’000			US$’000
NON-CURRENT ASSETS
Property, plant and equipment		113,091		—			(40,749	)		—			(40,749	)		72,342
Advance payments for property, plant and equipment		224		—			—			—			—			224
Right-of-use assets		8,009		—			31,533			—			31,533			39,542
Intangible assets		2,852		—			—			—			—			2,852
Other non-current assets		3,973		—			9,216			—			9,216			13,189
Total non-current assets		128,149		—			—			—			—			128,149
CURRENT ASSETS
Inventories		1,800		—			—			—			—			1,800
Trade receivables		74,978		22			—			—			22			75,000
Prepayments, other receivables and other assets		10,007		—			—			445			445			10,452
Lease receivables		—		—			619			—			619			619
pledged deposits		384		—			—			—			—			384
Time deposits		50,000		—			—			—			—			50,000
Cash and cash equivalents		455,689		—			—			—			—			455,689
Total current assets		592,858		22			619			445			1,086			593,944
Total assets		721,007		22			619			445			1,086			722,093
CURRENT LIABILITIES
Trade payables		5,238		—			—			—			—			5,238
Other payables and accruals		99,168		—			619			—			619			99,787
Government grants		283		—			—			—			—			283
Lease liabilities		1,464		—			—			—			—			1,464
Tax payable		—		—			—			8,795			8,795			8,795
Contract liabilities, current		55,014		(55,014	)		—			—			(55,014	)		—
Total current liabilities		161,167		(55,014	)		619			8,795			(45,600	)		115,567
NON-CURRENT LIABILITIES
Contract liabilities, non-current		275,071		(275,071	)		—			—			(275,071	)		—
Lease liabilities		1,909		—			—			—			—			1,909
Government grants		2,051		—			—			—			—			2,051
Deferred tax liabilities		—		—			—			4,241			4,241			4,241
Other non-current liabilities		554		—			—			—			—			554
Total non-current liabilities		279,585		(275,071	)		—			4,241			(270,830	)		8,755
Total liabilities		440,752		(330,085	)		619			13,036			(316,430	)		124,322
EQUITY
Share capital		27		—			—			—			—			27
Reserves		280,228		330,107			—			(12,591	)		317,516			597,744
Total ordinary shareholders’ equity		280,255		330,107			—			(12,591	)		317,516			597,771
Total equity		280,255		330,107			—			(12,591	)		317,516			597,771
Total liabilities and equity		721,007		22			619			445			1,086			722,093

	Consolidated Statements of Changes in Equity as at December 31, 2020
	As Previously Reported			Total Restatement Impacts		As Restated
	US$’000			US$’000		US$’000
As at December 31, 2020
Share capital		27			—		27
Share premium		708,306			—		708,306
Share-based compensation reserves		6,314			—		6,314
Foreign currency translation reserve		(3,633	)		3,282		(351	)
Accumulated losses		(430,759	)		314,234		(116,525	)
Total equity		280,255			317,516		597,771

	Consolidated statements of cash flows for the year ended December 31, 2020
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax		(307,622	)		(663	)		(308,285	)
Adjustments for:
Finance income		(2,930	)		—			(2,930	)
Finance costs		4,209			—			4,209
Provision/(reversal of) for the impairment of trade receivables		13			(13	)		—
Depreciation of property, plant and equipment		8,248			(2,014	)		6,234
Loss on disposal of property, plant and equipment		55						55
Amortization of intangible assets		192			—			192
Depreciation of right-of-use assets		1,493			2,014			3,507
Fair value loss of convertible redeemable preferred shares		79,984			—			79,984
Fair value gains on financial assets measured at fair value change through profit or loss		(47	)		—			(47	)
Foreign currency exchange gain, net		(66	)		—			(66	)
Equity-settled share-based compensation expense		4,760			—			4,760
Deferred government grant		(114	)		—			(114	)
		(211,825	)		(676	)		(212,501	)
Increase in trade receivables		(45,000	)		—			(45,000	)
Decrease in prepayments, other receivables and other assets		3,366			—			3,366
Increase in other non-current assets		(3,973	)		—			(3,973	)
Increase in inventories		(643	)		—			(643	)
Government grant received		2,452			—			2,452
Decrease in trade and notes payables		(4,348	)		—			(4,348	)
Increase in other payables and accruals		20,230			6,702			26,932
Increase in other non-current liabilities		554			—			554
Increase/(decrease) in contract liabilities		6,026			(6,026	)		—
Increase in pledged deposits, net		(128	)		—			(128	)
Cash used in operations		(233,289	)		—			(233,289	)
Income tax paid		(278	)		—			(278	)
Finance income received		3,366			—			3,366
Income tax received		7,391			—			7,391
Interest on lease payments		(195	)		—			(195	)
Net cash flow used in operating activities		(223,005	)		—			(223,005	)

	Consolidated Statements of Cash Flows For the year ended December 31, 2020
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(45,747	)		19,493			(26,254	)
Purchase of intangible assets		(4,029	)		—			(4,029	)
Prepayment to collaborator for collaboration right-of-use assets		—			(19,493	)		(19,493	)
Purchase of financial assets measured at fair value through profit or loss		(22,682	)		—			(22,682	)
Cash received from withdrawal of financial assets measured at fair value through profit or loss		22,682			—			22,682
Cash receipts of investment income		47			—			47
Proceeds from disposal of property, plant and equipment		1			—			1
Addition in time deposits		(50,000	)		—			(50,000	)
Decrease in time deposits		75,559			—			75,559
Net cash flows used in investing activities		(24,169	)		—			(24,169	)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of cash advances from related parties		(4	)		—			(4	)
Proceeds from convertible redeemable preferred shares		160,450			—			160,450
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs		450,085			—			450,085
Proceeds from issuance of ordinary shares relating to private placement by GenScript		12,000			—			12,000
Proceeds from exercise of share options		1,464			—			1,464
Payments of expenses for issuance of convertible redeemable preferred shares		(2,514	)		—			(2,514	)
Principal portion of lease payments		(2,602	)		—			(2,602	)
Net cash flows from financing activities		618,879			—			618,879
NET INCREASE IN CASH AND CASH EQUIVALENTS		371,705			—			371,705
Effect of foreign exchange rate changes, net		620			—			620
Cash and cash equivalents at beginning of year		83,364			—			83,364
CASH AND CASH EQUIVALENTS AT END OF YEAR		455,689			—			455,689
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		506,073			—			506,073
Less: Pledged deposits		384			—			384
Time deposits		50,000			—			50,000
Cash and cash equivalents as stated in the statement of financial position		455,689			—			455,689
Cash and cash equivalents as stated in the statement of cash flows		455,689			—			455,689

	Consolidated statement of profit or loss and other comprehensive income for the year ended December 31, 2019
				Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets		Tax impacts		Total Adjustments			As Restated
	US$’000			US$’000			US$’000		US$’000		US$’000			US$’000
Revenue		57,264			2,716			—		—		2,716			59,980
Other income and gains		7,125			334			—		—		334			7,459
Research and development expenses		(161,943	)		—			—		—		—			(161,943	)
Administrative expenses		(6,752	)		1			—		—		1			(6,751	)
Selling and distribution expenses		(25,620	)		—			—		—		—			(25,620	)
Other expenses		(221	)		—			—		—		—			(221	)
Finance costs		(223	)		—			—		—		—			(223	)
Loss before tax		(130,370	)		3,051			—		—		3,051			(127,319	)
Income tax (expense)/credit		(2,602	)		—			—		28,331		28,331			25,729
Loss for the year		(132,972	)		3,051			—		28,331		31,382			(101,590	)
Attributable to: ordinary equity holders of the parent		(132,972	)		3,051			—		28,331		31,382			(101,590	)
Loss per share attributable to ordinary equity holders of the parent
Basic		(0.66	)		0.02			—		0.13		0.15			(0.51	)
Diluted		(0.66	)		0.02			—		0.13		0.15			(0.51	)
Exchange differences:
Exchange differences on translation of foreign operations		182			(1,584	)		—		134		(1,450	)		(1,268	)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods		182			(1,584	)		—		134		(1,450	)		(1,268	)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX		182			(1,584	)		—		134		(1,450	)		(1,268	)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(132,790	)		1,467			—		28,465		29,932			(102,858	)
Attributable to:
Ordinary equity holders of the parent		(132,790	)		1,467			—		28,465		29,932			(102,858	)

	Consolidated statements of financial position as at January 1, 2020
	Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets			Tax impacts			Total Adjustments			As Restated
	US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
NON-CURRENT ASSETS
Property, plant and equipment		70,079			—			(24,891	)		—			(24,891	)		45,188
Advance payments for property, plant and equipment		665			—			—			—			—			665
Right-of-use assets		9,348			—			18,442			—			18,442			27,790
Intangible assets		519			—			—			—			—			519
Other non-current assets		—			—			6,449			—			6,449			6,449
Total non-current assets		80,611			—			—			—			—			80,611
CURRENT ASSETS
Inventories		1,157			—			—			—			—			1,157
Trade receivables		29,991			9			—			—			9			30,000
Prepayments, other receivables and other assets		16,777			—			—			4,894			4,894			21,671
Pledged deposits		256			—			—			—			—			256
Time deposits		75,559			—			—			—			—			75,559
Cash and cash equivalents		83,364			—			—			—			—			83,364
Total current assets		207,104			9			—			4,894			4,903			212,007
Total assets		287,715			9			—			4,894			4,903			292,618
CURRENT LIABILITIES
Trade payables		9,586			—			—			—			—			9,586
Other payables and accruals		70,854			—			—			—			—			70,854
Lease liabilities		1,027			—			—			—			—			1,027
Tax payable		—			—			—			12,782			12,782			12,782
Contract liabilities, current		46,294			(46,294	)		—			—			(46,294	)		—
Total current liabilities		127,761			(46,294	)		—			12,782			(33,512	)		94,249
NON-CURRENT LIABILITIES
Contract liabilities, non-current		277,765			(277,765	)		—			—			(277,765	)		—
Lease liabilities		5,058			—			—			—			—			5,058
Deferred tax liabilities		—			—			—			41,988			41,988			41,988
Total non-current liabilities		282,823			(277,765	)		—			41,988			(235,777	)		47,046
Total liabilities		410,584			(324,059	)		—			54,770			(269,289	)		141,295
EQUITY
Share capital		20			—			—			—			—			20
Reserves		(122,889	)		324,068			—			(49,876	)		274,192			151,303
Total ordinary shareholders’ (deficit)/ equity		(122,869	)		324,068			—			(49,876	)		274,192			151,323
Total (deficit)/equity		(122,869	)		324,068			—			(49,876	)		274,192			151,323
Total liabilities and equity		287,715			9			—			4,894			4,903			292,618

	Consolidated Statements of Changes in Equity as at December 31, 2019
	As Previously Reported			Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
As at December 31, 2019
Share capital		20			—			20
Share premium		3,908			—			3,908
Share-based compensation reserves		1,976			—			1,976
Foreign currency translation reserve		(1,491	)		(2,938	)		(4,429	)
(Accumulated losses)/retained earnings		(127,282	)		277,130			149,848
Total (deficit)/equity		(122,869	)		274,192			151,323

	Consolidated statements of cash flow for the year ended December 31, 2019
	As Previously Reported			Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax		(130,370	)		3,051			(127,319	)
Adjustments for:
Finance income		(4,581	)		—			(4,581	)
Finance costs		223			—			223
Provision/(reversal of) for the impairment of trade receivables		1		(1)				—
Depreciation of property, plant and equipment		4,001			(838	)		3,163
Amortization of intangible assets		63			—			63
Depreciation of right-of-use assets		1,198			838			2,036
Fair value gains on financial assets measured at fair value change through profit or loss		(474	)		—			(474	)
Foreign currency exchange gain, net		(250	)		(334	)		(584	)
Equity-settled share-based compensation expense		1,272			—			1,272
		(128,917	)		2,716			(126,201	)
(Increase)/decrease in trade receivables		(3,771	)		25,000			21,229
Increase in prepayments, other receivables and other assets		(3,928	)		(1,250	)		(5,178	)
Increase in inventories		(22	)		—			(22	)
Increase in trade and notes payables		2,011			—			2,011
Increase in other payables and accruals		31,727			—			31,727
Increase/(decrease) in contract liabilities		26,466			(26,466	)		—
Cash used in operations		(76,434	)		—			(76,434	)
Income tax paid		(15,432	)		—			(15,432	)
Finance income received		9,024			—			9,024
Interest on loan from related party		(24	)		—			(24	)
Interest on lease payments		(199	)		—			(199	)
Net cash flow used in operating activities		(83,065	)		—			(83,065	)

	Consolidated Statements of Cash Flows For the year ended December 31, 2019
	As Previously Reported			Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(38,636	)		11,863			(26,773	)
Purchase of intangible assets		(534	)		—			(534	)
Prepayment to collaborator for collaboration right-of-use assets		—			(11,863	)		(11,863	)
Purchase of financial assets measured at fair value through profit or loss		(314,840	)		—			(314,840	)
Cash received from withdrawal of financial assets measured at fair value through profit or loss		320,854			—			320,854
Cash advances to related parties		(13,006	)		—			(13,006	)
Collection of cash advances to related parties		62,996			—			62,996
Proceeds from disposal of property, plant and equipment		74			—			74
Addition in time deposits		(75,559	)		—			(75,559	)
Addition in pledged deposits		(256	)		—			(256	)
Decrease in pledged deposits		255			—			255
Net cash flows used in investing activities		(58,652	)		—			(58,652	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from cash advances from related parties		38,945			—			38,945
Repayment of cash advances from related parties		(19,223	)		—			(19,223	)
Proceeds from loans from related parties		2,867			—			2,867
Repayments of loans from related parties		(2,867	)		—			(2,867	)
Principal portion of lease payments		(5,056	)		—			(5,056	)
Net cash flows from financing activities		14,666			—			14,666
NET DECREASE IN CASH AND CASH EQUIVALENTS		(127,051	)		—			(127,051	)
Effect of foreign exchange rate changes, net		249			—			249
Cash and cash equivalents at beginning of year		210,166			—			210,166
CASH AND CASH EQUIVALENTS AT END OF YEAR		83,364			—			83,364
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		159,179			—			159,179
Less: Pledged deposits		256			—			256
Time deposits		75,559			—			75,559
Cash and cash equivalents as stated in the statement of financial position		83,364			—			83,364
Cash and cash equivalents as stated in the statement of cash flows		83,364			—			83,364

Changes in Accounting Policies and Disclosures

12 Months Ended

Dec. 31, 2021

Disclosure Of Voluntary Change In Accounting Policy [Abstract]

Changes in Accounting Policies and Disclosures

2.3 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following revised IFRSs, for the first time for the current year’s financial statements. The adoption of these revised IFRSs did not have any material impact on the financial position and financial performance of the Group.

Amendments to IFRS 9,
IAS 39, IFRS 7,
IFRS 4 and IFRS 16	Interest Rate Benchmark Reform – Phase II

Issued But Not Yet Effective International Financial Reporting Standards

12 Months Ended

Dec. 31, 2021

Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Abstract]

Issued But Not Yet Effective International Financial Reporting Standards

2.4 ISSUED BUT NOT YET EFFECTIVE INTERNATIONAL FINANCIAL REPORTING STANDARDS

The Group has not applied the following new and revised IFRSs, that have been issued but are not yet effective, in these consolidated financial statements.

Amendments to IFRS 3		Reference to the Conceptual Framework¹
Amendments to IFRS 10 and IAS 28 (2011)		Sale or Contribution of Assets between an Investor and its Associate or Joint Venture³
IFRS 17		Insurance Contracts²
Amendments to IFRS 17		Insurance Contracts^2,⁴
Amendments to IAS 1		Classification of Liabilities as Current or Non-current²
Amendments to IAS 1 and IFRS Practice Statement 2		Disclosure of Accounting Policies²
Amendments to IAS 8		Definition of Accounting Estimates²
Amendments to IAS 12		Deferred Tax related to Assets and Liabilities arising from a Single Transaction²
Amendments to IAS 16		Property, Plant and Equipment: Proceeds before Intended Use¹
Amendments to IAS 37		Onerous Contracts - Cost of Fulfilling a Contract¹
Annual Improvements to IFRSs 2018-2020		Amendments to IFRS 1, IFRS 9, Illustrative Examples accompanying IFRS 16, and IAS 41¹

Effective for annual periods beginning on or after January 1, 2022

Effective for annual periods beginning on or after January 1, 2023

No mandatory effective date yet determined but available for adoption

⁴

As a consequence of the amendments to IFRS 17 issued in October 2020, IFRS 4 was amended to extend the temporary exemption that permits insurers to apply IAS 39 rather than IFRS 9 for annual periods beginning before January 1, 2023

The Group is currently assessing the impact of these standards. So far, the Group has expected that these standards will not have significant effect on the Group’s financial performance and financial position.

Summary of Significant Accounting Policies as Restated

12 Months Ended

Dec. 31, 2021

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2.5 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (AS RESTATED)

Fair value measurement

The Group measures its financial assets at fair value through profit or loss and warrant liability at fair value at the end of each reporting period. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant’s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 – based on quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly

Level 3 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognized in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for an asset is required (other than contract assets and financial assets,), the asset’s recoverable amount is estimated. An asset’s recoverable amount is the higher of the asset’s or cash-generating unit’s value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs.

An impairment loss is recognized only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognized impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognized impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortization) had no impairment loss been recognized for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.

Related parties

A party is considered to be related to the Group if:

(a)

the party is a person or a close member of that person’s family and that person

(i)

has control or joint control over the Group;

(ii)

has significant influence over the Group; or

(iii)

is a member of the key management personnel of the Group or of a parent of the Group;

(b)

the party is an entity where any of the following conditions applies:

(i)

the entity and the Group are members of the same group;

(ii)

one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

(iii)

the entity and the Group are joint ventures of the same third party;

(iv)

one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

(v)

the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;

(vi)

the entity is controlled or jointly controlled by a person identified in (a);

(vii)

a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and

(viii)

the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

Property, plant and equipment and depreciation

Property, plant and equipment, other than construction in progress, are stated at cost (or valuation) less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to the statement of profit or loss and other comprehensive income in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalized in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognizes such parts as individual assets with specific useful lives and depreciates them accordingly.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

Freehold land		Not depreciated
Buildings		2.6%
Leasehold improvement		10% to 20%
Machinery and equipment		10% to 20%
Computer, fixtures and office equipment		20% to 33.3%
Transportation equipment		10%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognized in the statement of profit or loss and other comprehensive income in the year the asset is derecognized is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress represents equipment under installation, which is stated at cost less any impairment losses, and is not depreciated. Cost comprises the direct costs of installation. Construction in progress is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

Intangible assets are amortized on the straight-line basis over the following useful economic lives:


Software		3-10 years

Research and development costs

All research costs are charged to the statement of profit or loss and other comprehensive income as incurred.

Expenditures incurred on projects to develop new products is capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

(a) Right-of-use assets

Right-of-use assets are recognized at the commencement date of the lease (that is the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any re-measurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received.

Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

Leasehold land		50 years
Building improvement		2 to 18 years
Machinery and equipment		5 to 10 years
Office equipment		3 to 5 years

If ownership of the leased asset transfers to the Group by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

(b) Lease liabilities

Lease liabilities are recognized at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate the lease. The variable lease payments that do not depend on an index or a rate are recognized as an expense in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is re-measured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

The Group applies the short-term lease recognition exemption to its short-term leases that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option.

Lease payments on short-term leases are recognized as an expense on a straight-line basis over the lease term.

Group as a lessor

When the Group acts as a lessor, it classifies at lease inception (or when there is a lease modification) each of its leases as either an operating lease or a finance lease.

Leases in which the Group does not transfer substantially all the risks and rewards incidental to ownership of an asset are classified as operating leases. Rental income is accounted for on a straight-line basis over the lease terms and is included in other income in the statement of profit or loss and other comprehensive income. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognized over the lease term on the same basis as rental income.

Leases of collaboration assets

The Group and its collaboration partner purchase assets to be used for their collaboration and share the associated costs in accordance with the terms and conditions of the Janssen Agreement. The Group accounts for leases to and by the collaboration by applying the guidance in IFRS 16 on joint arrangements by analogy.

The Group recognizes the full lease liability, rather than its share, for leases entered into on behalf of the collaboration if the Group has the primary responsibility for making the lease payments. This may be the case when the Group, as a lead operator of the collaboration, is the sole signatory to the lease. A finance sublease is subsequently recognised if the related right-of-use asset is subleased to the collaboration.

Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset’s contractual cash flow characteristics and the Group’s business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient of not adjusting the effect of a significant financing component, the Group initially measures a financial asset at its fair value, plus in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under IFRS 15 in accordance with the policies set out for “Revenue recognition” below.

In order for a financial asset to be classified and measured at amortized cost, it needs to give rise to cash flows that are solely payments of principal and interest (“SPPI”) on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Group’s business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortized cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows.

All regular way purchases and sales of financial assets are recognized on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace.

Subsequent measurement

Financial assets measured at amortized cost (debt instruments)

Financial assets measured at amortized cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the asset is derecognized, modified or impaired.

Financial assets measured at fair value through profit or loss

Financial assets measured at fair value through profit or loss are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss and other comprehensive income.

Derecognition of financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Group’s consolidated statement of financial position) when:

•

the rights to receive cash flows from the asset have expired; or

•

the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognize the transferred asset to the extent of the Group’s continuing involvement. In that case, the Group also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Impairment of financial assets

The Group recognizes an allowance for expected credit losses (“ECLs”) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

General approach

ECLs are recognized in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

At each reporting date, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

The Group considers a financial asset in default when contractual payments are 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Financial assets measured at amortized cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables and contract assets which apply the simplified approach as detailed below.

Stage 1 – Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs

Stage 2 – Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs

Stage 3 – Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs.

Simplified approach

For trade receivables and contract assets that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

Financial liabilities

Initial recognition and measurement

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group’s financial liabilities include trade and notes payables, other payables, warrant liability, interest-bearing loans and borrowings, and lease liabilities.

Subsequent measurement

Financial liabilities measured at amortized cost (Loans and borrowings)

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost, using the effective interest rate method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognized in the statement of profit or loss and other comprehensive income when the liabilities are derecognized as well as through the effective interest rate amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included in finance costs in the statement of profit or loss and other comprehensive income.

Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognized in the statement of profit or loss and other comprehensive income.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the assets and settle the liabilities simultaneously.

Inventories

Inventories are stated at the lower of cost and net realizable value. Cost is determined on the weighted average basis and, in the case of work in progress and finished goods, comprises direct materials, direct labour and an

appropriate proportion of overheads. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.

Cash and cash equivalents

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and demand deposits, and short term highly liquid investments that are readily convertible into known amounts of cash, are subject to an insignificant risk of changes in value, and have an original maturity of three months when acquired, less bank overdrafts which are repayable on demand and form an integral part of the Group’s cash management.

For the purpose of the consolidated statement of financial position, cash and cash equivalents comprise cash on hand and at banks, including deposits, and assets similar in nature to cash, which are not restricted as to use.

Time deposits

Time deposits represent cash placed with banks with original maturities of more than three months when acquired. The time deposits are presented as a non-current asset if the collection of time deposits is expected more than one year.

Provisions

A provision is recognized when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognized for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in the statement of profit or loss and other comprehensive income.

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognized outside profit or loss is recognized outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognized for all taxable temporary differences, except:

•

where the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

•

in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax assets are recognized for all deductible temporary differences, the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable

profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilized, except:

•

when the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and

•

in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognized to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are reassessed at the end of each reporting period and are recognized to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the end of the reporting period.

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable entity or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Government grants

Government grants are recognized at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognized as income on a systematic basis over the periods that the costs, for which it is intended to compensate, are expensed.

Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to the statement of profit or loss and comprehensive income over the expected useful life of the relevant asset by equal annual instalments.

Collaboration Arrangements

The Group enters into collaboration arrangements with pharmaceutical and biotechnology collaboration partners, under which the Group may grant licenses to a collaboration partner to further develop and commercialize one of the Group’s drug candidates. The Group may also perform research, development, manufacturing and commercial activities under a collaboration arrangement. Consideration under these contracts may include an upfront payment, development and regulatory milestones, commercial sales milestones and other contingent payments, expense reimbursements, and profit-sharing.

For collaboration arrangements that contain multiple elements, at contract inception the Group determines whether elements of the collaboration are reflective of a vendor-customer relationship and therefore are within the scope of IFRS 15. Elements of the collaboration arrangements that involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards of such activities are not arrangements with a customer and are outside the scope of IFRS 15. For a distinct bundle of goods or services within the arrangement that is not with a customer, the recognition and measurement of that unit of

account shall be based on other authoritative accounting literature, or if there is no appropriate authoritative accounting literature, a reasonable, rational and consistently applied accounting policy election.

If the Group concludes that a collaboration partner is not a customer for certain activities and associated payments, such as for certain collaborative research, development, manufacturing and commercial activities, the Group presents payments from the collaboration partner as a reduction of expense, based on where the Group presents the underling expense. If the collaborator performs research and development, manufacturing or commercialization-related activities, the Group recognizes as expense (e.g. research and development expense or selling and distribution expense, as applicable) in the period when the collaborator incurs such expenses, the portion of the collaborator’s expenses that the Group is obligated to reimburse.

Revenue recognition

Revenue from contracts with customers

The Group recognizes revenue in accordance with IFRS 15, Revenue from Contracts with Customers (IFRS 15). Under IFRS 15, revenue from contracts with customers is recognized when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services. To determine revenue recognition for agreements that we determine are within the scope of IFRS 15, the Group performs the following five-steps: (i) identify the contract, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

Once a contract is determined to be within the scope of IFRS 15, at contract inception the Group assesses the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. A good or service that is promised to a customer is distinct if both of the following criteria are met: (a) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer; and (b) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.

The group determines the transaction price based on the amount of consideration the Group expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. When the consideration in a contract includes a variable amount, the amount of consideration is estimated to which the Group will be entitled in exchange for transferring the goods or services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant revenue reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved. The contracts generally do not include a significant financing component.

The Group recognizes revenue only when it satisfies a performance obligation by transferring control of the promised goods or services. The transfer of control can occur over time or at a point in time. A performance obligation is satisfied over time if it meets one of the following criteria: (i) The counterparty simultaneously receives and consumes the benefits provided by the Group’s performance as the Group performs; or (ii) The Group’s performance creates or enhances an asset that the counterparty controls as the asset is created or enhanced.

The portion of the transaction price that is allocated to performance obligations satisfied at a point in time is recognized as revenue when control of the goods or services is transferred to the counterparty. If the performance obligation is satisfied over time, the portion of the transaction price allocated to that performance obligation is recognized as revenue as the performance obligation is satisfied. The Group adopts an appropriate method of measuring progress for purposes of recognizing revenue. The Group evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Contracts may be amended to account for changes in contract specifications and requirements. Contract modifications exist when the amendment either creates new, or changes existing, enforceable rights and obligations. When contract modifications create new performance obligations and the increase in consideration approximates the

standalone selling price for goods and services related to such new performance obligations as adjusted for specific facts and circumstances of the contract, the modification is considered to be a separate contract.

If a contract modification is not accounted for as a separate contract, the Group accounts for the promised goods or services not yet transferred at the date of the contract modification (the remaining promised goods or services) prospectively, as if it were a termination of the existing contract and the creation of a new contract, if the remaining goods or services are distinct from the goods or services transferred on or before the date of the contract modification. For a change in transaction price that occurs after a contract modification, the Group allocates the change in the transaction price to the performance obligations identified in the contract before the modification if, and to the extent that, the change in the transaction price is attributable to an amount of variable consideration promised before the modification.

The Group accounts for a contract modification as if it were a part of the existing contract if the remaining goods or services are not distinct and, therefore, form part of a single performance obligation that is partially satisfied at the date of the contract modification. In such case, the effect that the contract modification has on the transaction price, and on the entity’s measure of progress toward complete satisfaction of the performance obligation, is recognized as an adjustment to revenue (either as an increase in or a reduction of revenue) at the date of the contract modification (the adjustment to revenue is made on a cumulative catch-up basis).

(a) License and collaboration revenue

License of Intellectual Property

For collaboration arrangements that include a grant of a license to the Group’s intellectual property, the Group consider whether the license grant is distinct from the other performance obligations included in the arrangement. In assessing whether a license is distinct from the other promises, the Group considers factors such as the research, development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Group considers whether the counterparty can benefit from a license for its intended purpose without the receipt of the remaining promise(s) by considering whether the value of the license is dependent on the unsatisfied promise(s), whether there are other vendors that could provide the remaining promise(s), and whether it is separately identifiable from the remaining promise(s). We evaluated that the license is a single performance obligation in the Janssen Agreement, including a technology transfer service, which represents a right to use our license as it exists at the point in time that the license is granted. Revenue from licenses is recognized when the control of the right to use of the license is transferred to the customer.

Milestone Payments

Milestone payments, which are included in the transaction price to the extent that it is highly probable that a significant reversal of accumulative revenue recognized will not occur, represent a form of variable consideration when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes milestone payments, the Group evaluates whether the milestones are considered highly probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are received. The Group evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgement involved in determining whether it is highly probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Group re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price.

When the Company cannot conclude that it is highly probable that a significant revenue reversal of cumulative revenue under the contract will not occur, the Company constrains the related variable consideration resulting in its exclusion from the transaction price. At the end of each subsequent reporting period, the Group re-evaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price.

Royalty Payments

The Company recognizes revenue for sales-based milestone payments promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

(a) the subsequent sale occurs; and

(b) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).

Janssen Agreement

The Group entered into a license and collaboration agreement with one customer (Janssen). The terms of the arrangement include: non-refundable upfront fees of US$350 million and milestone payments for the achievement of specified manufacturing milestones, specified development milestones, specified regulatory milestones and specified net trade sales milestones of US$125 million, US$215 million, US$800 million and US$210 million, respectively. The Group has assessed that there is one distinct performance obligation, being the transfer of a license of intellectual property, including a technology transfer service. The Group considers this performance obligation is distinct from other collaborative activities as the license has stand-alone value without the Company being further involved in the research and development or other collaborative activities. Upon contract inception, the Group has estimated that the total transaction price is constrained to US$400 million, which included upfront fees of US$350 million and milestone payments of US$50 million. The transaction price was allocated to the single performance obligation in the contract.

Upfront fees

Upfront payment is allocated to the single performance obligation in the Janssen Agreement. The upfront fees of US$350 million were included in the transaction price upon contract inception in 2017 and were recognized when the single performance obligation to deliver the intellectual property, including a technology transfer service, was completed in 2018. The US$350 million upfront fees were fully received by the Group in 2018.

Milestone payments

Certain milestone payments were allocated to the single performance obligation in the Janssen Agreement to deliver the license of intellectual property. The initial two milestone payments of aggregate US$50 million were included in the transaction price at contract inception in 2017 and recognized when the single performance obligation to deliver the intellectual property, including a technology transfer service, was completed in 2018. Subsequently in 2019, an additional two milestone payments of US$60 million were included in the transaction price when the milestones triggered by dosing of a specified number of patients in the CARTITUDE-1 clinical trial were achieved. In 2020, an additional milestone with a payment of US$75 million was achieved relating to the clinical development of cilta-cel. In 2021, three additional milestone payments amounting to US$65 million were achieved relating to the submission of a Marketing Authorization to the EMA, enrollment of a specified number of patients in the CARTITUDE-5 clinical trial and filing of a Drug approval application for a product by the Ministry of Health, Labour and Welfare in Japan.

As of December 31, 2021, pursuant to the license and collaboration agreement, the remaining future contractual milestone payments for the Group aggregated to US$1,100 million for the achievement of various development, regulatory, manufacturing and net trade sales milestones. More specifically, the future contractual milestones consist of US$125 million for the achievement of specified manufacturing milestones, US$60 million for the achievement of specified development milestones, US$705 million for the achievement of specified regulatory milestones and US$210 million for the achievement of specified net trade sales milestones. The Group’s development plans and research progresses might change from time to time, which would increase the uncertainties of achieving future contractual milestones. The Company does not believe US$280 million of the remaining US$1,100 million contractual milestone payments would be eligible to be received based on a subsequent change in development plan with the collaborator. Furthermore, the Company assessed that achievement of all the remaining

contractual milestones is highly uncertain and the related milestone payments are not included in the transaction price. The milestone is achieved when the triggering event described in the agreement occurs.

Collaborative activities

In addition to the license of intellectual property, the Janssen Agreement includes joint development, manufacturing and commercial activities that are performed by the Group and its collaboration partner. These activities and the related consideration for these activities are outside the scope of IFRS 15 as the Group and its collaboration partner are both active participants in the activities and are exposed to significant risks and rewards of such activities.

Product Sales

Revenue from the sale of goods is recognized at the point in time when control of the goods is transferred to the customer, generally on delivery of the goods.

Other income

Interest income is recognized on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

Dividend income is recognized when the shareholders’ right to receive payment has been established, it is probable that the economic benefits associated with the dividend will flow to the Group and the amount of the dividend can be measured reliably.

Share-based payments

The Group operates a share option scheme and a restricted stock unit scheme (“RUS scheme”) for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. Employees (including directors) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (“equity-settled transactions”).

The cost of equity-settled transactions with employees is measured by reference to the fair value at the date at which they are granted. The fair value of share option is determined by an external valuer using a binomial model, and the fair value of each RSU is determined by reference to market price of the Group’s shares at the respective grant date, further details of which are given in notes 27 and 28 to the consolidated financial statements.

The cost of equity-settled transactions is recognized, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled in employee benefit expense. The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit to profit or loss for a period represents the movement in the cumulative expense recognized as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

For awards that do not ultimately vest because non-market performance and/or service conditions have not been met, no expense is recognized. Where awards include a market or non-vesting condition, the transactions are

treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

Where the terms of an equity-settled award are modified, as a minimum an expense is recognized as if the terms had not been modified, if the original terms of the award are met. In addition, an expense is recognized for any modification that increases the total fair value of the share-based payments, or is otherwise beneficial to the employee as measured at the date of modification.

Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. This includes any award where non-vesting conditions within the control of either the Group or the employee are not met. However, if a new award is substituted for the cancelled award, and is designated as a replacement award on the date that it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect of outstanding options and RSUs are reflected as additional share dilution in the computation of earnings per share.

Other employee benefits

Pension scheme

The employees of the Group’s subsidiaries which operates in Mainland China and Hong Kong are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute certain percentage of its payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

Foreign currencies

These consolidated financial statements are presented in United States dollars, which is the Company’s functional currency. Each entity in the Group determines its own functional currency and items included in the consolidated financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognized in the statement of profit or loss and comprehensive income.

Differences arising on settlement or translation of monetary items are recognized in the statement of profit or loss and comprehensive income with the exception of monetary items that are designated as part of the hedge of the Group’s net investment of a foreign operation. These are recognized in other comprehensive income until the net investment is disposed of, at which time the cumulative amount is reclassified to the statement of profit or loss and comprehensive income. Tax charges and credits attributable to exchange differences on those monetary items are also recorded in other comprehensive income.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognized in other comprehensive income or profit or loss is also recognized in other comprehensive income or profit or loss, respectively).

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of initial transaction is the date on which the Group initially recognizes the non-monetary asset or non-monetary

liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

The functional currencies of certain subsidiaries established in the PRC and Europe are currencies other than the United States dollar. As at the end of the reporting period, the assets and liabilities of these entities are translated into United States dollars at the exchange rates prevailing at the end of the reporting period and their statements of profit or loss are translated into United States dollars at exchange rates that approximate to those prevailing at the dates of the transactions.

The resulting exchange differences are recognized in other comprehensive income and accumulated in the foreign currency translation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognized in the statement of profit or loss and comprehensive income.

For the purpose of the consolidated statements of cash flows, the cash flows of the subsidiaries established in the PRC and Europe are translated into United States dollars at the exchange rates ruling at the dates of the cash flows. Frequently recurring cash flows of the companies established in the PRC and Europe which arise throughout the year are translated into United States dollars at the weighted average exchange rates for the year.

The preparation of the Group’s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

Impact of covid-19

The COVID-19 situation is very fluid across the world where each country or the sites within a country could be impacted differently. For the year ended December 31, 2021, COVID-19 has had limited impact on the Group’s operations.

There are still uncertainties of COVID-19’s future impact on the Group’s business, results of operations and financial condition, and the extent of the impact will depend on numerous evolving factors including, but not limited to: the magnitude and duration of COVID-19, the development and progress of distribution of COVID-19 vaccines and other medical treatments, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. If the situation materially deteriorates, the Group’s business, results of operations and financial condition could be materially and adversely affected. The Group will continue to monitor and assess the impact of the ongoing development of the epidemic on the financial position and operating results of the Group and respond accordingly.

Significant Accounting Judgements and Estimates as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Significant Accounting Judgements And Estimates [Abstract]

Significant Accounting Judgements and Estimates as Restated

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES (AS RESTATED)

Judgement

In the process of applying the Group’s accounting policies, management has made the following judgement, apart from those involving estimations, which has the most significant effect on the amounts recognized in the consolidated financial statements:

Revenue from contracts with customers

The Group has applied the following judgements that significantly affect the determination of the performance obligations and the method to estimate variable consideration of revenue from contracts with customers, specifically the Janssen Agreement:

(i) Determining the performance obligations of the contract

A good or service that is promised to a customer is distinct if both of the following criteria are met: (a) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer; and (b) the entity’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract. The Group determined that the license is capable of being distinct. In assessing whether the license has standalone value to the customer, the Group considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace, which indicates that the customer can benefit from the license on its own. The Group determined that the license of intellectual property and technology transfer service form a single performance obligation. The license of intellectual property and technology transfer are highly interdependent and are not separately identifiable from each other. The technology transfer is essential for the customer’s ability to obtain the use of and benefit from the license. The promise to transfer the license, including a technology transfer service, is distinct within the context of the contract. The license of intellectual property, including a technology transfer service, is separately identifiable in the contract and is meant to be transferred separate from other collaborative activities. The license, including a technology transfer service, is not an input that will be integrated with the service which represents a combined output. The preparation and attendance of the various steering committees and participation in the collaborative activities (e.g. joint development) is to assist in conducting clinical trials and obtaining regulatory approval of the technology, but does not modify the license and technology. In addition, the license, including the technology transfer service, is not highly interdependent or highly interrelated with the JSC and other collaborative activities, because the delivery of license and technology transfer service is not dependent on these activities to be provided in the future, and accordingly, it is not interdependent or interrelated with these activities.

In determining whether the license, including the technology transfer service, transfers to a customer either at a point in time or over time, the Group considers whether the nature of the Group’s promise in granting the license to a customer is to provide a right to access or a right to use the Group’s intellectual property. The Group assessed that the Group provides a right to use the license as the license exists (in terms of form and functionality) at a point in time at which it is granted and the technology transfer occurred, which is when the customer can use and benefit from the license. The license is already developed and has positive results on cancer patient candidates. The next step is to perform clinical trials again in a controlled and monitored environment.

The Group has allocated the entire transaction price to the license of intellectual property, as this is the sole performance obligation in the arrangement.

(ii) Determining the method to estimate variable consideration

Certain contracts includes milestone payments that give rise to variable consideration. In estimating the variable consideration, the Group is required to use either the expected value method or the most likely amount method based on which method better predicts the amount of consideration to which it will be entitled. The Group determined that the most likely amount method is the appropriate method to use in estimating the variable consideration for the milestone payments as this method better predicts the amount of variable consideration to which the Group will be entitled.

Before including any amount of variable consideration in the transaction price, the Group considers whether the amount of variable consideration is constrained. The Group evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment.

Estimation uncertainty

The key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below.

Impairment of non-financial assets (other than goodwill)

The Group assesses whether there are any indicators of impairment for all non-financial assets (including the right-of-use assets) at the end of each reporting period. Non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm’s length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value in use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit and choose a suitable discount rate in order to calculate the present value of those cash flows. There were no indicators of impairment for all periods presented.

Deferred tax assets

Deferred tax assets are recognized for unused tax losses and deductible temporary differences to the extent that it is probable that taxable profit will be available against which the losses and deductible temporary differences can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and level of future taxable profits together with future tax planning strategies. The outcome of their actual utilization may be different. As at December 31, 2021 and 2020, the Group recognized gross deferred tax assets (before offset with deferred tax labilities) of US$22.8 million and US$30.8 million, respectively, and the amount of unrecognized deferred tax assets for tax losses as at December 31, 2021 and 2020 was US$609.2 million and US$200.5 million, respectively. Further details are contained in note 22 to the consolidated financial statements.

Warrant liability

The fair value of the warrant liability is determined by using the binominal model. The use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Management estimates expected volatility based on the historical volatility of the stock of comparable companies. The risk-free interest rate is based on treasury yield curve rates with a remaining term which approximates to the expected life of the warrant. Changes in these input variables would affect fair value of the warrant. Further details are contained in notes 23 and 34 to the consolidated financial statements.

Share-based compensation

The fair value of share options granted by the Group is estimated using the binomial model. The use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Management estimates expected volatility based on the historical volatility of the stock of comparable companies. Expiration date is the basis for determining the expected life of an option. The risk-free interest rate is based on treasury yield curve rates with a remaining term which approximates to the expected life assumed at the date of grant. Changes in these input variables would affect the amount of expense associated with share-based compensation. The compensation expense recognized for all share-based awards is net of estimated forfeitures. The Company estimates forfeiture rates based on historical analysis of option forfeitures. If actual forfeitures vary from estimated forfeitures, adjustments to the compensation expense may be required. For the years ended December 31, 2021, 2020 and 2019, the equity-settled share option expense was US$2.4 million, US$1.9 million and US$1.3 million respectively. Further details are contained in note 27 to the consolidated financial statements.

Operating Segment Information as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Operating Segments [Abstract]

Operating Segment Information as Restated

4. OPERATING SEGMENT INFORMATION (AS RESTATED)

IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reporting about components of the Group that are regularly reviewed by the chief operating decision-maker in order to allocate resources to segments and to assess their performance. The information reported to the directors of the Company, who are the chief operating decision makers, for the purposes of resource allocation and assessment of

performance does not contain discrete operation segment financial information and the directors reviewed the financial results of the Group as a whole. Therefore, no further information on the operating segment is presented.

Geographic information

(a) Revenue from external customers as restated

	2021		2020		2019
	US$’000		US$’000		US$’000
United States of America		65,402		75,000		59,977
China		3,424		—		3
Total		68,826		75,000		59,980

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	December 31, 2021		December 31, 2020
	US$’000		US$’000
United States of America		103,648		78,022
China		50,800		43,953
Other		10,462		6,174
Total		164,910		128,149

The non-current asset information above is based on the locations of assets and excludes non-current time deposits.

Information about major customer

Revenue of US$65.4 million, US$75.0 million and US$60.0 million for the years ended December 31, 2021, 2020 and 2019, respectively, was derived from sales to a single customer. Revenue of US$3.4 million for the year ended December 31, 2021 was generated from the exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd. and its affiliates and subsequent sales-based royalties for using the aforementioned licensing (note 32).

Revenue, Other Income and Gains as Restated

12 Months Ended

Dec. 31, 2021

Revenue Other Income And Gains [Abstract]

Revenue, Other Income and Gains as Restated

5. REVENUE, OTHER INCOME AND GAINS (AS RESTATED)

An analysis of revenue is as follows:

	2021		2020		2019
	US$’000		US$’000		US$’000
Revenue from contracts with customer
Sales of goods		—		—		3
License and collaboration revenue
- Licensing of intellectual property		65,402		75,000		59,977
Licensing and Royalties		3,424		—		—
		68,826		75,000		59,980

Revenue from sales of goods and licensing of intellectual property is recognized at a point in time. Revenue from licensing of intellectual property represents variable consideration relating to the milestone payments which were constrained in prior years but included in the transaction price when the milestones were highly probable being achieved. At inception of the Janssen Agreement, the amount allocated to licensing of intellectual property was US$400 million for both U.S. and non-U.S. territories, which was updated to US$600 million as at December 31, 2021.

Licensing and royalties related to an exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd. and its affiliates and related subsequent sales-based royalties.

	2021		2020		2019
	US$’000		US$’000		US$’000
Other income and gains
Other income:
Finance income		971		2,930		4,581
Government grants*		1,736		3,072		1,682
Others		35		4		138
		2,742		6,006		6,401
Gains:
Foreign currency exchange gain, net		—		66		584
Fair value gains on financial assets measured at fair value change through profit or loss		—		47		474
Others**		317		—		—
		317		113		1,058
		3,059		6,119		7,459

*	The amount represents subsidies received from local government authorities to support the Group’s business. There were no unfulfilled conditions and other contingencies attached to these government grants.

**	The amount mainly represents reimbursement of depositary fees that are related to the establishment and maintenance of the American Depository Receipts (ADR) program.

Loss Before Tax as Restated

12 Months Ended

Dec. 31, 2021

Profit Loss [Abstract]

Loss Before Tax as Restated

6. LOSS BEFORE TAX (AS RESTATED)

The Group’s loss before tax is arrived at after charging:

	2021		2020		2019
	US$’000		US$’000		US$’000
Loss on disposal of assets		974		55		—
IPO expenses		—		1,439		—
Follow-on expenses		400		—		—
Employee benefit expense (including directors’ remuneration):
Wages and salaries		105,751		70,682		37,038
Pension scheme contributions (defined contribution schemes)		2,257		640		1,166
Equity-settled share-based compensation expense		20,158		4,760		1,272

Finance Costs

12 Months Ended

Dec. 31, 2021

Finance Costs [Abstract]

Finance Costs

7. FINANCE COSTS

	2021		2020		2019
	US$’000		US$’000		US$’000
Interest on lease liabilities		142		195		199
Interest on interest-bearing loans and borrowings (note 25)		758		—		—
Expenses for issuance of convertible redeemable preferred shares		—		4,014		—
Interest on an entrusted loan from a related party		—		—		24
Total		900		4,209		223

Income Tax as Restated

12 Months Ended

Dec. 31, 2021

Major Components Of Tax Expense Income [Abstract]

Income Tax as Restated

8. INCOME TAX (AS RESTATED)

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains.

British Virgin Islands

Under the current laws of the British Virgin Islands (“BVI”), Legend BVI is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Group’s subsidiaries incorporated in the British Virgin Islands to their shareholders, no withholding tax will be imposed.

Hong Kong

Under the current laws of Hong Kong, the subsidiary which operates in Hong Kong is subject to the two-tiered profits tax rates regime. The first HK$2,000,000 (2020 and 2019: HK$2,000,000) of assessable profits were taxed at 8.25% (2020 and 2019: 8.25%) and the remaining assessable profits were taxed at 16.5% (2020 and 2019: 16.5%). Under the Hong Kong tax law, the subsidiaries in Hong Kong are exempted from income tax on their foreign derived income and there are no withholding taxes in Hong Kong on remittance of dividends.

United States of America

Under the current laws of the United States of America (“USA”), the subsidiary which operates in the United States of America is subject to federal tax at a rate of 21% (2020 and 2019: 21%) and state tax at a rate of 9% (2020 and 2019: 9%) without including 2.5% NJ Surcharge due to the anticipated timing of utilization of the NJ NOL in New Jersey. The 2.5% NJ Surcharge will be expired as of December 31, 2023. Dividends payable by the Group’s US entity, to non US resident enterprises shall be subject to 30% withholding tax, unless the respective non US resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with US that provides for a reduced withholding tax rate or an exemption from withholding tax.

Ireland

Under the current laws of the Ireland, the subsidiary which operates in Ireland is subject to CIT at a rate of 12.5% (2020 and 2019: 12.5%) on its taxable trading income. Any non-trading income is subject to CIT at a rate of 25% (2020 and 2019: 25%). Dividend withholding tax is imposed on distributions made by Irish companies at a rate of 25% (2020: 25% and 2019: 20%) with many exemptions provided.

Mainland China

Pursuant to the Corporate Income Tax Law of the PRC and the respective regulations (the “CIT Law”), the subsidiaries which operate in Mainland China are subject to CIT at a rate of 25% on the taxable income. During the years ended December 31, 2021, 2020 and 2019, the applicable income tax rate was 25%. Dividends, interests, rent or royalties payable by the Group’s PRC entities, to non PRC resident enterprises, and proceeds from any such non-resident enterprise investor’s disposition of assets (after deducting the net value of such assets) shall be subject to 10% EIT, namely withholding tax, unless the respective non PRC resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.

Belgium

Under the current laws of Belgium, the subsidiary which operates in Belgium is subject to CIT at a rate of 25% on its taxable trading income. Dividend withholding tax is imposed on distributions made by Belgium companies at a rate of 30% with many exemptions provided.

Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the jurisdictions in which the Group operates.

	2021			2020			2019
	US$’000			US$’000			US$’000
Current – United States of America		211			(4,548	)		(2,933	)
Current – Elsewhere		416			383			(4,787	)
Deferred (note 22)		(4,241	)		(37,747	)		(18,009	)
Total tax credit for the year		(3,614	)		(41,912	)		(25,729	)

A reconciliation of the tax charge/(credit) applicable to loss before tax at the statutory rates for the countries (or jurisdictions) in which the Company and the majority of its subsidiaries are domiciled to the tax expense/(credit) at the effective tax rates is as follows:

	2021						2020						2019
	US$’000			%			US$’000			%			US$’000			%
Loss before tax		(407,196	)					(308,285	)					(127,319	)
At the statutory blended income tax rate of 28.1% (2020 and 2019: 28.1%)		(114,463	)		28.1			(86,659	)		28.1			(35,789	)	28.1
Effect of tax rate differences in other countries and regions		15,027			(3.7	)		35,062			(11.4	)		5,528			(4.3	)
Research and development credit		(954	)		0.2			(15,643	)		5.1			(3,324	)		2.6
Effect of non-deductible expenses		2,298			(0.6	)		383			(0.1	)		1,532			(1.2	)
Tax losses and deductible temporary differences not recognized		102,481			(25.2	)		26,040			(8.4	)		5,212			(4.1	)
Option income tax benefit		(9,532	)		2.3			(442	)		0.1			—			—
Others		1,529			(0.4	)		(653	)		0.2			1,112			(0.9	)
Tax credit at the Group’s effective rate		(3,614	)		0.9			(41,912	)		13.6			(25,729	)		20.2

The Group’s provision for income tax related to uncertain tax position with penalty and interest accrued including in the tax payables for the years ended December 31, 2021, 2020 and 2019 was as follows:

	2021		2020		2019
	US$’000		US$’000		US$’000
Balance as of December 31		9,488		8,795		12,782

The Group’s uncertain tax positions arose from a temporary inconsistency between the tax filings and accounting book for collaboration revenue. The Group has recorded the tax provision based on the most likely amounts and included the amounts in the consolidated statements of financial position but has not made revisions to the tax filing.

Loss per Share Attributable to Ordinary Equity Holders of the Parent as Restated

12 Months Ended

Dec. 31, 2021

Basic Earnings Per Share [Abstract]

Loss per Share Attributable to Ordinary Equity Holders of the Parent as Restated

9. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (AS RESTATED)

The calculation of the basic loss per share amount is based on the loss for the year attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 281,703,291, 236,305,234 and 200,000,000 in issue during the years ended December 31, 2021, 2020 and 2019, respectively.

The calculation of the diluted earnings per share amount is based on the loss for the year attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the year, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise of all dilutive potential ordinary shares into ordinary shares.

No adjustment has been made to the basic loss per share amounts presented for the years ended December 31, 2021, 2020 and 2019 in respect of a dilution as the impact of the outstanding share options, restricted stock units and warrant liability had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	2021			2020			2019
	US$’000			US$’000			US$’000
Earnings
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation		(403,582	)		(266,373	)		(101,590	)

	Number of shares
	2021		2020		2019
Shares
Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation		281,703,291		236,305,234		200,000,000

Property, Plant and Equipment as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Property Plant And Equipment [Abstract]

Property, Plant and Equipment as Restated

10. PROPERTY, PLANT AND EQUIPMENT (AS RESTATED)

	Freehold land		Buildings			Leasehold improvement			Machinery and equipment			Computer, fixtures, and office equipment			Transportation equipment			Construction in progress			Total
	US’000		US$’000			US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
December 31, 2021
At January 1, 2021
Cost		2,889		11,210			11,887			25,841			3,281			44			27,811			82,963
Accumulated depreciation		—		(817	)		(1,854	)		(6,514	)		(1,426	)		(10	)		—			(10,621	)
Net carrying amount		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342
At January 1, 2021, net of accumulated depreciation		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342
Additions		—		—			—			1,603			7			—			37,269			38,879
Disposals		—		—			(859	)		(177	)		(77	)		—			—			(1,113	)
Depreciation provided during the year		—		(543	)		(1,833	)		(4,967	)		(792	)		(4	)		—			(8,139	)
Exchange realignment		—		—			123			358			10			1			45			537
Transfers		—		4,801			9,941			8,675		341				—			(23,758	)	—
At December 31, 2021, net of accumulated depreciation		2,889		14,651			17,405			24,819			1,344			31			41,367			102,506
At December 31, 2021:
Cost		2,889		16,011			20,908			35,251			2,977			45			41,367			119,448
Accumulated depreciation		—		(1,360	)		(3,503	)		(10,432	)		(1,633	)		(14	)		—			(16,942	)
Net carrying amount		2,889		14,651			17,405			24,819			1,344			31			41,367			102,506

	Freehold land		Buildings			Leasehold improvement			Machinery and equipment			Computer, fixtures, and office equipment			Transportation equipment			Construction in progress			Total
	US’000		US$’000			US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
December 31, 2020
At January 1, 2020
Cost		2,889		10,072			10,382			20,802			1,297		42				3,687			49,171
Accumulated depreciation		—		(330	)		(770	)		(2,537	)		(340	)		(6	)		—			(3,983	)
Net carrying amount		2,889		9,742			9,612			18,265		957			36				3,687			45,188
At January 1, 2020, net of accumulated depreciation		2,889		9,742			9,612			18,265			957			36			3,687			45,188
Additions		—		—			—			—			560			—			31,625			32,185
Disposals		—		—			—			(165	)		—			—			—			(165	)
Depreciation provided during the year		—		(487	)		(1,019	)		(3,638	)		(1,086	)		(4	)		—			(6,234	)
Exchange realignment		—		—		375				775			12			2			204			1,368
Transfers		—		1,138			1,065			4,090			1,412			—			(7,705	)		—
At December 31, 2020, net of accumulated depreciation		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342
At December 31, 2020:
Cost		2,889		11,210			11,887			25,841			3,281			44			27,811			82,963
Accumulated depreciation		—		(817	)		(1,854	)		(6,514	)		(1,426	)		(10	)		—			(10,621	)
Net carrying amount		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342

Intangible Assets

12 Months Ended

Dec. 31, 2021

Disclosure Of Intangible Assets [Abstract]

Intangible Assets

11. INTANGIBLE ASSETS

	Software
	US$’000
December 31, 2021
At January 1, 2021
Cost		3,186
Accumulated amortization		(334	)
Net carrying amount		2,852
At January 1, 2021, net of accumulated amortization		2,852
Additions		3,207
Amortization provided during the year		(1,379	)
Exchange realignment		4
At December 31, 2021, net of accumulated amortization		4,684
At December 31, 2021
Cost		6,402
Accumulated amortization		(1,718	)
Net carrying amount		4,684
December 31, 2020
At January 1, 2020
Cost		598
Accumulated amortization		(79	)
Net carrying amount		519
At January 1, 2020, net of accumulated amortization		519
Additions		2,583
Amortization provided during the year		(192	)
Exchange realignment		(58	)
At December 31, 2020, net of accumulated amortization		2,852
At December 31, 2020
Cost		3,186
Accumulated amortization		(334	)
Net carrying amount		2,852

Other Non-Current Assets as Restated

12 Months Ended

Dec. 31, 2021

Categories Of Current Financial Assets [Abstract]

Other Non-Current Assets as Restated

12. OTHER NON-CURRENT ASSETS (AS RESTATED)

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Value-added Tax (“VAT”) recoverable		4,080		3,542
Prepaid expenses		1,068		431
Collaboration Assets-Prepaid Lease		12,121		9,216
		17,269		13,189

Leases as Restated

12 Months Ended

Dec. 31, 2021

Lease [Abstract]

Leases as Restated

13. LEASES (AS RESTATED)

The Group as a lessee

The Group has lease contracts for leasehold land and buildings. Leases of buildings (including car park spaces) generally have lease terms between 2 and 10 years. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of 50 years, and no ongoing payments will be made under the terms of these leasehold land. Other buildings and rooms generally have lease terms of 12 months or less from the commencement date and do not contain a purchase option. The group applies the short-term lease recognition exemption to its short-term leases. Collaboration assets represent the Group’s share of assets leased to the collaboration from Janssen, which purchased the assets on behalf of the collaboration, in connection with the Janssen Agreement. Collaboration assets under construction that will be leased to the collaboration from Janssen when placed into service are classified as Collaboration Assets – Prepaid Lease in note 12 to the financial statements.

(a)

Right-of-use assets

	December 31,		December 31,
	2021		2020
	US$’000		US$’000
Leasehold land		4,862		4,851
Lease buildings		2,324		3,158
Collaboration assets		31,097		31,533
		38,283		39,542

The carrying amounts of the Group’s right-of-use assets and the movements during the year are as follows:

	Non-Collaboration Assets Leased						Collaboration Assets Leased
	Leasehold land			Buildings			Buildings			Machinery And equipment			Computer and office equipment			Total
	US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
December 31, 2021
Right-of-use assets at January 1, 2021		4,851			3,158			21,311			10,201		21				39,542
Additions		—			678		7				2,517		—				3,202
Disposals		—			(59	)	—				(53	)	—				(112	)
Exchange realignment		112			(62	)	—				—		—			50
Depreciation of right-of-use assets		(101	)		(1,391	)		(1,411	)		(1,491	)		(5	)		(4,399	)
Right-of-use assets at December 31, 2021		4,862			2,324			19,907			11,174		16				38,283
December 31, 2020
Right-of-use assets at January 1, 2020		4,630			4,718			11,639			6,787		16				27,790
Additions		—			491			10,726			4,369		10				15,596
Lease modifications		—			(928	)	—			—			—				(928	)
Exchange realignment		318			273		—			—			—			591
Depreciation of right-of-use assets		(97	)		(1,396	)		(1,054	)		(955	)		(5	)		(3,507	)
Right-of-use assets at December 31, 2020		4,851			3,158			21,311			10,201		21				39,542

(b) Lease liabilities

Lease liabilities are as indicated below:

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term.

	2021			2020
	US$’000			US$’000
Carrying amount at January 1		3,373			6,085
Additions		678			491
Lease modifications		—			(928	)
Disposals		(68	)		—
Accretion of interest recognized during the year		142			195
Payments		(1,561	)		(2,797	)
Exchange realignment		(60	)		327
Carrying amount at December 31		2,504			3,373
Analyzed into:
Current portion		911			1,464
Non-current portion		1,593			1,909
		2,504			3,373

	2021		2020
	US$’000		US$’000
Interest on lease liabilities		142		195
Depreciation charge of right-of-use assets		4,399		3,507
Expense relating to short-term leases		182		69
Total amount recognized in profit or loss		4,723		3,771

The maturity analysis of lease liabilities is disclosed in note 35 to the financial statements. The total cash outflow for leases is disclosed in note 30 (c) to the financial statements.

The Group as a lessor

The Group leases its right-of-use assets above consisting of five car parking spaces in Ireland for a lease term of 12 months. For these operating leases, rental income recognized by the Group for the year ended December 31, 2021 was US$13,000 (2020: 4,000). The Group also leases assets it owns to the collaboration in accordance with the Janssen Agreement. These are finance leases for which the Group did not recognize any finance income for the year ended December 31, 2021 and 2020 because the Group’s collaboration partner pre-paid these lease payments.

At December 31, 2021 and 2020, the undiscounted minimum lease payments receivables by the Group in future periods under non-cancellable finance leases and operating leases with its tenants are as follows:

	2021		2020
	US$’000		US$’000

Finance leases:
Within one year		94		619

Operating leases:
Within one year		13		4

Convertible Redeemable Preferred Shares

12 Months Ended

Dec. 31, 2021

Disclosure Of Classes Of Share Capital [Abstract]

Convertible Redeemable Preferred Shares

14. CONVERTIBLE REDEEMABLE PREFERRED SHARES

On March 30, 2020 and on April 16, 2020, the Company issued a total of 20,591,629 Series A convertible redeemable preferred shares (the “Series A Preference Shares”) to independent third parties, at the price of US$7.792 per share for an aggregate purchase consideration of US$160.5 million.

The key terms of the Series A Preference Shares are summarized as follows:

(1) Dividends rights

Each Series A Preference Shares holder is entitled to dividends at the rate of 8% of the Series A original issue price per annum per share shall accrue on such Series A Preference Shares. Such dividends (i) will be declared by the board of directors and paid to the holders of Series A Preference Shares each fiscal quarter, or (ii) if not declared and, with respect to any fiscal quarter, paid to the holders of Series A Preference Shares within thirty days after such fiscal quarter, such undeclared and unpaid dividends will accrue day to day from the last day of such fiscal quarter, will be cumulative and compound annually, and will only be paid upon a redemption or liquidation event or converted into ordinary shares upon an initial public offering.

(2) Conversion rights

Optional conversion

Each Series A Preference Share is convertible, at the option of the holder, at any time after the date of issuance of such Series A Preference Share, into such number of fully paid and non-assessable ordinary shares as is determined by dividing the Series A original issue price, by a conversion price equal to the lower of (i) the conversion price at the time in effect for such Series A Preference Share and (ii) the price per share that equals the lowest net price per ordinary share received by the Company in a public offering that is not a Qualified IPO.

Automatic conversion

Each Series A Preference Share will be automatically converted upon the closing of a Qualified IPO into a number of ordinary shares as is determined by dividing the Series A original issue price by a conversion price is equal to the lower of (i) the conversion price at the time in effect for such Series A Preference Share and (ii) the price per share that equals 90% of the lowest net price per ordinary share received by the Company in the Qualified IPO.

(3) Redemption rights

At any time on or after the occurrence of a Trigger Event (as defined below), each investor may require the Company to redeem the Series A Preference Shares issued to the investor and require the Company to immediately pay the investor an amount equal to the redemption price, plus 8% annualized. A “Trigger Event” means the occurrence of one or more of the following events: (A) as of September 30, 2021, the Company has not consummated a qualified IPO, (B) the Company consummates a non-Qualified IPO, (C) the License Agreement (i) is terminated as a result of a material breach by any party thereto or (ii) is amended in such a way that with (or without) the passage of time would reasonably be expected to adversely affect the value of the Company or the Series A Preference Shares in any material respect and (D) there occurs or it is discovered that there is a material adverse issue with respect to the patents, know-how and all other intellectual property owned or controlled by the Company or its affiliates and licensed to a customer under a license and collaboration agreement, which is not capable of being cured within a reasonable period.

(4) Liquidation

Upon any liquidation, dissolution or winding up of the Company (collectively, a “Liquidation Event”), before any distribution or payment shall be made to the holders of any Ordinary Shares, the holders of Series A Preference Shares will be entitled to be paid out of the assets of the Company legally available for distribution for each Series A Preference Share, an amount per Series A Preference Share equal to the sum of (i) the Series A Original Issue Price,

plus (ii) any accrued but unpaid Dividends on each Series A Preference Share. If, upon any such Liquidation Event, the assets of the Company will be insufficient to make payment in full to all holders of Series A Preference Shares, then such assets (or consideration) will be distributed among the holders of Series A Preference Shares at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled.

All Series A Preferred Shares were converted into ordinary shares of the Company and all accrued but unpaid dividends were settled in the form of ordinary shares upon qualified IPO in June 2020. A fair value loss of $80.0 million was recorded in the fiscal year ended December 31, 2020 due to change in fair value upon conversion.

Inventories

12 Months Ended

Dec. 31, 2021

Classes Of Inventories [Abstract]

Inventories

15. INVENTORIES

December 31,

2021

December 31,

2020

US$’000

Raw materials and consumables

1,749

1,800

Trade Receivables as Restated

12 Months Ended

Dec. 31, 2021

Trade And Other Receivables [Abstract]

Trade Receivables as Restated

16. TRADE RECEIVABLES (AS RESTATED)

December 31,

2021

December 31,

2020

US$’000

Trade receivables

50,410

75,000

The Group’s trading terms with its customers are mainly on credit. The credit period is 45 to 60 days. The Group seeks to maintain strict control over its outstanding receivables and overdue balances are reviewed regularly by management. Trade receivables are non-interest-bearing. The Group has concentration of credit risk as US$50.0 million (or 99.2%) and US$75.0 million (or 100%), respectively, of trade receivables were due from one single customer, Janssen, under a license and collaboration agreement as at December 31, 2021 and 2020. As at December 31, 2021, the remaining US$0.4 million of trade receivables were about royalties due from Nanjing Probio Biotech Co., Ltd. (note 32).

As at December 31, 2021 and 2020, the expected credit loss is insignificant.

Prepayments, Other Receivables and Other Assets as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]

Prepayments, Other Receivables and Other Assets as Restated

17. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS (AS RESTATED)

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Interest receivable		230		80
Other receivables		837		264
Income tax refund		4,712		4,712
VAT recoverable		2,264		1,941
Prepayments		5,715		3,455
		13,758		10,452

As at December 31, 2021 and 2020, amounts due from the Group’s related parties that are repayable on demand, which were included in the Group’s other receivables, were US$262,000 and US$20,000, respectively (note 32). As at December 31, 2021 and 2020, amounts prepaid to the Group’s related parties were US$1,199,000 and nil, respectively (note 32).

None of the above assets is either past due or impaired. The financial assets included in the above balances relate to receivables for which there was no recent history of default. The majority of the above balances were

settled within 12 months and had no history of default. The Group estimated that the expected credit loss for the above receivables as at December 31, 2021 and 2020 is insignificant.

Financial Assets Measured At Amortized Cost

12 Months Ended

Dec. 31, 2021

Categories Of Financial Assets [Abstract]

Financial Assets Measured At Amortized Cost

18. FINANCIAL ASSETS MEASURED AT AMORTIZED COST

December 31,

2021

December 31,

2020

US$’000

Financial assets measured at amortized cost

29,937

—

Financial assets measured at amortized cost was related to commercial paper issued by a financial institution with principal amount of US$30.0 million, discounted bid yield of 0.5% per annum and one year maturity date as June 1, 2022.

Cash and Cash Equivalents, Time Deposits and Pledged Deposits

12 Months Ended

Dec. 31, 2021

Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]

Cash and Cash Equivalents, Time Deposits and Pledged Deposits

19. CASH AND CASH EQUIVALENTS, TIME DEPOSITS AND PLEDGED DEPOSITS

	December 31, 2021			December 31, 2020
	US$’000			US$’000
Cash and bank balances		858,607			506,073
Less: Pledged deposits		(1,444	)		(384	)
Time deposits		(168,225	)		(50,000	)

Cash and cash equivalents		688,938			455,689

Denominated in USD		681,025			451,165
Denominated in RMB		5,875			4,335
Denominated in EUR		2,038			189

Cash and cash equivalents		688,938			455,689

The cash and bank balances of the Group denominated in Renminbi (“RMB”) amounted to US$5.9 million and US$4.3 million in the consolidated statements of financial position as at December 31, 2021 and 2020, respectively. The RMB is not freely convertible into other currencies, however, under Mainland China’s Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorized to conduct foreign exchange business.

The pledged deposit as at December 31, 2021 was pledged for issuing a letter of guarantee to a supplier of the Group and for credit card facilities. The pledged deposit as at December 31, 2020 was pledged for issuing bank acceptance notes to suppliers of the Group and credit card facilities.

Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default. The carrying amounts of the cash and cash equivalents approximate to their fair values.

Trade and Notes Payables

12 Months Ended

Dec. 31, 2021

Trade And Other Payables [Abstract]

Trade and Notes Payables

20. TRADE AND NOTES PAYABLES

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Trade payables		7,043		4,911
Notes payable		—		327
		7,043		5,238

The trade payables are non-interest-bearing and are normally settled on 30-day terms.

As at December 31, 2021 and 2020, amounts due to the Group’s related parties, included in the Group’s trade payables, were US$2.4 million and US$2.1 million, respectively (note 32).

Other Payables and Accruals as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Other Payables And Accruals [Abstract]

Other Payables and Accruals as Restated

21. OTHER PAYABLES AND ACCRUALS (AS RESTATED)

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Accrued payroll		19,207		13,609
Accrued expense		81,364		56,863
Other payables		16,867		25,760
Payable for Collaboration Assets		5,605		3,399
Other tax payables		515		156
		123,558		99,787

Other payables are non-interest-bearing and repayable on demand.

As at December 31, 2021 and 2020, amounts due to the Group’s related parties, included in the Group’s other payables, were US$3.3 million and US$3.7 million, respectively (note 32).

Deferred Tax as Restated

12 Months Ended

Dec. 31, 2021

Deferred Tax Assets And Liabilities [Abstract]

Deferred Tax as Restated

22. DEFERRED TAX (AS RESTATED)

The movements in deferred tax liabilities and assets during the years ended December 31, 2021 and 2020 are as follows:

Deferred tax liabilities

	Collaboration revenue			Difference allowance in excess of related depreciation			Right of use assets			Total
	US$’000			US$’000			US$’000			US$’000
At January 1, 2020		(42,317	)		(5,387	)	—				(47,704	)
Deferred tax charged/(credited) to the statement of profit or loss during the year		14,106			(1,285	)		(159	)		12,662
Gross deferred tax liabilities at December 31, 2020		(28,211	)		(6,672	)		(159	)		(35,042	)
At January 1, 2021		(28,211	)		(6,672	)		(159	)		(35,042	)
Deferred tax charged/(credited) to the statement of profit or loss during the year		14,086			(1,964	)		159			12,281
Gross deferred tax liabilities at December 31, 2021		(14,125	)		(8,636	)	—				(22,761	)

Deferred tax assets

	Losses available for offsetting against future taxable profits		Difference in intangible assets amortization			Accrued expense		Lease liabilities			R&D credit			Total
	US$’000		US$’000			US$’000		US$’000			US$’000			US$’000
At January 1, 2020		216		4,845			—		—			655			5,716
Deferred tax charged to the statement of profit or loss during the year		14,865		497			608		165			8,950			25,085
Gross deferred tax assets at December 31, 2020		15,081		5,342			608		165			9,605			30,801
At January 1, 2021		15,081		5,342			608		165			9,605			30,801
Deferred tax charged to the statement of profit or loss during the year		5,367		(4,286	)		649		(165	)		(9,605	)		(8,040	)
Gross deferred tax assets at December 31, 2021		20,448		1,056			1,257		—			—			22,761

For presentation purposes, certain deferred tax assets and liabilities have been offset in the statement of financial position. The following is an analysis of the deferred tax balances of the Group for financial reporting purposes:

2021

2020

US$’000

Net deferred tax liabilities recognised in the consolidated statement of

financial position

—

4,241

The Group has tax losses arising in Hong Kong of US$38,000 in 2021 (2020: US$25,000) that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose.

The Group has tax losses arising in Mainland China of US$91.8million in 2021 (2020: US$60.0 million) that will expire in 5 years for offsetting against future taxable profits of the companies in which the losses arose.

The Group has tax losses arising in Ireland of US$82.9 million in 2021 (2020 US$71.3 million) that can be carried back for 1 year and carried forward indefinitely for offsetting against taxable profits of the company.

The Group has tax losses arising in the United States of America of US$226.6 million in 2021 (2020: nil) that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose.

The Group has tax losses arising in Belgium of US$0.5 million in 2021 (2020: nil) that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose.

Deferred tax assets have not been recognized in respect of these tax losses as it is not considered probable that taxable profits will be available against which the tax losses can be utilized.

Deferred tax assets have not been recognized in respect of the following items:

	2021		2020
	US$’000		US$’000
Deductible temporary differences		15,420		12,842
Tax losses		609,200		200,523
		624,620		213,365

Deferred income tax assets are recognized for tax losses carried-forward to the extent that realization of the related tax benefit through future taxable profits is probable. Deferred tax assets have not been recognized in respect of the above items as it is not considered probable that taxable profits will be available against which the above items can be utilized.

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement is effective from January 1, 2008 and applies to earnings after December 31, 2007. A lower withholding tax rate may be applied if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors. For the Group, the applicable rate is 10%. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in Mainland China in respect of earnings generated from January 1, 2008.

At December 31, 2021 and 2020, the subsidiaries in Mainland China had no distributable retained earnings.

According to the US tax laws, dividends payable by the Group’s US entity, to non-US resident enterprises shall be subject to 30% withholding tax. A lower withholding tax rate may be applied if there is a tax treaty between US and the jurisdiction of the foreign investors. For the Group, the applicable rate is 5%. The Group is therefore liable for withholding taxes on dividends distributed by those subsidiaries established in US.

At December 31, 2021 and 2020, the subsidiary in US had no distributable retained earnings.

Warrant Liability

12 Months Ended

Dec. 31, 2021

Disclosure Of Reserves Within Equity [Abstract]

Warrant Liability

23. WARRANT LIABILITY

On May 13, 2021, the Company entered into a subscription agreement with an institutional investor relating to the offer and sale of 20,809,850 ordinary shares of the Company, par value US$0.0001 per share, in a private placement at a purchase price of US$14.41625 per ordinary share (the “PIPE Offering”). The total proceeds from the PIPE Offering is US$300.0million. Pursuant to the subscription agreement, the Company also agreed to issue and sell concurrently with the PIPE offering a warrant (the “Warrant”) exercisable for up to an aggregate of 10,000,000 ordinary shares (such transaction together with the PIPE Offering, the “Transactions”). The Transactions were completed on May 21, 2021(the “Closing Date”). The Warrant is exercisable, in whole or in part, at an exercise price of US$20.00 per ordinary share, at any time prior to the two-year anniversary of the Closing Date.

The Warrant is accounted for as a financial liability because the Warrant may be net share settleable at the holder’s option. The fair value of the warrant liability is assessed at US$81.7 million and is recognized upon closing of the Transactions. As of December 31, 2021, the fair value of the Warrant was assessed at US$87.9 million. A fair value loss of US$6.2 million was recorded in profit or loss for the year ended December 31, 2021 due to change of the fair value. Management considered that there is no significant change of the Company’s own credit risk that drives the fair value change of the warrant liability during the year ended December 31, 2021.

The movement of the warrant liability is set out as below:

	Total
	US$’000
At January 1, 2021		—
Issuance of the warrant liability		81,700
Fair value loss of the warrant liability		6,200
At December 31, 2021		87,900

Government Grants

12 Months Ended

Dec. 31, 2021

Government Grant [Abstract]

Government Grants

24. GOVERNMENT GRANTS

	2021		2020
	US$’000		US$’000
Deferred government grants		2,170		2,334
Current		304		283
Non-current		1,866		2,051

The grants were related to the subsidies received from local government authorities for the purpose of compensation for the expenditure on certain facilities and were credited to a deferred income account. The grants were released to other income and gains over the expected useful lives of the relevant assets. The group also received certain financial subsidies from local government authorities to support local business. There were no unfulfilled conditions and other contingencies attached to these government grants. These government grants were recognized in other income and gains upon receipt.

Interest-Bearing Loans and Borrowings

12 Months Ended

Dec. 31, 2021

Disclosure Of Detailed Information About Borrowings [Abstract]

Interest-Bearing Loans and Borrowings

25. INTEREST-BEARING LOANS AND BORROWINGS

Effective interest rate

Maturity

December 31,

2021

US$’000

Non-current

Loans from a collaborator

3.03

No specific maturity date

120,462

Pursuant to the license and collaboration agreement entered into with a collaborator, the Company is entitled to receive funding advances from the collaborator when certain operational conditions are met. As a result, the Company took an initial funding advance with principal amounting to US$17.3 million on June 18, 2021, a second funding advance with principal amounting to US$53.1 million on September 17, 2021, and a third funding advance with principal amounting to US$49.3 million on December 17, 2021, by reducing the same amount of other payables due to the collaborator, respectively (collectively, the “Funding Advances”).

These Funding Advances are accounted for as interest-bearing borrowings funded by the collaborator, constituted by a principal amounting to US$119.7 million and applicable interests accrued amounting to US$0.8 million upon such principal. The respective interest rate of each borrowing is based on the average annual London Interbank Offered Rate (LIBOR) for U.S. Dollars as reported in the Wall Street Journal on the due date of the quarterly invoice or the next business date should the due date fall on a weekend or holiday, plus 250 basis points, calculated on the number of days from the date on which the Company applied such borrowings. For each of the three batches of funding advances, interest started to accrue from June 18, 2021, September 17, 2021 and December 17, 2021, respectively.

Pursuant to the terms of the license and collaboration agreement, the collaborator may recoup the aggregate amount of Funding Advances together with interest thereon from Company’s share of pre-tax profits from the first profitable year of the collaboration program. The Company’s management estimated the loan will not be recouped

by the collaborator within one year, nor does the Company expect to repay the funding advances within one year, and thus the loan was classified as a long-term liability.

Share Capital and Share Premium

12 Months Ended

Dec. 31, 2021

Disclosure Of Classes Of Share Capital [Abstract]

Share Capital and Share Premium

26. SHARE CAPITAL AND SHARE PREMIUM

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Authorized:
2,000,000,000 shares of US$0.0001 each		200		200
Issued and fully paid:
308,456,852 (2020: 266,010,256) ordinary shares of US$0.0001 each		31		27

A summary of movements in the Company’s share capital and share premium is as follows:

	Number of shares in issue		Share capital		Share premium		Total
			US$’000		US$’000		US$’000
At December 31, 2019 and January 1, 2020		200,000,000	20			3,908		3,928

Issuance of ordinary shares for conversion of preferred shares		20,907,282	2			240,432		240,434
Issuance of ordinary shares for initial public offering, net of issuance cost		42,377,500	4			450,081		450,085
Issuance of ordinary shares for private placement by GenScript		1,043,478		—		12,000		12,000
Exercise of share options		1,681,996	1			1,885		1,886

At December 31, 2020 and January 1, 2021		266,010,256		27		708,306		708,333

Issuance of ordinary shares relating to private placement for an institutional investor (note 23)		20,809,850		2		218,298		218,300
Issuance of ordinary shares for follow-on public offering, net of issuance cost (note)		17,231,150		2		323,438		323,440
Exercise of share options		4,056,380		—		6,089		6,089
Reclassification of vesting of restricted stock units		349,216		—		5,323		5,323

At December 31, 2021		308,456,852		31		1,261,454		1,261,485

Note: On December 20, 2021, the Company completed a follow-on public offering by issuing 17,231,150 ordinary shares, in aggregate, at US$20.00 per ordinary share and received net proceeds of US$323.4 million, after deduction of related issuance costs of US$21.2 million.

Share Option Scheme

12 Months Ended

Dec. 31, 2021

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]

Share Option Scheme

27. SHARE OPTION SCHEME

The Company operates a share option scheme (the “Scheme”) for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. Eligible participants of the Scheme include the Company’s directors, including independent non-executive directors, and employees of any member of the Group. The Scheme became effective on December 21, 2017 and, unless otherwise cancelled or

amended, will remain in force for 10 years from that date. The Scheme has a performance vesting condition and is subject to forfeiture if the participants cannot meet certain performance targets set by the board of directors.

Share options do not confer any voting rights, or rights to participate in any dividends or distributions. The following share options were outstanding under the Scheme during the year:

	2021					2020					2019
	Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options
	US$ per share		’000			US$ per share		’000			US$ per share		’000
At January 1,		1.9353		14,241			0.9273		18,013			0.7782		14,311
Granted during the year		15.4774		595			15.6128		679			1.4973		3,757
Forfeited during the year		2.9987		(1,251	)		0.9963		(2,769	)		1.0909		(55	)
Exercised during the year		1.3346		(4,056	)		1.0131		(1,682	)	—		—
At December 31,		2.8970		9,529			1.9353		14,241			0.9273		18,013
Exercisable at December 31		1.4334		2,828			1.0703		4,619			0.7852		2,484

The weighted average share price at the date of exercise for share options exercised during the year was US$18.4846 per share (2020: US$14.9131, 2019: No share options were exercised).

The exercise prices and exercise periods of the share options outstanding as at the end of the reporting period are as follows:

December 31, 2021
Number of options ’000		Exercise price* US$ per share		Exercise period
	4,054		0.5	2019/12/25 – 2027/12/25
	1,849		1.0	2019/07/01 – 2028/08/29
	382		1.0	2019/12/31 – 2028/12/30
	1,822		1.5	2020/07/02 – 2029/07/01
	332		11.5	2020/11/29 – 2029/11/28
	90		11.5	2021/06/05 – 2030/06/04
	385		16.3	2021/09/01 – 2030/08/31
	20		13.6	2021/11/19 – 2030/11/18
	430		14.1	2022/03/29 – 2031/03/28
	165		19.0	2022/08/27 – 2031/08/26
	9,529

December 31, 2020
Number of options ’000		Exercise price* US$ per share		Exercise period
	5,393		0.5	2019/12/25 - 2027/12/25
	4,317		1.0	2019/07/01 - 2028/08/29
	540		1.0	2019/12/31 - 2028/12/30
	2,868		1.5	2020/07/02 - 2029/07/01
	444		11.5	2020/11/29 - 2029/11/28
	90		11.5	2021/06/05 - 2030/06/04
	569		16.3	2021/09/01 - 2030/08/31
	20		13.6	2021/11/19 - 2030/11/18
	14,241

December 31, 2019
Number of options ’000		Exercise price* US$ per share		Exercise period
	6,347	0.5		2019/12/25 - 2027/12/25
	7,283		1.0	2019/07/01 - 2028/08/29
656			1.0	2019/12/31 - 2028/12/30
	3,225	1.5		2020/07/02 - 2029/07/01
502		1.5		2020/11/29 - 2029/11/28
	18,013

The exercise price of the share options is subject to adjustment in the case of rights or bonus issues, or other similar changes in the Company’s share capital. Pursuant to certain listing rules of the Hong Kong Stock Exchange to which members of the Genscript Group are subject to, the Company adjusted the exercise price of options granted during November 29, 2019 through December 9, 2019 to $11.50 per share. Concurrent with this adjustment, the Company agreed to pay each employee holding affected share options an amount in cash representing the difference between the adjusted exercise price over the original exercise price upon exercising the share options.

The fair value of the share options granted during the year ended December 31, 2021 was US$5.7 million (US$9.497 each) (2020: US$6.7 million, US$9.817 each; 2019: US$1.1 million, US$0.294 each). The Group recognized share option expense of US$2.4 million (2020: US$1.9 million, 2019: US$1.3 million) during the year ended December 31, 2021.

The fair value of equity-settled share options granted during the period was estimated, using a binomial model, taking into account the terms and conditions upon which the options were granted. The following table lists the inputs to the model used:

	2021		2020		2019
Dividend yield (%)		—		—		—
Expected volatility (%)	73.2-76.4		73.0-87.2		66.4-80.3
Risk-free interest rate (%)	0.03-1.72		0.07-0.91		1.98-2.69
Expected life of options (year)		10		10		10

The volatility measured at the standard deviation of expected share price returns is based on statistical analysis of comparable listed companies in the same industry. The weighted average share price was US$15.4774 used in the share option fair value valuation model during the year ended December 31, 2021.

As at December 31, 2021, the Company had 9,529,158 share options outstanding under the Scheme. The exercise in full of the outstanding share options would, under the present capital structure of the Company, result in

the issue of 9,529,158 additional ordinary shares of the Company, an additional share capital of US$953 and a share premium of US$27.6 million (before issue expenses).

At the date of approval of these financial statements, the Company had 9,529,158 share options outstanding under the share option scheme, which represented approximately 3.1% of the Company's shares in issue as at that date.

Restricted Stock Units

12 Months Ended

Dec. 31, 2021

Restricted Stock Units [Abstract]

Restricted Stock Units

28. RESTRICTED STOCK UNITS

The Company operates a restricted stock units scheme (the “RSU Scheme”) for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group’s operations. Eligible participants of the Scheme include the Company’s directors, including independent non-executive directors, and employees of any member of the Group. The Scheme became effective on May 26, 2020 and, unless otherwise cancelled or amended, will remain in force for 10 years from that date. The Scheme has a performance vesting condition and is subject to forfeiture if the participants cannot meet certain performance target set by the board of directors.

The movement in the number of RSU outstanding for the year ended 31 December 2021 and 2020 was as follow:

	2021
	Number of RSU			Weighted average grant date fair value
	’000			US$ per unit
Outstanding at January 1	1,113			15.3409
Granted during the year	2,133			15.0120
Vested during the year	(349		)	15.2420
Forfeited during the year		(296	)	14.4913
Outstanding at December 31	2,601			15.1808

	2020
	Number of RSU			Weighted average grant date fair value
	’000			US$ per unit
Outstanding at January 1, 2020	—			—
Granted during the year	1,139			15.3639
Forfeited during the year		(26	)	16.3350
Outstanding at December 31, 2020	1,113			15.3409

The weighted-average remaining contractual life for outstanding RSUs granted under the RSU Scheme was 8.16 years and 8.84 years as of December 31, 2021 and 2020, respectively.

The fair value of the awarded shares was calculated based on the market price of the Group’s shares at the respective grant date.

The fair value of the RSU granted during the period was US$32.0 million (US$15.012 each), of which the Group recognized RSU expense of US$17.8 million during the year ended 31 December 2021.

The fair value of the RSU granted during the period was US$17.5 million (US$15.364 each), of which the Group recognized RSU expense of US$2.9 million during the year ended 31 December 2020.

At the date of approval of these financial statements, the Company had 2,601,187 RSUs outstanding under the restricted shares plan, which represented approximately 0.8% of the Company's shares in issue as at that date.

Reserves as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Reserves Within Equity [Abstract]

Reserves as Restated

29. RESERVES (AS RESTATED)

The amounts of the Group’s reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity of the consolidated financial statements.

The foreign currency translation reserve comprises all foreign exchange differences arising from the translation of the financial statements of operations with a functional currency other than US$.

Under PRC laws and regulations, there are restrictions on the Company’s PRC subsidiaries with respect to transferring certain of their net assets to the Company either in the form of dividends, loans, or advances. Amounts of net assets restricted include paid in capital and reserve funds of the Company’s PRC subsidiary, totaling US$71.9 million and US$31.9 million as at December 31, 2021 and 2020, respectively.

Notes to the Consolidated Statement of Cash Flows as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]

Notes to the Consolidated Statement of Cash Flows as Restated

30. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (AS RESTATED)

(a) Major non-cash transactions

For the year ended December 31, 2021, the Group had non-cash additions to interest-bearing loans and borrowings of US$119.7 million which was received through the deduction of other payables to a collaborator.

For the year ended December 31, 2021, the Group had non-cash fair value loss of US$6.2 million of warrant liability.

For the year ended December 31, 2021, the Group had non-cash prepayment of US$1.5 million in exchange of research and development service from Nanjing Probio Biotech Co., Ltd. and Jiangsu GenScript Probio Biotech Co., Ltd.

For the years ended December 31, 2021, 2020 and 2019, the Group had non-cash additions to right-of-use assets of US$0.7 million, US$0.5 million and US$2.2 million, and lease liabilities of US$0.7 million, US$0.5 million and US$2.2 million, in respect of lease arrangements for buildings, respectively.

For the years ended December 31, 2021, 2020 and 2019, the Group had non-cash additions to lease receivables of US$0.3 million, US$0.6 million and US$0.7 million, respectively, resulting from financial leases for the assets leased to the collaboration, and settled lease receivables of US$0.2 million, nil and US$0.7 million, respectively, through the deduction of other payable to the collaboration partner.

For the years ended December 31, 2021, 2020 and 2019, the Group had non-cash additions to other non-current assets included in the other payables and accruals for the assets leased from the collaboration partner of US$7.6 million, US$5.2 million and US$6.8 million, respectively, and had non-cash additions to property, plant and equipment included in other payables and accruals of US$6.7 million, US$8.6 million and US$2.2 million, respectively.

For the year ended December 31, 2020, the Group had non-cash additions to finance costs of US$1.5 million and other payable of US$1.5 million, in respect of expenses for convertible redeemable preferred shares.

For the year ended December 31, 2020, the Group had non-cash fair value loss of $80.0 million of convertible redeemable preferred shares.

For the year ended December 31, 2019, Genscript Biotech Corporation utilized the balance due from the Group to settle the balance due to Genscript USA Incorporated in the amount of US$4.4 million.

For the year ended December 31, 2019, Genscript Biotech Corporation and Genscript USA Incorporated utilized the outstanding balance due from the Group to settle part of the outstanding balance due to the Group of US$19.5 million and US$5.5 million, respectively.

(b) Changes in liabilities arising from financing activities

	Convertible redeemable preferred shares			Other payables to related parties			Lease liabilities
	US$’000			US$’000			US$’000
At January 1, 2021		—			—			3,373
Additions of lease liabilities		—			—			678
Changes from financing cash flows		—			—			(1,419	)
Disposal		—			—			(68	)
Interest expense		—			—			142
Interest paid classified as operating cash flows		—			—			(142	)
Foreign exchange movement		—			—			(60	)
At December 31, 2021		—			—			2,504
At January 1, 2020		—			4			6,085
Additions of lease liabilities		—			—			(437	)
Changes from financing cash flows		160,450			(4	)		(2,602	)
Interest expense		—			—			195
Interest paid classified as operating cash flows		—			—			(195	)
Fair value loss of the convertible redeemable preferred shares		79,984			—			—
Conversion to ordinary shares		(240,434	)		—			—
Foreign exchange movement		—			—			327
At December 31, 2020		—			—			3,373
At January 1, 2019		—			4,688			4,317
Additions of lease liabilities		—			—			6,840
Changes from financing cash flows		—			19,722			(5,056	)
Non-cash transaction (note 30(a))		—			(24,374	)		—
Interest expense		—			—			199
Interest paid classified as operating cash flows		—			—			(199	)
Foreign exchange movement		—			(32	)		(16	)
At December 31, 2019		—			4			6,085

The total cash outflow for leases included in the statement of cash flows is as follows:

	2021		2020		2019
	US$’000		US$’000		US$’000
Right-of-use assets
Within operating activities		142		195		199
Within financing activities		1,419		2,602		5,056
Short-term leases		182		69		272
		1,743		2,866		5,527

Commitments and Contingencies as Restated

12 Months Ended

Dec. 31, 2021

Capital Commitments [Abstract]

Commitments and Contingencies as Restated

31. COMMITMENTS AND CONTINENCIES (AS RESTATED)

(a)

Capital commitments

The Group had the following capital commitments at the end of the year:

	2021		2020		2019
	US$’000		US$’000		US$’000
Construction in progress		25,897		33,637		2,844

(b)

Loss contingencies

In September 2021, a former employee elected to enter into arbitration against Legend Biotech USA Inc. (“Legend USA”) with the American Arbitration Association, claiming such former employee was discriminated against due to her gender and wrong fully terminated in retaliation for engaging in alleged protected activity. The former employee demanded Legend USA to pay damages of approximately US$3.0 million for alleged lost pay, lost equity, damage to reputation, emotional distress and other related losses.

Management believes that the former employee’s claims above are without merit and intends to defend vigorously. At the early stage of the process, management cannot predict the ultimate outcome of the above claims, whether in whole or in part, which may result in a loss, if any. Therefore, in the opinion of management and legal counsel, an estimate of the amount or arrange of reasonably possible losses cannot be made at this time. Accordingly, no provision for any liability has been made in the financial statements.

We are party to a lease with Janssen under which we expect to lease an approximately 106,000 square foot manufacturing facility from Janssen located in Raritan, New Jersey. That lease will become effective and recorded as a lease in a future date contingent on the FDA’s approval of our or BLA for cilta-cel, which we referred to as the Facility Transition Date. For this facility, which we collaboratively operate with Janssen, we continue to invest in manufacturing, quality, information technology and distribution capabilities to support the launch of CARVYKTI™.

Related Party Transactions

12 Months Ended

Dec. 31, 2021

Disclosure Of Transactions Between Related Parties [Abstract]

Related Party Transactions

32. RELATED PARTY TRANSACTIONS

Company		Relationship
Nanjing GenScript Biotech Co., Ltd. (formerly named as Nanjing Jinsirui Biotechnology Co., Ltd.)		Company controlled by the ultimate holding company
Nanjing Bestzyme Bioengineering Co., Ltd.		Company controlled by the ultimate holding company
Jiangsu GenScript Biotech Co., Ltd.		Company controlled by the ultimate holding company
Genscript (HongKong) Ltd.		Company controlled by the ultimate holding company
Genscript USA Incorporated		Company controlled by the ultimate holding company
Genscript USA Holdings Inc		Company controlled by the ultimate holding company
Genscript Biotech (Netherlands) B.V.		Company controlled by the ultimate holding company
Nanjing Probio Biotech Co., Ltd.		Company controlled by the ultimate holding company
Jiangsu GenScript Probio Biotech Co., Ltd.		Company controlled by the ultimate holding company
Genscript Netherlands		Company controlled by the ultimate holding company
Genscript Biotech Corporation (“GenScript”)		Company controlled by the ultimate holding company
Genscript (Nanjing) Co., Ltd. (formerly named as Jinsikang Technology (Nanjing) Co., Ltd.)		Company controlled by the ultimate holding company

(a)

In addition to the transactions detailed elsewhere in the consolidated financial statements, the Group had the following transactions with related parties during the year :

(i)

Licensing of patents to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing Probio Biotech Co., Ltd.		3,019		—		—

The sale was generated from an exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd and its affiliates.

(ii)

Sales-based royalties from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing Probio Biotech Co., Ltd.		405		—		—

The sale was generated from sales-based royalties related to the exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd and its affiliates.

(iii)

Sales of materials to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing Genscript Biotech Co., Ltd.		—		—		3

The terms of these services and materials were charged based on the prices agreed by both parties.

(iv)

Other income to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		12		—		265

The other income was the income for sublease to Nanjing GenScript Biotech Co., Ltd. The price and terms are agreed by both parties

(v)

Purchases from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		9,615		4,162		4,480
Genscript USA Incorporated		786		424		296
Jiangsu GenScript Probio Biotech Co., Ltd		334	—		—
Jiangsu GenScript Biotech Co., Ltd		146		41		198
Nanjing Probio Biotech Co., Ltd.		21	—		—
Genscript Netherlands		6	—		—
Genscript Biotech (Netherlands) B.V.	—			7	—
Genscript USA Holdings Inc	—		—			4
		10,908		4,634		4,978

The transactions were made according to the price and terms agreed with related parties.

(vi)

Management fee:

	2021	2020	2019
	US$’000	US$’000	US$’000
Genscript USA Incorporated	—	95	198
Genscript (HongKong) Ltd	—	59	—
	—	154	198

The management fee was charged by related parties based on the cost of services provided.

(vii)

Shared services:

During the years ended December 31, 2021, 2020 and 2019, Nanjing GenScript Biotech Co., Ltd. provided certain accounting, legal, IT and administrative shared services to the Group for a consideration of US$1.6 million, US$3.3 million and US$2.1 million, respectively. During the year ended December 31, 2021, Genscript USA Incorporated provided certain IT shared service to the Group for a consideration of US$3,000.

(viii)

Compensation fee for termination of service agreement:

	2021		2020		2019
	US$’000		US$’000		US$’000
Jiangsu GenScript Biotech Co., Ltd.		2,666		—		—

In May 2021, pursuant to a settlement agreement between the Group and Jiangsu GenScript Biotech Co., Ltd., the Group incurred compensation charges for the termination of a service agreement related to the design and construction of a lab facility.

(ix)

Cash advances from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		28,199
Nanjing GenScript Biotech Co., Ltd.		—		—		2,168
Genscript USA Incorporated		—		—		8,000
Genscript (Nanjing) Co., Ltd.		—		—		578
		—		—		38,945

(x)

Repayment of cash advances from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		4,335
Nanjing GenScript Biotechnology Co., Ltd.		—		—		6,310
Genscript USA Incorporated		—		—		8,000
Genscript (Nanjing) Co., Ltd.		—		—		578
Genscript (HongKong) Ltd.		—		4		—
		—		4		19,223

(xi)

Cash advances to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		13,006

(xii)

Collection of cash advances to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		48,496
Genscript USA Incorporated		—		—		14,500
				—		62,996

The above cash advances from/to related parties were unsecured, interest free and repayable on demand.

(xiii)

Entrusted loan from a related party:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript (Nanjing) Co., Ltd.		—		—		2,867

(xiv)

Repayments of entrusted loan from a related party:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript (Nanjing) Co., Ltd.		—		—		2,867

The above entrusted loan from a related party was unsecured, bearing an interest rate of 4.35% p.a. and was repaid in December 2019, with an interest expense of US$24,000 recognized in 2019.

(xv)

Purchase of equipment

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		—		54		7

(xvi)

Sale of equipment

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		—		—		13

The sale or purchase of equipment was made at their respective carrying values.

(xvii)

Financing from follow-on public offering, net of issuance cost

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		84,600		—		—

Genscript Biotech Corporation purchased 4,500,000 ordinary shares, in the form of ADSs issued as part of the follow-on public offering on December 20, 2021, at the same price as these shares issued to the public(note 26).

(xviii)

Lease contract guarantee

In 2018, Legend Ireland entered into a copy property lease agreement with a third party in Dublin with lease period from 2018 to August 2028. Genscript Biotech Corporation provided a guarantee on Legend Ireland’s payment obligations under the lease agreement for nil consideration.

(b)

Outstanding balances with related parties:

The Group had the following significant balances with its related parties at the end of the year:

(i)

Due from related parties

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Trade receivables
Nanjing Probio Biotech Co., Ltd.		409		—

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Other receivables
Genscript USA Incorporated		19		6
Nanjing GenScript Biotech Co., Ltd.		243		14
		262		20

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Prepayment
Jiangsu GenScript Probio Biotech Co., Ltd	925			—
Nanjing Probio Biotech Co., Ltd.	274			—
		1,199		—

(ii)

Due to related parties.

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Trade payables
Nanjing GenScript Biotech Co., Ltd.		2,301		1,547
Genscript USA Incorporated		46		555
Nanjing Probio Biotech Co., Ltd.		22	—
Jiangsu GenScript Biotech Co., Ltd		1		1
		2,370		2,103

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Other payables
Nanjing GenScript Biotech Co., Ltd.		3,293		3,736
Genscript USA Incorporated		50	—
		3,343		3,736

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Lease liabilities
Nanjing GenScript Biotech Co., Ltd.		286		351
Genscript USA Holdings Inc		—		582
		286		933

Except for lease liabilities with incremental borrowing rates between 2.00% and 8.89% repayable over 5 years, all other related party balances are unsecured and repayable on demand and interest free.

(c)

Compensation of key management personnel of the Group:

	2021		2020		2019
	US$’000		US$’000		US$’000
Short-term employee benefits		1,942		1,733		1,036
Equity-settled share-based compensation expense		2,907		529		590
Termination payment		—		774		—
		4,849		3,036		1,626

Financial Instruments by Category as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Financial Instruments [Abstract]

Financial Instruments by Category as Restated

33. FINANCIAL INSTRUMENTS BY CATEGORY (AS RESTATED)

The carrying amounts of each of the categories of financial instruments as at the end of each of the reporting periods are as follows:

As at December 31, 2021

Financial assets

	Financial assets at amortized cost
	US$’000
Trade receivables		50,410
Financial assets included in prepayments, other receivables and other assets (note 17)		1,067
Financial assets measured at amortized cost		29,937
Lease receivables		94
Time deposits		168,225
Pledged deposits		1,444
Cash and cash equivalents		688,938
		940,115

Financial liabilities

	Financial liabilities at amortized cost		Financial liabilities at fair value through profit and loss
	US$’000		US$’000
Trade and notes payables		7,043	—
Warrant liability		—		87,900
Financial liabilities included in other payables and accruals (note 21)		16,867	—
Interest-bearing loans and borrowings		120,462	—
Lease liabilities		2,504	—
		146,876		87,900

As at December 31, 2020

Financial assets

	Financial assets at amortized cost
	US$’000
Trade receivables		75,000
Financial assets included in prepayments, other receivables and other assets (note 17)		344
Lease receivables		619
Time deposits		50,000
Pledged deposits		384
Cash and cash equivalents		455,689
		582,036

Financial liabilities

	Financial liabilities at amortized cost
	US$’000
Trade and notes payables		5,238
Financial liabilities included in other payables and accruals (note 21)		25,760
Lease liabilities		3,373
		34,371

Fair Value and Fair Value Hierarchy of Financial Instruments

12 Months Ended

Dec. 31, 2021

Disclosure Of Fair Value Of Financial Instruments [Abstract]

Fair Value and Fair Value Hierarchy of Financial Instruments

34. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, time deposits, financial assets included in prepayments, other receivables and other assets, trade receivables, trade and notes payables and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The Group’s finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance department reports directly to the finance manager. At each reporting date, the finance department analyzed the movements in the values of financial instruments and determined the major inputs applied in the valuation. The valuation was reviewed and approved by the finance manager. The valuation process and results are discussed with the directors once a year for annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The following table illustrates the fair value measurement hierarchy of the Group’s financial instruments:

Liability measured at fair value:

As at December 31, 2021

Fair value measurement using

Quoted

prices

in active

markets

(Level 1)

Significant

observable

inputs

(Level 2)

Significant

unobservable

inputs

(Level 3)

Total

US$’000

Warrant liability

—

87,900

—

87,900

The following table lists the inputs to the binominal model used for the fair value valuation of warrant liability:

		December 31, 2021
Underlying stock price		US$23.31
Volatility		70.5%
Risk free rate		0.58%
Dividend		0%

During the year ended December 31, 2021, 2020 and 2019, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities.

Financial Risk Management Objectives and Policies as Restated

12 Months Ended

Dec. 31, 2021

Disclosure Of Financial Instruments [Abstract]

Financial Risk Management Objectives and Policies as Restated

35. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (AS RESTATED)

The Group’s principal financial instruments comprise cash and cash equivalents, pledged deposits, time deposits, financial assets measured at amortized cost, prepayments, other receivables and other assets, and financial liabilities included in other payables and accruals. The main purpose of these financial instruments is to raise finance for the Group’s operations. The Group has various other financial assets and liabilities such as trade receivables and trade and notes payables, which arise directly from its operations.

The main risks arising from the Group’s financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarized below.

Interest rate risk

As at December 31, 2021, the Group's exposure to the risk of changes in interest rates primarily relates to the Group's Funding Advances with a floating interest rate as disclosed in note 25 to the consolidated financial statements. As at December 31, 2021, management considered that any reasonable changes in the interest rate would not have significant impact on the interest expense from the Funding Advances. Accordingly, no sensitivity analysis for interest rate risk is presented.

Foreign currency risk

The Group has transactional currency exposures. Such exposures arise from sales or purchases by operating units in currencies other than the units’ functional currencies. Approximately 54% in 2021 (2020 and 2019: nil and 15%) of the Group’s sales were denominated in currencies other than the functional currencies of the operating units making the sale.

As at December 31, 2021, 2020 and 2019, the Group had no outstanding foreign currency forward exchange contract. At present, the Group does not intend to seek to hedge its exposure to foreign exchange fluctuations. However, management constantly monitors the economic situation and the Group’s foreign exchange risk profile and will consider appropriate hedging measures in the future should the need arise.

The following table demonstrates the sensitivity at the end of the reporting period to a reasonably possible change in the EUR and RMB exchange rate against US$, with all other variables held constant, of the Group’s loss before tax (due to changes in the fair values of monetary assets and liabilities).

	Increase/ (decrease) in the rate of foreign currency			Decrease/ (increase) in loss before tax
	%			US$’000
Year ended December 31, 2021
If US$ strengthens against RMB		5			1,215
If US$ weakens against RMB		(5	)		(1,215	)
If US$ strengthens against EUR		5			(3,086	)
If US$ weakens against EUR		(5	)		3,086
Year ended December 31, 2020
If US$ strengthens against RMB		5			678
If US$ weakens against RMB		(5	)		(678	)
If US$ strengthens against EUR		5			(817	)
If US$ weakens against EUR		(5	)		817
Year ended December 31, 2019
If US$ strengthens against RMB		5			329
If US$ weakens against RMB		(5	)		(329	)
If US$ strengthens against EUR		5			3,310
If US$ weakens against EUR		(5	)		(3,310	)

Credit risk

The Group trades only with recognized and creditworthy third parties. It is the Group’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group’s exposure to bad debts is not significant. For transactions that are not denominated in the functional currency of the relevant operating unit, the Group does not offer credit terms without the specific approval of the Head of Credit Control.

The credit risk of the Group’s other financial assets, which comprise cash and cash equivalents, pledged deposits, financial assets measured at amortized cost and other receivables, arises from default of the counterparty, with a maximum exposure equal to the carrying amounts of these instruments. Further quantitative data in respect of the Group’s exposure to credit risk arising from trade receivables and other receivables are disclosed in notes 16 and 17 to the consolidated financial statements, respectively.

Since the Group trades only with recognized and creditworthy third parties, there is no requirement for collateral. Concentrations of credit risk are managed by debtor. The Group had certain concentrations of credit risk with respect to trade receivables, which are disclosed in note 16 to the consolidated financial statements.

Liquidity risk

The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial investments and financial assets (e.g., trade receivables and other financial assets) and projected cash flows from operations.

The maturity profile of the Group’s financial liabilities as at the end of the reporting period, based on contractual undiscounted payments, is as follows:

As at December 31, 2021
	Less than 1 years		Over 1 years		Total
	US$’000		US$’000		US$’000
Trade and notes payables		7,043		—		7,043
Other payables and accruals		16,867		—		16,867
Warrant liability		87,900		—		87,900
Interest-bearing loans and borrowings (note)		—		120,462		120,462
Lease liabilities		911		1,708		2,619
		112,721		122,170		234,891

As at December 31, 2020
	Less than 1 years		Over 1 years		Total
	US$’000		US$’000		US$’000
Trade and notes payables		5,238		—		5,238
Other payables and accruals		25,760		—		25,760
Lease liabilities		1,464		2,099		3,563
		32,462		2,099		34,561

Note: Pursuant to the terms of the license and collaboration agreement, the collaborator may recoup the aggregate amount of Funding Advances together with interest thereon from Company’s share of pre-tax profits for the first profitable year of the collaboration program. The Company’s management estimated the loan will not be recouped by the collaborator within one year.

Capital management

The primary objectives of the Group’s capital management are to safeguard the Group’s ability to continue as a going concern and to maintain a strong credit rating and healthy capital ratios in order to support its business and maximize shareholders’ value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the reporting periods.

The Group monitors capital using a gearing ratio, which is total liabilities divided by total assets. The gearing ratios as at the end of each year were as follows:

	December 31, 2021			December 31, 2020
	US$’000			US$’000
Total liabilities		353,521			124,322
Total assets		1,119,465			722,093
Gearing ratio		32	%		17	%

Approval of the Consolidated Financial Statements as Restated

12 Months Ended

Dec. 31, 2021

Statement Of Financial Position [Abstract]

Approval of the Consolidated Financial Statements as Restated

36. APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS (AS RESTATED)

The consolidated financial statements were approved and authorized for issue by the board of directors on February 17, 2023.

Summary of Significant Accounting Policies as Restated (Policies)

12 Months Ended

Dec. 31, 2021

Summary Of Significant Accounting Policies [Abstract]

Fair value measurement

Level 1 – based on quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly

Level 3 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

Impairment of non-financial assets

Related parties

A party is considered to be related to the Group if:

(a)

the party is a person or a close member of that person’s family and that person

(i)

has control or joint control over the Group;

(ii)

has significant influence over the Group; or

(iii)

is a member of the key management personnel of the Group or of a parent of the Group;

(b)

the party is an entity where any of the following conditions applies:

(i)

the entity and the Group are members of the same group;

(ii)

one entity is an associate or joint venture of the other entity (or of a parent, subsidiary or fellow subsidiary of the other entity);

(iii)

the entity and the Group are joint ventures of the same third party;

(iv)

one entity is a joint venture of a third entity and the other entity is an associate of the third entity;

(v)

the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;

(vi)

the entity is controlled or jointly controlled by a person identified in (a);

(vii)

a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity); and

(viii)

the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the parent of the Group.

Property, plant and equipment and depreciation

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

Freehold land		Not depreciated
Buildings		2.6%
Leasehold improvement		10% to 20%
Machinery and equipment		10% to 20%
Computer, fixtures and office equipment		20% to 33.3%
Transportation equipment		10%

Intangible assets

Intangible assets are amortized on the straight-line basis over the following useful economic lives:


Software		3-10 years

Research and development costs

All research costs are charged to the statement of profit or loss and other comprehensive income as incurred.

Leases

Group as a lessee

(a) Right-of-use assets

Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

Leasehold land		50 years
Building improvement		2 to 18 years
Machinery and equipment		5 to 10 years
Office equipment		3 to 5 years

(b) Lease liabilities

Lease payments on short-term leases are recognized as an expense on a straight-line basis over the lease term.

Group as a lessor

When the Group acts as a lessor, it classifies at lease inception (or when there is a lease modification) each of its leases as either an operating lease or a finance lease.

Leases of collaboration assets

Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, and fair value through profit or loss.

Subsequent measurement

Financial assets measured at amortized cost (debt instruments)

Financial assets at fair value through profit or loss

Financial assets measured at fair value through profit or loss

Derecognition of financial assets

•

the rights to receive cash flows from the asset have expired; or

•

Impairment of financial assets

General approach

Stage 1 – Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs

Simplified approach

Financial liabilities

Initial recognition and measurement

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group’s financial liabilities include trade and notes payables, other payables, warrant liability, interest-bearing loans and borrowings, and lease liabilities.

Subsequent measurement

Financial liabilities measured at amortized cost (Loans and borrowings)

Derecognition of financial liabilities

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

Offsetting of financial instruments

Inventories

appropriate proportion of overheads. Net realizable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.

Cash and cash equivalents

Time deposits

Provisions

Income tax

Deferred tax liabilities are recognized for all taxable temporary differences, except:

•

profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilized, except:

•

Government grants

Collaboration Arrangements

Revenue recognition

Revenue from contracts with customers

(a) License and collaboration revenue

License of Intellectual Property

Milestone Payments

Royalty Payments

The Company recognizes revenue for sales-based milestone payments promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

(a) the subsequent sale occurs; and

(b) the performance obligation to which some or all of the sales-based royalty has been allocated has been satisfied (or partially satisfied).

Janssen Agreement

Upfront fees

Milestone payments

Collaborative activities

Product Sales

Revenue from the sale of goods is recognized at the point in time when control of the goods is transferred to the customer, generally on delivery of the goods.

Other income

Share-based payments

treated as vesting irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

The dilutive effect of outstanding options and RSUs are reflected as additional share dilution in the computation of earnings per share.

Other employee benefits

Pension scheme

Foreign currencies

Impact of covid-19

Corporate Information (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Significant Investments In Subsidiaries [Abstract]

Information About Subsidiaries

Information about subsidiaries

Company

Place and date

incorporation

Issued ordinary

shares/paid-up

capital

Percentage of equity

interest attributable

to the Company

Principal

activities

Direct %

Indirect %

Legend Biotech Limited (“Legend

BVI”)

The British Virgin

Islands

June 2, 2015

US$

80,000,000

100

—

Investment holding

Legend Biotech HK Limited

(“Legend HK”)

Hong Kong

June 3, 2015

US$

80,000,000

—

100

Investment holding

Nanjing Legend Biotechnology Co.,

Ltd. (“Legend Nanjing”)

PRC*

November 17, 2014

US$

162,500,000

—

100

Manufacture and

sale of life science

research products

and services

Legend Biotech USA Incorporated

(“Legend USA”)

United States of

America

August 31, 2017

—

100

Manufacture and

sale of life science

research products

and services

Legend Biotech Ireland Limited

(“Legend Ireland”)

Ireland

November 13, 2017

—

100

Manufacture and

sale of life science

research products

and services

Legend Biotech Belgium B.V.

(“Legend Belgium”)

Belgium

June 23, 2021

US$

2,423,693

—

100

Manufacture and

sale of life science

research products

and services

Hainan Chuanji Biotechnology Co.,

Ltd. (“Hainan Chuanji”)

PRC

October 25, 2021

—

100

Life science

research and

development

Restatement of Previously Issued Consolidated Financial Statements (Tables)

12 Months Ended

Dec. 31, 2021

Restatement Of Previously Issued Consolidated Financial Statements [Abstract]

Summary of Restatement of Previously Issued Consolidated Financial Statements

	Consolidated statement of profit or loss and other comprehensive income for the year ended December 31, 2021
				Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets		Tax impacts		Total Adjustments			As Restated
	US$’000			US$’000			US$’000		US$’000		US$’000			US$’000
Revenue		89,792			(20,966	)		—		—		(20,966	)		68,826
Other income and gains		3,059			—			—		—		—			3,059
Research and development expenses		(313,346	)		—			—		—		—			(313,346	)
Administrative expenses		(46,939	)		(22	)		—		—		(22	)		(46,961	)
Selling and distribution expenses		(102,542	)		—			—		—		—			(102,542	)
Other expenses		(9,132	)		—			—		—		—			(9,132	)
Fair value loss of warrant liability		(6,200	)		—			—		—		—			(6,200	)
Finance costs		(900	)		—			—		—		—			(900	)
Loss before tax		(386,208	)		(20,988	)		—		—		(20,988	)		(407,196	)
Income tax (expense)/credit		(1	)		—			—		3,615		3,615			3,614
Loss for the year		(386,209	)		(20,988	)		—		3,615		(17,373	)		(403,582	)
Attributable to: ordinary equity holders of the parent		(386,209	)		(20,988	)		—		3,615		(17,373	)		(403,582	)
Loss per share attributable to ordinary equity holders of the parent
Basic		(1.37	)		(0.07	)		—	0.01			(0.06	)		(1.43	)
Diluted		(1.37	)		(0.07	)		—	0.01			(0.06	)		(1.43	)
Exchange differences:
Exchange differences on translation of foreign operations		10,620			(5,897	)		—	492			(5,405	)		5,215
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods		10,620			(5,897	)		—	492			(5,405	)		5,215
OTHER COMPREHENSIVE INCOME FOR THE YEAR, NET OF TAX		10,620			(5,897	)		—	492			(5,405	)		5,215
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(375,589	)		(26,885	)		—		4,107		(22,778	)		(398,367	)
Attributable to:
Ordinary equity holders of the parent		(375,589	)		(26,885	)		—		4,107		(22,778	)		(398,367	)

	Consolidated statements of financial position as at December 31, 2021
			Adjustments by category
	As Previously Reported		Revenue Recognition			Collaboration assets			Tax impacts			Total Adjustments			As Restated
	US$’000		US$’000			US$’000			US$’000			US$’000			US$’000
NON-CURRENT ASSETS
Property, plant and equipment		145,724		—			(43,218	)		—			(43,218	)		102,506
Advance payments for property, plant and equipment		2,168		—			—			—			—			2,168
Right-of-use assets		7,186		—			31,097			—			31,097			38,283
Time deposits		4,705		—			—			—			—			4,705
Intangible assets		4,684		—			—			—			—			4,684
Other non-current assets		5,148		—			12,121			—			12,121			17,269
Total non-current assets		169,615		—			—			—			—			169,615
CURRENT ASSETS
Inventories		1,749		—			—			—			—			1,749
Trade receivables		50,410		—			—			—			—			50,410
Prepayments, other receivables and other assets		12,754		—			—			1,004			1,004			13,758
Financial assets measured at amortized cost		29,937		—			—			—			—			29,937
Lease receivables		—		—			94						94			94
Pledged deposits		1,444		—			—			—			—			1,444
Time deposits		163,520		—			—			—			—			163,520
Cash and cash equivalents		688,938		—			—			—			—			688,938
Total current assets		948,752		—			94			1,004			1,098			949,850
Total assets		1,118,367		—			94			1,004			1,098			1,119,465
CURRENT LIABILITIES
Trade and notes payables		7,043		—			—			—			—			7,043
Other payables and accruals		123,464		—			94			—			94			123,558
Government grants		304		—			—			—			—			304
Lease liabilities		911		—			—			—			—			911
Tax payable		—		—			—			9,488			9,488			9,488
Warrant liability		87,900		—			—			—			—			87,900
Contract liabilities, current		60,644		(60,644	)		—			—			(60,644	)		—
Total current liabilities		280,266		(60,644	)		94			9,488			(51,062	)		229,204
NON-CURRENT LIABILITIES
Interest-bearing loans and borrowings		120,462		—			—			—			—			120,462
Contract liabilities, non-current		242,578		(242,578	)		—			—			(242,578	)		—
Lease liabilities		1,593		—			—			—			—			1,593
Government grants		1,866		—			—			—			—			1,866
Other non-current liabilities		396		—			—			—			—			396
Total non-current liabilities		366,895		(242,578	)		—			—			(242,578	)		124,317
Total liabilities		647,161		(303,222	)		94			9,488			(293,640	)		353,521
EQUITY
Share capital		31		—			—			—			—			31
Reserves		471,175		303,222			—			(8,484	)		294,738			765,913
Total ordinary shareholders’ equity		471,206		303,222			—			(8,484	)		294,738			765,944
Total equity		471,206		303,222			—			(8,484	)		294,738			765,944
Total liabilities and equity		1,118,367		—			94			1,004			1,098			1,119,465

	Consolidated Statements of Changes in Equity as at December 31, 2021
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
As at December 31, 2021
Share capital		31			—			31
Share premium		1,261,454			—			1,261,454
Share-based compensation reserves		19,702			—			19,702
Foreign currency translation reserve		6,987			(2,123	)		4,864
Accumulated losses		(816,968	)		296,861			(520,107	)
Total equity		471,206			294,738			765,944

	Consolidated statements of cash flows during the year ended December 31, 2021
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax		(386,208	)		(20,988	)		(407,196	)
Adjustments for:
Finance income		(971	)		—			(971	)
Finance costs		900			—			900
(Reversal of)/provision for the impairment of trade receivables		(22	)		22			—
Depreciation of property, plant and equipment		11,046			(2,907	)		8,139
Loss on disposal of property, plant and equipment		974			—			974
Amortization of intangible assets		1,379			—			1,379
Depreciation of right-of-use assets		1,492			2,907			4,399
Fair value loss of warrant liability		6,200			—			6,200
Foreign currency exchange loss, net		4,867			—			4,867
Equity-settled share-based compensation expense		20,158			—			20,158
Deferred government grant		(295	)		—			(295	)
		(340,480	)		(20,966	)		(361,446	)
Decrease in trade receivables		24,590			—			24,590
Increase in prepayments, other receivables and other assets		(2,966	)		—			(2,966	)
Increase in other non-current assets		(1,175	)		—			(1,175	)
Decrease in inventories		51			—			51
Government grant received		80			—			80
Increase in trade and notes payables		1,805			—			1,805
Increase/(decrease) in other payables and accruals		142,091			(1,344	)		140,747
Decrease in other non-current liabilities		(158	)		—			(158	)
(Decrease)/increase in contract liabilities		(22,310	)		22,310			—
Increase in pledged deposits, net		(1,060	)		—			(1,060	)
Cash used in operations		(199,532	)		—			(199,532	)
Finance income received		652			—			652
Income tax received		557			—			557
Interest on lease payments		(142	)		—			(142	)
Net cash flow used in operating activities		(198,465	)		—			(198,465	)

	Consolidated statements of cash flows during the year ended December 31, 2021
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(43,905	)		1,708			(42,197	)
Purchase of intangible assets		(3,207	)		—			(3,207	)
Prepayment to collaborator for collaboration right-of-use assets		—			(1,708	)		(1,708	)
Purchase of financial assets measured at fair value through profit or loss		(50,000	)		—			(50,000	)
Cash received from withdrawal of financial assets measured at fair value through profit or loss		50,081			—			50,081
Proceeds from disposal of property, plant and equipment		4			—			4
Addition in time deposits		(298,107	)		—			(298,107	)
Decrease in time deposits		180,000			—			180,000
Purchase of financial assets measured at amortized cost		(29,849	)		—			(29,849	)
Net cash flows used in investing activities		(194,983	)		—			(194,983	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs		323,440			—			323,440
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor		300,000			—			300,000
Proceeds from exercise of share options		4,642			—			4,642
Principal portion of lease payments		(1,419	)		—			(1,419	)
Net cash flows from financing activities		626,663			—			626,663
NET INCREASE IN CASH AND CASH EQUIVALENTS		233,215			—			233,215
Effect of foreign exchange rate changes, net		34			—			34
Cash and cash equivalents at beginning of year		455,689			—			455,689
CASH AND CASH EQUIVALENTS AT END OF YEAR		688,938			—			688,938
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		858,607			—			858,607
Less: Pledged deposits		1,444			—			1,444
Time deposits		168,225			—			168,225
Cash and cash equivalents as stated in the statement of financial position		688,938			—			688,938
Cash and cash equivalents as stated in the statement of cash flows		688,938			—			688,938

	Consolidated Statement of profit or loss and other comprehensive income for the year ended December 31, 2020
				Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets		Tax impacts			Total Adjustments			As Restated
	US$’000			US$’000			US$’000		US$’000			US$’000			US$’000
Revenue		75,676			(676	)		—		—			(676	)		75,000
Other income and gains		6,119			—			—		—			—			6,119
Research and development expenses		(232,160	)		—			—		—			—			(232,160	)
Administrative expenses		(23,147	)		13			—		—			13			(23,134	)
Selling and distribution expenses		(49,571	)		—			—		—			—			(49,571	)
Other expenses		(346	)		—			—		—			—			(346	)
Fair value loss of convertible redeemable preferred shares		(79,984	)		—			—		—			—			(79,984	)
Finance costs		(4,209	)		—			—		—			—			(4,209	)
Loss before tax		(307,622	)		(663	)		—		—			(663	)		(308,285	)
Income tax credit		4,145			—			—		37,767			37,767			41,912
Loss for the year		(303,477	)		(663	)		—		37,767			37,104			(266,373	)
Attributable to: ordinary equity holders of the parent		(303,477	)		(663	)		—		37,767			37,104			(266,373	)
Loss per share attributable to ordinary equity holders of the parent
Basic		(1.28	)		—			—		0.15			0.15			(1.13	)
Diluted		(1.28	)		—			—		0.15			0.15			(1.13	)
Exchange differences:
Exchange differences on translation of foreign operations		(2,142	)		6,702			—		(482	)		6,220			4,078
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods		(2,142	)		6,702			—		(482	)		6,220			4,078
OTHER COMPREHENSIVE (LOSS)/ INCOME FOR THE YEAR, NET OF TAX		(2,142	)		6,702			—		(482	)		6,220			4,078
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(305,619	)		6,039			—		37,285			43,324			(262,295	)
Attributable to:
Ordinary equity holders of the parent		(305,619	)		6,039			—		37,285			43,324			(262,295	)

	Consolidated Statements of Financial Position as at December 31, 2020
			Adjustments by category
	As Previously Reported		Revenue Recognition			Collaboration assets			Tax impacts			Total Adjustments			As Restated
	US$’000		US$’000			US$’000			US$’000			US$’000			US$’000
NON-CURRENT ASSETS
Property, plant and equipment		113,091		—			(40,749	)		—			(40,749	)		72,342
Advance payments for property, plant and equipment		224		—			—			—			—			224
Right-of-use assets		8,009		—			31,533			—			31,533			39,542
Intangible assets		2,852		—			—			—			—			2,852
Other non-current assets		3,973		—			9,216			—			9,216			13,189
Total non-current assets		128,149		—			—			—			—			128,149
CURRENT ASSETS
Inventories		1,800		—			—			—			—			1,800
Trade receivables		74,978		22			—			—			22			75,000
Prepayments, other receivables and other assets		10,007		—			—			445			445			10,452
Lease receivables		—		—			619			—			619			619
pledged deposits		384		—			—			—			—			384
Time deposits		50,000		—			—			—			—			50,000
Cash and cash equivalents		455,689		—			—			—			—			455,689
Total current assets		592,858		22			619			445			1,086			593,944
Total assets		721,007		22			619			445			1,086			722,093
CURRENT LIABILITIES
Trade payables		5,238		—			—			—			—			5,238
Other payables and accruals		99,168		—			619			—			619			99,787
Government grants		283		—			—			—			—			283
Lease liabilities		1,464		—			—			—			—			1,464
Tax payable		—		—			—			8,795			8,795			8,795
Contract liabilities, current		55,014		(55,014	)		—			—			(55,014	)		—
Total current liabilities		161,167		(55,014	)		619			8,795			(45,600	)		115,567
NON-CURRENT LIABILITIES
Contract liabilities, non-current		275,071		(275,071	)		—			—			(275,071	)		—
Lease liabilities		1,909		—			—			—			—			1,909
Government grants		2,051		—			—			—			—			2,051
Deferred tax liabilities		—		—			—			4,241			4,241			4,241
Other non-current liabilities		554		—			—			—			—			554
Total non-current liabilities		279,585		(275,071	)		—			4,241			(270,830	)		8,755
Total liabilities		440,752		(330,085	)		619			13,036			(316,430	)		124,322
EQUITY
Share capital		27		—			—			—			—			27
Reserves		280,228		330,107			—			(12,591	)		317,516			597,744
Total ordinary shareholders’ equity		280,255		330,107			—			(12,591	)		317,516			597,771
Total equity		280,255		330,107			—			(12,591	)		317,516			597,771
Total liabilities and equity		721,007		22			619			445			1,086			722,093

	Consolidated Statements of Changes in Equity as at December 31, 2020
	As Previously Reported			Total Restatement Impacts		As Restated
	US$’000			US$’000		US$’000
As at December 31, 2020
Share capital		27			—		27
Share premium		708,306			—		708,306
Share-based compensation reserves		6,314			—		6,314
Foreign currency translation reserve		(3,633	)		3,282		(351	)
Accumulated losses		(430,759	)		314,234		(116,525	)
Total equity		280,255			317,516		597,771

	Consolidated statements of cash flows for the year ended December 31, 2020
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax		(307,622	)		(663	)		(308,285	)
Adjustments for:
Finance income		(2,930	)		—			(2,930	)
Finance costs		4,209			—			4,209
Provision/(reversal of) for the impairment of trade receivables		13			(13	)		—
Depreciation of property, plant and equipment		8,248			(2,014	)		6,234
Loss on disposal of property, plant and equipment		55						55
Amortization of intangible assets		192			—			192
Depreciation of right-of-use assets		1,493			2,014			3,507
Fair value loss of convertible redeemable preferred shares		79,984			—			79,984
Fair value gains on financial assets measured at fair value change through profit or loss		(47	)		—			(47	)
Foreign currency exchange gain, net		(66	)		—			(66	)
Equity-settled share-based compensation expense		4,760			—			4,760
Deferred government grant		(114	)		—			(114	)
		(211,825	)		(676	)		(212,501	)
Increase in trade receivables		(45,000	)		—			(45,000	)
Decrease in prepayments, other receivables and other assets		3,366			—			3,366
Increase in other non-current assets		(3,973	)		—			(3,973	)
Increase in inventories		(643	)		—			(643	)
Government grant received		2,452			—			2,452
Decrease in trade and notes payables		(4,348	)		—			(4,348	)
Increase in other payables and accruals		20,230			6,702			26,932
Increase in other non-current liabilities		554			—			554
Increase/(decrease) in contract liabilities		6,026			(6,026	)		—
Increase in pledged deposits, net		(128	)		—			(128	)
Cash used in operations		(233,289	)		—			(233,289	)
Income tax paid		(278	)		—			(278	)
Finance income received		3,366			—			3,366
Income tax received		7,391			—			7,391
Interest on lease payments		(195	)		—			(195	)
Net cash flow used in operating activities		(223,005	)		—			(223,005	)

	Consolidated Statements of Cash Flows For the year ended December 31, 2020
	As Previously Reported			Total Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(45,747	)		19,493			(26,254	)
Purchase of intangible assets		(4,029	)		—			(4,029	)
Prepayment to collaborator for collaboration right-of-use assets		—			(19,493	)		(19,493	)
Purchase of financial assets measured at fair value through profit or loss		(22,682	)		—			(22,682	)
Cash received from withdrawal of financial assets measured at fair value through profit or loss		22,682			—			22,682
Cash receipts of investment income		47			—			47
Proceeds from disposal of property, plant and equipment		1			—			1
Addition in time deposits		(50,000	)		—			(50,000	)
Decrease in time deposits		75,559			—			75,559
Net cash flows used in investing activities		(24,169	)		—			(24,169	)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of cash advances from related parties		(4	)		—			(4	)
Proceeds from convertible redeemable preferred shares		160,450			—			160,450
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs		450,085			—			450,085
Proceeds from issuance of ordinary shares relating to private placement by GenScript		12,000			—			12,000
Proceeds from exercise of share options		1,464			—			1,464
Payments of expenses for issuance of convertible redeemable preferred shares		(2,514	)		—			(2,514	)
Principal portion of lease payments		(2,602	)		—			(2,602	)
Net cash flows from financing activities		618,879			—			618,879
NET INCREASE IN CASH AND CASH EQUIVALENTS		371,705			—			371,705
Effect of foreign exchange rate changes, net		620			—			620
Cash and cash equivalents at beginning of year		83,364			—			83,364
CASH AND CASH EQUIVALENTS AT END OF YEAR		455,689			—			455,689
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		506,073			—			506,073
Less: Pledged deposits		384			—			384
Time deposits		50,000			—			50,000
Cash and cash equivalents as stated in the statement of financial position		455,689			—			455,689
Cash and cash equivalents as stated in the statement of cash flows		455,689			—			455,689

	Consolidated statement of profit or loss and other comprehensive income for the year ended December 31, 2019
				Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets		Tax impacts		Total Adjustments			As Restated
	US$’000			US$’000			US$’000		US$’000		US$’000			US$’000
Revenue		57,264			2,716			—		—		2,716			59,980
Other income and gains		7,125			334			—		—		334			7,459
Research and development expenses		(161,943	)		—			—		—		—			(161,943	)
Administrative expenses		(6,752	)		1			—		—		1			(6,751	)
Selling and distribution expenses		(25,620	)		—			—		—		—			(25,620	)
Other expenses		(221	)		—			—		—		—			(221	)
Finance costs		(223	)		—			—		—		—			(223	)
Loss before tax		(130,370	)		3,051			—		—		3,051			(127,319	)
Income tax (expense)/credit		(2,602	)		—			—		28,331		28,331			25,729
Loss for the year		(132,972	)		3,051			—		28,331		31,382			(101,590	)
Attributable to: ordinary equity holders of the parent		(132,972	)		3,051			—		28,331		31,382			(101,590	)
Loss per share attributable to ordinary equity holders of the parent
Basic		(0.66	)		0.02			—		0.13		0.15			(0.51	)
Diluted		(0.66	)		0.02			—		0.13		0.15			(0.51	)
Exchange differences:
Exchange differences on translation of foreign operations		182			(1,584	)		—		134		(1,450	)		(1,268	)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods		182			(1,584	)		—		134		(1,450	)		(1,268	)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX		182			(1,584	)		—		134		(1,450	)		(1,268	)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR		(132,790	)		1,467			—		28,465		29,932			(102,858	)
Attributable to:
Ordinary equity holders of the parent		(132,790	)		1,467			—		28,465		29,932			(102,858	)

	Consolidated statements of financial position as at January 1, 2020
	Adjustments by category
	As Previously Reported			Revenue Recognition			Collaboration assets			Tax impacts			Total Adjustments			As Restated
	US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
NON-CURRENT ASSETS
Property, plant and equipment		70,079			—			(24,891	)		—			(24,891	)		45,188
Advance payments for property, plant and equipment		665			—			—			—			—			665
Right-of-use assets		9,348			—			18,442			—			18,442			27,790
Intangible assets		519			—			—			—			—			519
Other non-current assets		—			—			6,449			—			6,449			6,449
Total non-current assets		80,611			—			—			—			—			80,611
CURRENT ASSETS
Inventories		1,157			—			—			—			—			1,157
Trade receivables		29,991			9			—			—			9			30,000
Prepayments, other receivables and other assets		16,777			—			—			4,894			4,894			21,671
Pledged deposits		256			—			—			—			—			256
Time deposits		75,559			—			—			—			—			75,559
Cash and cash equivalents		83,364			—			—			—			—			83,364
Total current assets		207,104			9			—			4,894			4,903			212,007
Total assets		287,715			9			—			4,894			4,903			292,618
CURRENT LIABILITIES
Trade payables		9,586			—			—			—			—			9,586
Other payables and accruals		70,854			—			—			—			—			70,854
Lease liabilities		1,027			—			—			—			—			1,027
Tax payable		—			—			—			12,782			12,782			12,782
Contract liabilities, current		46,294			(46,294	)		—			—			(46,294	)		—
Total current liabilities		127,761			(46,294	)		—			12,782			(33,512	)		94,249
NON-CURRENT LIABILITIES
Contract liabilities, non-current		277,765			(277,765	)		—			—			(277,765	)		—
Lease liabilities		5,058			—			—			—			—			5,058
Deferred tax liabilities		—			—			—			41,988			41,988			41,988
Total non-current liabilities		282,823			(277,765	)		—			41,988			(235,777	)		47,046
Total liabilities		410,584			(324,059	)		—			54,770			(269,289	)		141,295
EQUITY
Share capital		20			—			—			—			—			20
Reserves		(122,889	)		324,068			—			(49,876	)		274,192			151,303
Total ordinary shareholders’ (deficit)/ equity		(122,869	)		324,068			—			(49,876	)		274,192			151,323
Total (deficit)/equity		(122,869	)		324,068			—			(49,876	)		274,192			151,323
Total liabilities and equity		287,715			9			—			4,894			4,903			292,618

	Consolidated Statements of Changes in Equity as at December 31, 2019
	As Previously Reported			Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
As at December 31, 2019
Share capital		20			—			20
Share premium		3,908			—			3,908
Share-based compensation reserves		1,976			—			1,976
Foreign currency translation reserve		(1,491	)		(2,938	)		(4,429	)
(Accumulated losses)/retained earnings		(127,282	)		277,130			149,848
Total (deficit)/equity		(122,869	)		274,192			151,323

	Consolidated statements of cash flow for the year ended December 31, 2019
	As Previously Reported			Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax		(130,370	)		3,051			(127,319	)
Adjustments for:
Finance income		(4,581	)		—			(4,581	)
Finance costs		223			—			223
Provision/(reversal of) for the impairment of trade receivables		1		(1)				—
Depreciation of property, plant and equipment		4,001			(838	)		3,163
Amortization of intangible assets		63			—			63
Depreciation of right-of-use assets		1,198			838			2,036
Fair value gains on financial assets measured at fair value change through profit or loss		(474	)		—			(474	)
Foreign currency exchange gain, net		(250	)		(334	)		(584	)
Equity-settled share-based compensation expense		1,272			—			1,272
		(128,917	)		2,716			(126,201	)
(Increase)/decrease in trade receivables		(3,771	)		25,000			21,229
Increase in prepayments, other receivables and other assets		(3,928	)		(1,250	)		(5,178	)
Increase in inventories		(22	)		—			(22	)
Increase in trade and notes payables		2,011			—			2,011
Increase in other payables and accruals		31,727			—			31,727
Increase/(decrease) in contract liabilities		26,466			(26,466	)		—
Cash used in operations		(76,434	)		—			(76,434	)
Income tax paid		(15,432	)		—			(15,432	)
Finance income received		9,024			—			9,024
Interest on loan from related party		(24	)		—			(24	)
Interest on lease payments		(199	)		—			(199	)
Net cash flow used in operating activities		(83,065	)		—			(83,065	)

	Consolidated Statements of Cash Flows For the year ended December 31, 2019
	As Previously Reported			Restatement Impacts			As Restated
	US$’000			US$’000			US$’000
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(38,636	)		11,863			(26,773	)
Purchase of intangible assets		(534	)		—			(534	)
Prepayment to collaborator for collaboration right-of-use assets		—			(11,863	)		(11,863	)
Purchase of financial assets measured at fair value through profit or loss		(314,840	)		—			(314,840	)
Cash received from withdrawal of financial assets measured at fair value through profit or loss		320,854			—			320,854
Cash advances to related parties		(13,006	)		—			(13,006	)
Collection of cash advances to related parties		62,996			—			62,996
Proceeds from disposal of property, plant and equipment		74			—			74
Addition in time deposits		(75,559	)		—			(75,559	)
Addition in pledged deposits		(256	)		—			(256	)
Decrease in pledged deposits		255			—			255
Net cash flows used in investing activities		(58,652	)		—			(58,652	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from cash advances from related parties		38,945			—			38,945
Repayment of cash advances from related parties		(19,223	)		—			(19,223	)
Proceeds from loans from related parties		2,867			—			2,867
Repayments of loans from related parties		(2,867	)		—			(2,867	)
Principal portion of lease payments		(5,056	)		—			(5,056	)
Net cash flows from financing activities		14,666			—			14,666
NET DECREASE IN CASH AND CASH EQUIVALENTS		(127,051	)		—			(127,051	)
Effect of foreign exchange rate changes, net		249			—			249
Cash and cash equivalents at beginning of year		210,166			—			210,166
CASH AND CASH EQUIVALENTS AT END OF YEAR		83,364			—			83,364
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances		159,179			—			159,179
Less: Pledged deposits		256			—			256
Time deposits		75,559			—			75,559
Cash and cash equivalents as stated in the statement of financial position		83,364			—			83,364
Cash and cash equivalents as stated in the statement of cash flows		83,364			—			83,364

Summary of Significant Accounting Policies as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Summary Of Significant Accounting Policies [Abstract]

Summary of Depreciation Calculated on Straight-line Basis Over Estimated Useful Lives of Assets

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

Freehold land		Not depreciated
Buildings		2.6%
Leasehold improvement		10% to 20%
Machinery and equipment		10% to 20%
Computer, fixtures and office equipment		20% to 33.3%
Transportation equipment		10%

Summary of Intangible Assets Amortised

Intangible assets are amortized on the straight-line basis over the following useful economic lives:


Software		3-10 years

Summary of Estimated Useful Lives of Right-of-Use Assets

Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease terms and the estimated useful lives of the assets as follows:

Leasehold land		50 years
Building improvement		2 to 18 years
Machinery and equipment		5 to 10 years
Office equipment		3 to 5 years

Operating Segment Information as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Operating Segments [Abstract]

Summary of Revenue from External Customers as Restated

(a) Revenue from external customers as restated

	2021		2020		2019
	US$’000		US$’000		US$’000
United States of America		65,402		75,000		59,977
China		3,424		—		3
Total		68,826		75,000		59,980

Summary of Non-current Assets

(b) Non-current assets

	December 31, 2021		December 31, 2020
	US$’000		US$’000
United States of America		103,648		78,022
China		50,800		43,953
Other		10,462		6,174
Total		164,910		128,149

Revenue, Other Income and Gains as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Revenue Other Income And Gains [Abstract]

Summary of Analysis of Revenue

An analysis of revenue is as follows:

	2021		2020		2019
	US$’000		US$’000		US$’000
Revenue from contracts with customer
Sales of goods		—		—		3
License and collaboration revenue
- Licensing of intellectual property		65,402		75,000		59,977
Licensing and Royalties		3,424		—		—
		68,826		75,000		59,980

Other Income and Gains

	2021		2020		2019
	US$’000		US$’000		US$’000
Other income and gains
Other income:
Finance income		971		2,930		4,581
Government grants*		1,736		3,072		1,682
Others		35		4		138
		2,742		6,006		6,401
Gains:
Foreign currency exchange gain, net		—		66		584
Fair value gains on financial assets measured at fair value change through profit or loss		—		47		474
Others**		317		—		—
		317		113		1,058
		3,059		6,119		7,459

*	The amount represents subsidies received from local government authorities to support the Group’s business. There were no unfulfilled conditions and other contingencies attached to these government grants.

**	The amount mainly represents reimbursement of depositary fees that are related to the establishment and maintenance of the American Depository Receipts (ADR) program.

Loss Before Tax as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Profit Loss [Abstract]

Schedule of Profit Loss Before Tax Arrived After Charging Explanatory

The Group’s loss before tax is arrived at after charging:

	2021		2020		2019
	US$’000		US$’000		US$’000
Loss on disposal of assets		974		55		—
IPO expenses		—		1,439		—
Follow-on expenses		400		—		—
Employee benefit expense (including directors’ remuneration):
Wages and salaries		105,751		70,682		37,038
Pension scheme contributions (defined contribution schemes)		2,257		640		1,166
Equity-settled share-based compensation expense		20,158		4,760		1,272

Finance Costs (Tables)

12 Months Ended

Dec. 31, 2021

Finance Costs [Abstract]

Summary of Finance Costs

	2021		2020		2019
	US$’000		US$’000		US$’000
Interest on lease liabilities		142		195		199
Interest on interest-bearing loans and borrowings (note 25)		758		—		—
Expenses for issuance of convertible redeemable preferred shares		—		4,014		—
Interest on an entrusted loan from a related party		—		—		24
Total		900		4,209		223

Income Tax as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Major Components Of Tax Expense Income [Abstract]

Summary of Tax Credits

Taxes on profits assessable elsewhere have been calculated at the rates of tax prevailing in the jurisdictions in which the Group operates.

	2021			2020			2019
	US$’000			US$’000			US$’000
Current – United States of America		211			(4,548	)		(2,933	)
Current – Elsewhere		416			383			(4,787	)
Deferred (note 22)		(4,241	)		(37,747	)		(18,009	)
Total tax credit for the year		(3,614	)		(41,912	)		(25,729	)

Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates

	2021						2020						2019
	US$’000			%			US$’000			%			US$’000			%
Loss before tax		(407,196	)					(308,285	)					(127,319	)
At the statutory blended income tax rate of 28.1% (2020 and 2019: 28.1%)		(114,463	)		28.1			(86,659	)		28.1			(35,789	)	28.1
Effect of tax rate differences in other countries and regions		15,027			(3.7	)		35,062			(11.4	)		5,528			(4.3	)
Research and development credit		(954	)		0.2			(15,643	)		5.1			(3,324	)		2.6
Effect of non-deductible expenses		2,298			(0.6	)		383			(0.1	)		1,532			(1.2	)
Tax losses and deductible temporary differences not recognized		102,481			(25.2	)		26,040			(8.4	)		5,212			(4.1	)
Option income tax benefit		(9,532	)		2.3			(442	)		0.1			—			—
Others		1,529			(0.4	)		(653	)		0.2			1,112			(0.9	)
Tax credit at the Group’s effective rate		(3,614	)		0.9			(41,912	)		13.6			(25,729	)		20.2

Summary of Income Tax Related to Uncertain Tax Position

	2021		2020		2019
	US$’000		US$’000		US$’000
Balance as of December 31		9,488		8,795		12,782

Loss per Share Attributable to Ordinary Equity Holders of the Parent as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Basic Earnings Per Share [Abstract]

Summary of Calculations of Basic and Diluted Loss per Share

The calculations of basic and diluted loss per share are based on:

	2021			2020			2019
	US$’000			US$’000			US$’000
Earnings
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation		(403,582	)		(266,373	)		(101,590	)

	Number of shares
	2021		2020		2019
Shares
Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation		281,703,291		236,305,234		200,000,000

Property, Plant and Equipment as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Property Plant And Equipment [Abstract]

Schedule of Property, Plant and Equipment

	Freehold land		Buildings			Leasehold improvement			Machinery and equipment			Computer, fixtures, and office equipment			Transportation equipment			Construction in progress			Total
	US’000		US$’000			US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
December 31, 2021
At January 1, 2021
Cost		2,889		11,210			11,887			25,841			3,281			44			27,811			82,963
Accumulated depreciation		—		(817	)		(1,854	)		(6,514	)		(1,426	)		(10	)		—			(10,621	)
Net carrying amount		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342
At January 1, 2021, net of accumulated depreciation		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342
Additions		—		—			—			1,603			7			—			37,269			38,879
Disposals		—		—			(859	)		(177	)		(77	)		—			—			(1,113	)
Depreciation provided during the year		—		(543	)		(1,833	)		(4,967	)		(792	)		(4	)		—			(8,139	)
Exchange realignment		—		—			123			358			10			1			45			537
Transfers		—		4,801			9,941			8,675		341				—			(23,758	)	—
At December 31, 2021, net of accumulated depreciation		2,889		14,651			17,405			24,819			1,344			31			41,367			102,506
At December 31, 2021:
Cost		2,889		16,011			20,908			35,251			2,977			45			41,367			119,448
Accumulated depreciation		—		(1,360	)		(3,503	)		(10,432	)		(1,633	)		(14	)		—			(16,942	)
Net carrying amount		2,889		14,651			17,405			24,819			1,344			31			41,367			102,506

	Freehold land		Buildings			Leasehold improvement			Machinery and equipment			Computer, fixtures, and office equipment			Transportation equipment			Construction in progress			Total
	US’000		US$’000			US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
December 31, 2020
At January 1, 2020
Cost		2,889		10,072			10,382			20,802			1,297		42				3,687			49,171
Accumulated depreciation		—		(330	)		(770	)		(2,537	)		(340	)		(6	)		—			(3,983	)
Net carrying amount		2,889		9,742			9,612			18,265		957			36				3,687			45,188
At January 1, 2020, net of accumulated depreciation		2,889		9,742			9,612			18,265			957			36			3,687			45,188
Additions		—		—			—			—			560			—			31,625			32,185
Disposals		—		—			—			(165	)		—			—			—			(165	)
Depreciation provided during the year		—		(487	)		(1,019	)		(3,638	)		(1,086	)		(4	)		—			(6,234	)
Exchange realignment		—		—		375				775			12			2			204			1,368
Transfers		—		1,138			1,065			4,090			1,412			—			(7,705	)		—
At December 31, 2020, net of accumulated depreciation		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342
At December 31, 2020:
Cost		2,889		11,210			11,887			25,841			3,281			44			27,811			82,963
Accumulated depreciation		—		(817	)		(1,854	)		(6,514	)		(1,426	)		(10	)		—			(10,621	)
Net carrying amount		2,889		10,393			10,033			19,327			1,855			34			27,811			72,342

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Intangible Assets [Abstract]

Summary of Intangible Assets

	Software
	US$’000
December 31, 2021
At January 1, 2021
Cost		3,186
Accumulated amortization		(334	)
Net carrying amount		2,852
At January 1, 2021, net of accumulated amortization		2,852
Additions		3,207
Amortization provided during the year		(1,379	)
Exchange realignment		4
At December 31, 2021, net of accumulated amortization		4,684
At December 31, 2021
Cost		6,402
Accumulated amortization		(1,718	)
Net carrying amount		4,684
December 31, 2020
At January 1, 2020
Cost		598
Accumulated amortization		(79	)
Net carrying amount		519
At January 1, 2020, net of accumulated amortization		519
Additions		2,583
Amortization provided during the year		(192	)
Exchange realignment		(58	)
At December 31, 2020, net of accumulated amortization		2,852
At December 31, 2020
Cost		3,186
Accumulated amortization		(334	)
Net carrying amount		2,852

Other Non-Current Assets as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Categories Of Current Financial Assets [Abstract]

Summary of Other Non-Current Assets

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Value-added Tax (“VAT”) recoverable		4,080		3,542
Prepaid expenses		1,068		431
Collaboration Assets-Prepaid Lease		12,121		9,216
		17,269		13,189

Leases as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Lease [Abstract]

Summary of Right-of-use Assets and Movements of Collaboration Assets

(a)

Right-of-use assets

	December 31,		December 31,
	2021		2020
	US$’000		US$’000
Leasehold land		4,862		4,851
Lease buildings		2,324		3,158
Collaboration assets		31,097		31,533
		38,283		39,542

The carrying amounts of the Group’s right-of-use assets and the movements during the year are as follows:

	Non-Collaboration Assets Leased						Collaboration Assets Leased
	Leasehold land			Buildings			Buildings			Machinery And equipment			Computer and office equipment			Total
	US$’000			US$’000			US$’000			US$’000			US$’000			US$’000
December 31, 2021
Right-of-use assets at January 1, 2021		4,851			3,158			21,311			10,201		21				39,542
Additions		—			678		7				2,517		—				3,202
Disposals		—			(59	)	—				(53	)	—				(112	)
Exchange realignment		112			(62	)	—				—		—			50
Depreciation of right-of-use assets		(101	)		(1,391	)		(1,411	)		(1,491	)		(5	)		(4,399	)
Right-of-use assets at December 31, 2021		4,862			2,324			19,907			11,174		16				38,283
December 31, 2020
Right-of-use assets at January 1, 2020		4,630			4,718			11,639			6,787		16				27,790
Additions		—			491			10,726			4,369		10				15,596
Lease modifications		—			(928	)	—			—			—				(928	)
Exchange realignment		318			273		—			—			—			591
Depreciation of right-of-use assets		(97	)		(1,396	)		(1,054	)		(955	)		(5	)		(3,507	)
Right-of-use assets at December 31, 2020		4,851			3,158			21,311			10,201		21				39,542

Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term.

	2021			2020
	US$’000			US$’000
Carrying amount at January 1		3,373			6,085
Additions		678			491
Lease modifications		—			(928	)
Disposals		(68	)		—
Accretion of interest recognized during the year		142			195
Payments		(1,561	)		(2,797	)
Exchange realignment		(60	)		327
Carrying amount at December 31		2,504			3,373
Analyzed into:
Current portion		911			1,464
Non-current portion		1,593			1,909
		2,504			3,373

Summary of Lease Expense

	2021		2020
	US$’000		US$’000
Interest on lease liabilities		142		195
Depreciation charge of right-of-use assets		4,399		3,507
Expense relating to short-term leases		182		69
Total amount recognized in profit or loss		4,723		3,771

Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Finance Leases and Operating Leases

	2021		2020
	US$’000		US$’000

Finance leases:
Within one year		94		619

Operating leases:
Within one year		13		4

Inventories (Tables)

12 Months Ended

Dec. 31, 2021

Classes Of Inventories [Abstract]

Summary of Inventories

December 31,

2021

December 31,

2020

US$’000

Raw materials and consumables

1,749

1,800

Trade Receivables as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Trade And Other Receivables [Abstract]

Summary of Trade Receivables

December 31,

2021

December 31,

2020

US$’000

Trade receivables

50,410

75,000

Prepayments, Other Receivables and Other Assets as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Prepayments Other Receivables And Other Assets [Abstract]

Summary of Prepayments, Other Receivables and Other Assets

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Interest receivable		230		80
Other receivables		837		264
Income tax refund		4,712		4,712
VAT recoverable		2,264		1,941
Prepayments		5,715		3,455
		13,758		10,452

Financial Assets Measured At Amortized Cost (Tables)

12 Months Ended

Dec. 31, 2021

Categories Of Financial Assets [Abstract]

Summary of Financial Assets Measured at Amortized Cost

December 31,

2021

December 31,

2020

US$’000

Financial assets measured at amortized cost

29,937

—

Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Abstract]

Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits

	December 31, 2021			December 31, 2020
	US$’000			US$’000
Cash and bank balances		858,607			506,073
Less: Pledged deposits		(1,444	)		(384	)
Time deposits		(168,225	)		(50,000	)

Cash and cash equivalents		688,938			455,689

Denominated in USD		681,025			451,165
Denominated in RMB		5,875			4,335
Denominated in EUR		2,038			189

Cash and cash equivalents		688,938			455,689

Trade and Notes Payables (Tables)

12 Months Ended

Dec. 31, 2021

Trade And Other Payables [Abstract]

Summary of Trade and Notes Payables

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Trade payables		7,043		4,911
Notes payable		—		327
		7,043		5,238

Other Payables and Accruals as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Other Payables And Accruals [Abstract]

Summary of Other Payables and Accruals

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Accrued payroll		19,207		13,609
Accrued expense		81,364		56,863
Other payables		16,867		25,760
Payable for Collaboration Assets		5,605		3,399
Other tax payables		515		156
		123,558		99,787

Deferred Tax as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Deferred Tax Assets And Liabilities [Abstract]

Schedule of Movements in Deferred Tax Assets and Liabilities

The movements in deferred tax liabilities and assets during the years ended December 31, 2021 and 2020 are as follows:

Deferred tax liabilities

	Collaboration revenue			Difference allowance in excess of related depreciation			Right of use assets			Total
	US$’000			US$’000			US$’000			US$’000
At January 1, 2020		(42,317	)		(5,387	)	—				(47,704	)
Deferred tax charged/(credited) to the statement of profit or loss during the year		14,106			(1,285	)		(159	)		12,662
Gross deferred tax liabilities at December 31, 2020		(28,211	)		(6,672	)		(159	)		(35,042	)
At January 1, 2021		(28,211	)		(6,672	)		(159	)		(35,042	)
Deferred tax charged/(credited) to the statement of profit or loss during the year		14,086			(1,964	)		159			12,281
Gross deferred tax liabilities at December 31, 2021		(14,125	)		(8,636	)	—				(22,761	)

Deferred tax assets

	Losses available for offsetting against future taxable profits		Difference in intangible assets amortization			Accrued expense		Lease liabilities			R&D credit			Total
	US$’000		US$’000			US$’000		US$’000			US$’000			US$’000
At January 1, 2020		216		4,845			—		—			655			5,716
Deferred tax charged to the statement of profit or loss during the year		14,865		497			608		165			8,950			25,085
Gross deferred tax assets at December 31, 2020		15,081		5,342			608		165			9,605			30,801
At January 1, 2021		15,081		5,342			608		165			9,605			30,801
Deferred tax charged to the statement of profit or loss during the year		5,367		(4,286	)		649		(165	)		(9,605	)		(8,040	)
Gross deferred tax assets at December 31, 2021		20,448		1,056			1,257		—			—			22,761

2021

2020

US$’000

Net deferred tax liabilities recognised in the consolidated statement of

financial position

—

4,241

Summary of Items with Respect to, Deferred Tax Assets have not been Recognized

Deferred tax assets have not been recognized in respect of the following items:

	2021		2020
	US$’000		US$’000
Deductible temporary differences		15,420		12,842
Tax losses		609,200		200,523
		624,620		213,365

Warrant Liability (Tables)

12 Months Ended

Dec. 31, 2021

Statement Of Changes In Equity [Abstract]

Schedule of Movement of Warrant Liability

The movement of the warrant liability is set out as below:

	Total
	US$’000
At January 1, 2021		—
Issuance of the warrant liability		81,700
Fair value loss of the warrant liability		6,200
At December 31, 2021		87,900

Government Grants (Tables)

12 Months Ended

Dec. 31, 2021

Government Grant [Abstract]

Summary of Deferred Government Grants

	2021		2020
	US$’000		US$’000
Deferred government grants		2,170		2,334
Current		304		283
Non-current		1,866		2,051

Interest-Bearing Loans and Borrowings (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Detailed Information About Borrowings [Abstract]

Summary of Interest-Bearing Loans and Borrowings

Effective interest rate

Maturity

December 31,

2021

US$’000

Non-current

Loans from a collaborator

3.03

No specific maturity date

120,462

Share Capital and Share Premium (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Classes Of Share Capital [Abstract]

Summary of Shares

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Authorized:
2,000,000,000 shares of US$0.0001 each		200		200
Issued and fully paid:
308,456,852 (2020: 266,010,256) ordinary shares of US$0.0001 each		31		27

Summary of Movements in the Company's Share Capital and Share Premium

A summary of movements in the Company’s share capital and share premium is as follows:

	Number of shares in issue		Share capital		Share premium		Total
			US$’000		US$’000		US$’000
At December 31, 2019 and January 1, 2020		200,000,000	20			3,908		3,928

Issuance of ordinary shares for conversion of preferred shares		20,907,282	2			240,432		240,434
Issuance of ordinary shares for initial public offering, net of issuance cost		42,377,500	4			450,081		450,085
Issuance of ordinary shares for private placement by GenScript		1,043,478		—		12,000		12,000
Exercise of share options		1,681,996	1			1,885		1,886

At December 31, 2020 and January 1, 2021		266,010,256		27		708,306		708,333

Issuance of ordinary shares relating to private placement for an institutional investor (note 23)		20,809,850		2		218,298		218,300
Issuance of ordinary shares for follow-on public offering, net of issuance cost (note)		17,231,150		2		323,438		323,440
Exercise of share options		4,056,380		—		6,089		6,089
Reclassification of vesting of restricted stock units		349,216		—		5,323		5,323

At December 31, 2021		308,456,852		31		1,261,454		1,261,485

Share Option Scheme (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]

Summary of Share Options Outstanding Under the Scheme

	2021					2020					2019
	Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options
	US$ per share		’000			US$ per share		’000			US$ per share		’000
At January 1,		1.9353		14,241			0.9273		18,013			0.7782		14,311
Granted during the year		15.4774		595			15.6128		679			1.4973		3,757
Forfeited during the year		2.9987		(1,251	)		0.9963		(2,769	)		1.0909		(55	)
Exercised during the year		1.3346		(4,056	)		1.0131		(1,682	)	—		—
At December 31,		2.8970		9,529			1.9353		14,241			0.9273		18,013
Exercisable at December 31		1.4334		2,828			1.0703		4,619			0.7852		2,484

Summary of Exercise Prices and Exercise Periods of Share Options Outstanding

The exercise prices and exercise periods of the share options outstanding as at the end of the reporting period are as follows:

December 31, 2021
Number of options ’000		Exercise price* US$ per share		Exercise period
	4,054		0.5	2019/12/25 – 2027/12/25
	1,849		1.0	2019/07/01 – 2028/08/29
	382		1.0	2019/12/31 – 2028/12/30
	1,822		1.5	2020/07/02 – 2029/07/01
	332		11.5	2020/11/29 – 2029/11/28
	90		11.5	2021/06/05 – 2030/06/04
	385		16.3	2021/09/01 – 2030/08/31
	20		13.6	2021/11/19 – 2030/11/18
	430		14.1	2022/03/29 – 2031/03/28
	165		19.0	2022/08/27 – 2031/08/26
	9,529

December 31, 2020
Number of options ’000		Exercise price* US$ per share		Exercise period
	5,393		0.5	2019/12/25 - 2027/12/25
	4,317		1.0	2019/07/01 - 2028/08/29
	540		1.0	2019/12/31 - 2028/12/30
	2,868		1.5	2020/07/02 - 2029/07/01
	444		11.5	2020/11/29 - 2029/11/28
	90		11.5	2021/06/05 - 2030/06/04
	569		16.3	2021/09/01 - 2030/08/31
	20		13.6	2021/11/19 - 2030/11/18
	14,241

December 31, 2019
Number of options ’000		Exercise price* US$ per share		Exercise period
	6,347	0.5		2019/12/25 - 2027/12/25
	7,283		1.0	2019/07/01 - 2028/08/29
656			1.0	2019/12/31 - 2028/12/30
	3,225	1.5		2020/07/02 - 2029/07/01
502		1.5		2020/11/29 - 2029/11/28
	18,013

Summary of Fair Value of Equity Settled Share Options Granted

. The following table lists the inputs to the model used:

	2021		2020		2019
Dividend yield (%)		—		—		—
Expected volatility (%)	73.2-76.4		73.0-87.2		66.4-80.3
Risk-free interest rate (%)	0.03-1.72		0.07-0.91		1.98-2.69
Expected life of options (year)		10		10		10

Restricted Stock Units (Tables)

12 Months Ended

Dec. 31, 2021

Restricted Stock Units [Abstract]

Summary of Movement in Number of RSU Outstanding

The movement in the number of RSU outstanding for the year ended 31 December 2021 and 2020 was as follow:

	2021
	Number of RSU			Weighted average grant date fair value
	’000			US$ per unit
Outstanding at January 1	1,113			15.3409
Granted during the year	2,133			15.0120
Vested during the year	(349		)	15.2420
Forfeited during the year		(296	)	14.4913
Outstanding at December 31	2,601			15.1808

	2020
	Number of RSU			Weighted average grant date fair value
	’000			US$ per unit
Outstanding at January 1, 2020	—			—
Granted during the year	1,139			15.3639
Forfeited during the year		(26	)	16.3350
Outstanding at December 31, 2020	1,113			15.3409

Notes to the Consolidated Statement of Cash Flows as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]

Summary of Changes in Liabilities Arising from Financing Activities

(b) Changes in liabilities arising from financing activities

	Convertible redeemable preferred shares			Other payables to related parties			Lease liabilities
	US$’000			US$’000			US$’000
At January 1, 2021		—			—			3,373
Additions of lease liabilities		—			—			678
Changes from financing cash flows		—			—			(1,419	)
Disposal		—			—			(68	)
Interest expense		—			—			142
Interest paid classified as operating cash flows		—			—			(142	)
Foreign exchange movement		—			—			(60	)
At December 31, 2021		—			—			2,504
At January 1, 2020		—			4			6,085
Additions of lease liabilities		—			—			(437	)
Changes from financing cash flows		160,450			(4	)		(2,602	)
Interest expense		—			—			195
Interest paid classified as operating cash flows		—			—			(195	)
Fair value loss of the convertible redeemable preferred shares		79,984			—			—
Conversion to ordinary shares		(240,434	)		—			—
Foreign exchange movement		—			—			327
At December 31, 2020		—			—			3,373
At January 1, 2019		—			4,688			4,317
Additions of lease liabilities		—			—			6,840
Changes from financing cash flows		—			19,722			(5,056	)
Non-cash transaction (note 30(a))		—			(24,374	)		—
Interest expense		—			—			199
Interest paid classified as operating cash flows		—			—			(199	)
Foreign exchange movement		—			(32	)		(16	)
At December 31, 2019		—			4			6,085

Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows

The total cash outflow for leases included in the statement of cash flows is as follows:

	2021		2020		2019
	US$’000		US$’000		US$’000
Right-of-use assets
Within operating activities		142		195		199
Within financing activities		1,419		2,602		5,056
Short-term leases		182		69		272
		1,743		2,866		5,527

Commitments and Contingencies as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Capital Commitments [Abstract]

Summary of Capital Commitments

The Group had the following capital commitments at the end of the year:

	2021		2020		2019
	US$’000		US$’000		US$’000
Construction in progress		25,897		33,637		2,844

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Transactions Between Related Parties [Abstract]

Summary of Nature of Related Party Relationship

Company		Relationship
Nanjing GenScript Biotech Co., Ltd. (formerly named as Nanjing Jinsirui Biotechnology Co., Ltd.)		Company controlled by the ultimate holding company
Nanjing Bestzyme Bioengineering Co., Ltd.		Company controlled by the ultimate holding company
Jiangsu GenScript Biotech Co., Ltd.		Company controlled by the ultimate holding company
Genscript (HongKong) Ltd.		Company controlled by the ultimate holding company
Genscript USA Incorporated		Company controlled by the ultimate holding company
Genscript USA Holdings Inc		Company controlled by the ultimate holding company
Genscript Biotech (Netherlands) B.V.		Company controlled by the ultimate holding company
Nanjing Probio Biotech Co., Ltd.		Company controlled by the ultimate holding company
Jiangsu GenScript Probio Biotech Co., Ltd.		Company controlled by the ultimate holding company
Genscript Netherlands		Company controlled by the ultimate holding company
Genscript Biotech Corporation (“GenScript”)		Company controlled by the ultimate holding company
Genscript (Nanjing) Co., Ltd. (formerly named as Jinsikang Technology (Nanjing) Co., Ltd.)		Company controlled by the ultimate holding company

Summary of Transactions with Related Parties

(a)

In addition to the transactions detailed elsewhere in the consolidated financial statements, the Group had the following transactions with related parties during the year :

(i)

Licensing of patents to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing Probio Biotech Co., Ltd.		3,019		—		—

The sale was generated from an exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd and its affiliates.

(ii)

Sales-based royalties from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing Probio Biotech Co., Ltd.		405		—		—

The sale was generated from sales-based royalties related to the exclusive licensing of certain patents to Nanjing Probio Biotech Co., Ltd and its affiliates.

(iii)

Sales of materials to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing Genscript Biotech Co., Ltd.		—		—		3

The terms of these services and materials were charged based on the prices agreed by both parties.

(iv)

Other income to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		12		—		265

The other income was the income for sublease to Nanjing GenScript Biotech Co., Ltd. The price and terms are agreed by both parties

(v)

Purchases from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		9,615		4,162		4,480
Genscript USA Incorporated		786		424		296
Jiangsu GenScript Probio Biotech Co., Ltd		334	—		—
Jiangsu GenScript Biotech Co., Ltd		146		41		198
Nanjing Probio Biotech Co., Ltd.		21	—		—
Genscript Netherlands		6	—		—
Genscript Biotech (Netherlands) B.V.	—			7	—
Genscript USA Holdings Inc	—		—			4
		10,908		4,634		4,978

The transactions were made according to the price and terms agreed with related parties.

(vi)

Management fee:

	2021	2020	2019
	US$’000	US$’000	US$’000
Genscript USA Incorporated	—	95	198
Genscript (HongKong) Ltd	—	59	—
	—	154	198

The management fee was charged by related parties based on the cost of services provided.

(vii)

Shared services:

(viii)

Compensation fee for termination of service agreement:

	2021		2020		2019
	US$’000		US$’000		US$’000
Jiangsu GenScript Biotech Co., Ltd.		2,666		—		—

(ix)

Cash advances from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		28,199
Nanjing GenScript Biotech Co., Ltd.		—		—		2,168
Genscript USA Incorporated		—		—		8,000
Genscript (Nanjing) Co., Ltd.		—		—		578
		—		—		38,945

(x)

Repayment of cash advances from related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		4,335
Nanjing GenScript Biotechnology Co., Ltd.		—		—		6,310
Genscript USA Incorporated		—		—		8,000
Genscript (Nanjing) Co., Ltd.		—		—		578
Genscript (HongKong) Ltd.		—		4		—
		—		4		19,223

(xi)

Cash advances to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		13,006

(xii)

Collection of cash advances to related parties:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		—		—		48,496
Genscript USA Incorporated		—		—		14,500
				—		62,996

The above cash advances from/to related parties were unsecured, interest free and repayable on demand.

(xiii)

Entrusted loan from a related party:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript (Nanjing) Co., Ltd.		—		—		2,867

(xiv)

Repayments of entrusted loan from a related party:

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript (Nanjing) Co., Ltd.		—		—		2,867

(xv)

Purchase of equipment

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		—		54		7

(xvi)

Sale of equipment

	2021		2020		2019
	US$’000		US$’000		US$’000
Nanjing GenScript Biotech Co., Ltd.		—		—		13

Disclosure of Outstanding Balances with Related Parties Explanatory

The sale or purchase of equipment was made at their respective carrying values.

(xvii)

Financing from follow-on public offering, net of issuance cost

	2021		2020		2019
	US$’000		US$’000		US$’000
Genscript Biotech Corporation		84,600		—		—

(xviii)

Lease contract guarantee

(b)

Outstanding balances with related parties:

The Group had the following significant balances with its related parties at the end of the year:

(i)

Due from related parties

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Trade receivables
Nanjing Probio Biotech Co., Ltd.		409		—

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Other receivables
Genscript USA Incorporated		19		6
Nanjing GenScript Biotech Co., Ltd.		243		14
		262		20

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Prepayment
Jiangsu GenScript Probio Biotech Co., Ltd	925			—
Nanjing Probio Biotech Co., Ltd.	274			—
		1,199		—

(ii)

Due to related parties.

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Trade payables
Nanjing GenScript Biotech Co., Ltd.		2,301		1,547
Genscript USA Incorporated		46		555
Nanjing Probio Biotech Co., Ltd.		22	—
Jiangsu GenScript Biotech Co., Ltd		1		1
		2,370		2,103

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Other payables
Nanjing GenScript Biotech Co., Ltd.		3,293		3,736
Genscript USA Incorporated		50	—
		3,343		3,736

	December 31, 2021		December 31, 2020
	US$’000		US$’000
Lease liabilities
Nanjing GenScript Biotech Co., Ltd.		286		351
Genscript USA Holdings Inc		—		582
		286		933

Summary of Compensation of Key Management Personnel

	2021		2020		2019
	US$’000		US$’000		US$’000
Short-term employee benefits		1,942		1,733		1,036
Equity-settled share-based compensation expense		2,907		529		590
Termination payment		—		774		—
		4,849		3,036		1,626

Financial Instruments by Category as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Financial Instruments [Abstract]

Summary of Financial Assets

Financial assets

	Financial assets at amortized cost
	US$’000
Trade receivables		50,410
Financial assets included in prepayments, other receivables and other assets (note 17)		1,067
Financial assets measured at amortized cost		29,937
Lease receivables		94
Time deposits		168,225
Pledged deposits		1,444
Cash and cash equivalents		688,938
		940,115

Financial assets

	Financial assets at amortized cost
	US$’000
Trade receivables		75,000
Financial assets included in prepayments, other receivables and other assets (note 17)		344
Lease receivables		619
Time deposits		50,000
Pledged deposits		384
Cash and cash equivalents		455,689
		582,036

Summary of Financial Liabilities

Financial liabilities

	Financial liabilities at amortized cost		Financial liabilities at fair value through profit and loss
	US$’000		US$’000
Trade and notes payables		7,043	—
Warrant liability		—		87,900
Financial liabilities included in other payables and accruals (note 21)		16,867	—
Interest-bearing loans and borrowings		120,462	—
Lease liabilities		2,504	—
		146,876		87,900

Financial liabilities

	Financial liabilities at amortized cost
	US$’000
Trade and notes payables		5,238
Financial liabilities included in other payables and accruals (note 21)		25,760
Lease liabilities		3,373
		34,371

Fair Value and Fair Value Hierarchy of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Fair Value Of Financial Instruments [Abstract]

Summary of Fair Value Measurement Hierarchy of Financial Instruments

The following table illustrates the fair value measurement hierarchy of the Group’s financial instruments:

Liability measured at fair value:

As at December 31, 2021

Fair value measurement using

Quoted

prices

in active

markets

(Level 1)

Significant

observable

inputs

(Level 2)

Significant

unobservable

inputs

(Level 3)

Total

US$’000

Warrant liability

—

87,900

—

87,900

Summary of Fair Value Valuation of Warrant Liability

The following table lists the inputs to the binominal model used for the fair value valuation of warrant liability:

		December 31, 2021
Underlying stock price		US$23.31
Volatility		70.5%
Risk free rate		0.58%
Dividend		0%

Financial Risk Management Objectives and Policies as Restated (Tables)

12 Months Ended

Dec. 31, 2021

Disclosure Of Financial Instruments [Abstract]

Summary of Sensitivity to Reasonably Possible Change in Exchange Rates

	Increase/ (decrease) in the rate of foreign currency			Decrease/ (increase) in loss before tax
	%			US$’000
Year ended December 31, 2021
If US$ strengthens against RMB		5			1,215
If US$ weakens against RMB		(5	)		(1,215	)
If US$ strengthens against EUR		5			(3,086	)
If US$ weakens against EUR		(5	)		3,086
Year ended December 31, 2020
If US$ strengthens against RMB		5			678
If US$ weakens against RMB		(5	)		(678	)
If US$ strengthens against EUR		5			(817	)
If US$ weakens against EUR		(5	)		817
Year ended December 31, 2019
If US$ strengthens against RMB		5			329
If US$ weakens against RMB		(5	)		(329	)
If US$ strengthens against EUR		5			3,310
If US$ weakens against EUR		(5	)		(3,310	)

Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments

The maturity profile of the Group’s financial liabilities as at the end of the reporting period, based on contractual undiscounted payments, is as follows:

As at December 31, 2021
	Less than 1 years		Over 1 years		Total
	US$’000		US$’000		US$’000
Trade and notes payables		7,043		—		7,043
Other payables and accruals		16,867		—		16,867
Warrant liability		87,900		—		87,900
Interest-bearing loans and borrowings (note)		—		120,462		120,462
Lease liabilities		911		1,708		2,619
		112,721		122,170		234,891

As at December 31, 2020
	Less than 1 years		Over 1 years		Total
	US$’000		US$’000		US$’000
Trade and notes payables		5,238		—		5,238
Other payables and accruals		25,760		—		25,760
Lease liabilities		1,464		2,099		3,563
		32,462		2,099		34,561

Summary of Monitoring Capital Using Gearing Ratio

The Group monitors capital using a gearing ratio, which is total liabilities divided by total assets. The gearing ratios as at the end of each year were as follows:

	December 31, 2021			December 31, 2020
	US$’000			US$’000
Total liabilities		353,521			124,322
Total assets		1,119,465			722,093
Gearing ratio		32	%		17	%

Corporate Information - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Address of entity's registered office	PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grant Cayman KY1-1002, Cayman Islands
Country of incorporation	Cayman Islands
Date of incorporation	May 27, 2015

Corporate Information - Information About Subsidiaries (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Share capital	$ 31	$ 27	$ 20
Legend Biotech Limited ("Legend BVI")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Legend Biotech Limited (“Legend BVI”)
Place and date of incorporation	The British Virgin Islands June 2, 2015
Share capital	$ 80,000,000
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Investment holding
Legend Biotech HK Limited (“Legend HK”)
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Legend Biotech HK Limited (“Legend HK”)
Place and date of incorporation	Hong Kong June 3, 2015
Share capital	$ 80,000,000
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Investment holding
Nanjing Legend Biotechnology Co.,Ltd. (“Legend Nanjing”)
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Nanjing Legend Biotechnology Co., Ltd. (“Legend Nanjing”)
Place and date of incorporation	PRC* November 17, 2014
Share capital	$ 162,500,000
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Manufacture and sale of life science research products and services
Legend Biotech USA Incorporated (“Legend USA”)
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Legend Biotech USA Incorporated (“Legend USA”)
Place and date of incorporation	United States of America August 31, 2017
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Manufacture and sale of life science research products and services
Legend Biotech Ireland Limited. ("Legend Ireland")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Legend Biotech Ireland Limited (“Legend Ireland”)
Place and date of incorporation	Ireland November 13, 2017
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Manufacture and sale of life science research products and services
Legend Biotech Belgium B.V. (“Legend Belgium”)
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Legend Biotech Belgium B.V. (“Legend Belgium”)
Place and date of incorporation	Belgium June 23, 2021
Share capital	$ 2,423,693
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Manufacture and sale of life science research products and services
Hainan Chuanji Biotechnology Co., Ltd. (“Hainan Chuanji”)
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Company	Hainan Chuanji Biotechnology Co., Ltd. (“Hainan Chuanji”)
Place and date of incorporation	PRC October 25, 2021
Percentage of equity interest attributable to the Company	100.00%
Principal activities	Life science research and development

Restatement of Previously Issued Consolidated Financial Statements - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($) PerformanceObligation	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
Milestone payments	$ 50
Upfront fees recognized as revenue	350			$ 350
Milestone license revenue				$ 50
Revenue recognition, development milestones	65	$ 75	$ 60
Janssen Agreement
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
Fixed upfront fee	350
Milestone payments	$ 50
Number of performance obligations \| PerformanceObligation	2

Restatement of Previously Issued Consolidated Financial Statements - Restatement on Consolidated Statements of Profit or Loss and Other Comprehensive Income (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
REVENUE	$ 68,826	$ 75,000	$ 59,980
Other income and gains	3,059	6,119	7,459
Research and development expenses	(313,346)	(232,160)	(161,943)
Administrative expenses	(46,961)	(23,134)	(6,751)
Selling and distribution expenses	(102,542)	(49,571)	(25,620)
Other expenses	(9,132)	(346)	(221)
Fair value loss of warrant liability	(6,200)
Fair value loss of convertible redeemable preferred shares		(79,984)
Finance costs	(900)	(4,209)	(223)
LOSS BEFORE TAX	(407,196)	(308,285)	(127,319)
Income tax (expense)/credit	3,614	41,912	25,729
LOSS FOR THE YEAR	(403,582)	(266,373)	(101,590)
Attributable to:
Ordinary equity holders of the parent	$ (403,582)	$ (266,373)	$ (101,590)
Loss per share attributable to ordinary equity holders of the parent
Basic	$ (1.43)	$ (1.13)	$ (0.51)
Diluted	$ (1.43)	$ (1.13)	$ (0.51)
Exchange differences:
Exchange differences on translation of foreign operations	$ 5,215	$ 4,078	$ (1,268)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	5,215	4,078	(1,268)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX	5,215	4,078	(1,268)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(398,367)	(262,295)	(102,858)
Attributable to:
Ordinary equity holders of the parent	(398,367)	(262,295)	(102,858)
As Previously Reported
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
REVENUE	89,792	75,676	57,264
Other income and gains	3,059	6,119	7,125
Research and development expenses	(313,346)	(232,160)	(161,943)
Administrative expenses	(46,939)	(23,147)	(6,752)
Selling and distribution expenses	(102,542)	(49,571)	(25,620)
Other expenses	(9,132)	(346)	(221)
Fair value loss of warrant liability	(6,200)
Fair value loss of convertible redeemable preferred shares		(79,984)
Finance costs	(900)	(4,209)	(223)
LOSS BEFORE TAX	(386,208)	(307,622)	(130,370)
Income tax (expense)/credit	(1)	4,145	(2,602)
LOSS FOR THE YEAR	(386,209)	(303,477)	(132,972)
Attributable to:
Ordinary equity holders of the parent	$ (386,209)	$ (303,477)	$ (132,972)
Loss per share attributable to ordinary equity holders of the parent
Basic	$ (1.37)	$ (1.28)	$ (0.66)
Diluted	$ (1.37)	$ (1.28)	$ (0.66)
Exchange differences:
Exchange differences on translation of foreign operations	$ 10,620	$ (2,142)	$ 182
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	10,620	(2,142)	182
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX	10,620	(2,142)	182
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(375,589)	(305,619)	(132,790)
Attributable to:
Ordinary equity holders of the parent	(375,589)	(305,619)	(132,790)
Total Adjustments
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
REVENUE	(20,966)	(676)	2,716
Other income and gains			334
Administrative expenses	(22)	13	1
LOSS BEFORE TAX	(20,988)	(663)	3,051
Income tax (expense)/credit	3,615	37,767	28,331
LOSS FOR THE YEAR	(17,373)	37,104	31,382
Attributable to:
Ordinary equity holders of the parent	$ (17,373)	$ 37,104	$ 31,382
Loss per share attributable to ordinary equity holders of the parent
Basic	$ (0.06)	$ 0.15	$ 0.15
Diluted	$ (0.06)	$ 0.15	$ 0.15
Exchange differences:
Exchange differences on translation of foreign operations	$ (5,405)	$ 6,220	$ (1,450)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	(5,405)	6,220	(1,450)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX	(5,405)	6,220	(1,450)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(22,778)	43,324	29,932
Attributable to:
Ordinary equity holders of the parent	(22,778)	43,324	29,932
Total Adjustments \| Revenue Recognition
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
REVENUE	(20,966)	(676)	2,716
Other income and gains			334
Administrative expenses	(22)	13	1
LOSS BEFORE TAX	(20,988)	(663)	3,051
LOSS FOR THE YEAR	(20,988)	(663)	3,051
Attributable to:
Ordinary equity holders of the parent	$ (20,988)	(663)	$ 3,051
Loss per share attributable to ordinary equity holders of the parent
Basic	$ (0.07)		$ 0.02
Diluted	$ (0.07)		$ 0.02
Exchange differences:
Exchange differences on translation of foreign operations	$ (5,897)	6,702	$ (1,584)
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	(5,897)	6,702	(1,584)
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX	(5,897)	6,702	(1,584)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	(26,885)	6,039	1,467
Attributable to:
Ordinary equity holders of the parent	(26,885)	6,039	1,467
Total Adjustments \| Tax Impacts
Restatement Of Previously Issued Consolidated Financial Statements [Line Items]
Income tax (expense)/credit	3,615	37,767	28,331
LOSS FOR THE YEAR	3,615	37,767	28,331
Attributable to:
Ordinary equity holders of the parent	$ 3,615	$ 37,767	$ 28,331
Loss per share attributable to ordinary equity holders of the parent
Basic	$ 0.01	$ 0.15	$ 0.13
Diluted	$ 0.01	$ 0.15	$ 0.13
Exchange differences:
Exchange differences on translation of foreign operations	$ 492	$ (482)	$ 134
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	492	(482)	134
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE YEAR, NET OF TAX	492	(482)	134
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	4,107	37,285	28,465
Attributable to:
Ordinary equity holders of the parent	$ 4,107	$ 37,285	$ 28,465

Restatement of Previously Issued Consolidated Financial Statements - Restatement on Consolidated Statements of Financial Positions (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
NON-CURRENT ASSETS
Property, plant and equipment	$ 102,506	$ 72,342	$ 45,188	$ 45,188
Advance payments for property, plant and equipment	2,168	224	665
Right-of-use assets	38,283	39,542	27,790	27,790
Time deposits	4,705
Intangible assets	4,684	2,852	519
Other non-current assets	17,269	13,189	6,449
Total non-current assets	169,615	128,149	80,611
CURRENT ASSETS
Inventories	1,749	1,800	1,157
Trade receivables	50,410	75,000	30,000
Prepayments, other receivables and other assets	13,758	10,452	21,671
Financial assets measured at amortized cost	29,937
Lease receivables	94	619
Pledged deposits	1,444	384	256
Time deposits	163,520	50,000	75,559
Cash and cash equivalents	688,938	455,689	83,364	83,364	$ 210,166
Total current assets	949,850	593,944	212,007
Total assets	1,119,465	722,093	292,618
CURRENT LIABILITIES
Trade and notes payables	7,043	5,238	9,586
Other payables and accruals	123,558	99,787	70,854
Government grants	304	283
Lease liabilities	911	1,464	1,027
Tax payable	9,488	8,795	12,782
Warrant liability	87,900
Total current liabilities	229,204	115,567	94,249
NON-CURRENT LIABILITIES
Interest-bearing loans and borrowings	120,462
Lease liabilities	1,593	1,909	5,058
Government grants	1,866	2,051
Deferred tax liabilities		4,241	41,988
Other non-current liabilities	396	554
Total non-current liabilities	124,317	8,755	47,046
Total liabilities	353,521	124,322	141,295
EQUITY
Share capital	31	27	20
Reserves	765,913	597,744	151,303	151,300
Total ordinary shareholders’ equity	765,944	597,771	151,323
Total equity	765,944	597,771	151,323	151,323	252,909
Total liabilities and equity	1,119,465	722,093	292,618
As Previously Reported
NON-CURRENT ASSETS
Property, plant and equipment	145,724	113,091	70,079
Advance payments for property, plant and equipment	2,168	224	665
Right-of-use assets	7,186	8,009	9,348
Time deposits	4,705
Intangible assets	4,684	2,852	519
Other non-current assets	5,148	3,973
Total non-current assets	169,615	128,149	80,611
CURRENT ASSETS
Inventories	1,749	1,800	1,157
Trade receivables	50,410	74,978	29,991
Prepayments, other receivables and other assets	12,754	10,007	16,777
Financial assets measured at amortized cost	29,937
Pledged deposits	1,444	384	256
Time deposits	163,520	50,000	75,559
Cash and cash equivalents	688,938	455,689	83,364	83,364	$ 210,166
Total current assets	948,752	592,858	207,104
Total assets	1,118,367	721,007	287,715
CURRENT LIABILITIES
Trade and notes payables	7,043	5,238	9,586
Other payables and accruals	123,464	99,168	70,854
Government grants	304	283
Lease liabilities	911	1,464	1,027
Warrant liability	87,900
Contract liabilities, current	60,644	55,014	46,294
Total current liabilities	280,266	161,167	127,761
NON-CURRENT LIABILITIES
Interest-bearing loans and borrowings	120,462
Contract liabilities, non-current	242,578	275,071	277,765
Lease liabilities	1,593	1,909	5,058
Government grants	1,866	2,051
Other non-current liabilities	396	554
Total non-current liabilities	366,895	279,585	282,823
Total liabilities	647,161	440,752	410,584
EQUITY
Share capital	31	27	20
Reserves	471,175	280,228	(122,889)
Total ordinary shareholders’ equity	471,206	280,255	(122,869)
Total equity	471,206	280,255	(122,869)	(122,869)
Total liabilities and equity	1,118,367	721,007	287,715
Total Adjustments
NON-CURRENT ASSETS
Property, plant and equipment	(43,218)	(40,749)	(24,891)
Right-of-use assets	31,097	31,533	18,442
Other non-current assets	12,121	9,216	6,449
CURRENT ASSETS
Trade receivables		22	9
Prepayments, other receivables and other assets	1,004	445	4,894
Lease receivables	94	619
Total current assets	1,098	1,086	4,903
Total assets	1,098	1,086	4,903
CURRENT LIABILITIES
Other payables and accruals	94	619
Tax payable	9,488	8,795	12,782
Contract liabilities, current	(60,644)	(55,014)	(46,294)
Total current liabilities	(51,062)	(45,600)	(33,512)
NON-CURRENT LIABILITIES
Contract liabilities, non-current	(242,578)	(275,071)	(277,765)
Deferred tax liabilities		4,241	41,988
Total non-current liabilities	(242,578)	(270,830)	(235,777)
Total liabilities	(293,640)	(316,430)	(269,289)
EQUITY
Reserves	294,738	317,516	274,192
Total ordinary shareholders’ equity	294,738	317,516	274,192
Total equity	294,738	317,516	274,192	$ 274,192
Total liabilities and equity	1,098	1,086	4,903
Total Adjustments \| Revenue Recognition
CURRENT ASSETS
Trade receivables		22	9
Total current assets		22	9
Total assets		22	9
CURRENT LIABILITIES
Contract liabilities, current	(60,644)	(55,014)	(46,294)
Total current liabilities	(60,644)	(55,014)	(46,294)
NON-CURRENT LIABILITIES
Contract liabilities, non-current	(242,578)	(275,071)	(277,765)
Total non-current liabilities	(242,578)	(275,071)	(277,765)
Total liabilities	(303,222)	(330,085)	(324,059)
EQUITY
Reserves	303,222	330,107	324,068
Total ordinary shareholders’ equity	303,222	330,107	324,068
Total equity	303,222	330,107	324,068
Total liabilities and equity		22	9
Total Adjustments \| Collaboration Assets
NON-CURRENT ASSETS
Property, plant and equipment	(43,218)	(40,749)	(24,891)
Right-of-use assets	31,097	31,533	18,442
Other non-current assets	12,121	9,216	6,449
CURRENT ASSETS
Lease receivables	94	619
Total current assets	94	619
Total assets	94	619
CURRENT LIABILITIES
Other payables and accruals	94	619
Total current liabilities	94	619
NON-CURRENT LIABILITIES
Total liabilities	94	619
EQUITY
Total liabilities and equity	94	619
Total Adjustments \| Tax Impacts
CURRENT ASSETS
Prepayments, other receivables and other assets	1,004	445	4,894
Total current assets	1,004	445	4,894
Total assets	1,004	445	4,894
CURRENT LIABILITIES
Tax payable	9,488	8,795	12,782
Total current liabilities	9,488	8,795	12,782
NON-CURRENT LIABILITIES
Deferred tax liabilities		4,241	41,988
Total non-current liabilities		4,241	41,988
Total liabilities	9,488	13,036	54,770
EQUITY
Reserves	(8,484)	(12,591)	(49,876)
Total ordinary shareholders’ equity	(8,484)	(12,591)	(49,876)
Total equity	(8,484)	(12,591)	(49,876)
Total liabilities and equity	$ 1,004	$ 445	$ 4,894

Restatement of Previously Issued Consolidated Financial Statements - Restatement on Consolidated Statements of Changes in Equity (Details) - USD ($)
$ in Thousands

Dec. 31, 2021

Dec. 31, 2020

Jan. 01, 2020

Dec. 31, 2019

Dec. 31, 2018

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

$ 765,944

$ 597,771

$ 151,323

$ 252,909

Share Capital

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

Share Premium

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

^[1]

1,261,454

708,306

3,908

Share-based Compensation Reserves

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

^[1]

19,702

6,314

1,976

704

Foreign Currency Translation Reserve

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

^[1]

4,864

(351)

(4,429)

(3,161)

Retained Earnings/(Accumulated Losses)

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

^[1]

(520,107)

(116,525)

149,848

$ 251,438

Total Restatement Impacts

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

294,738

317,516

274,192

Total Restatement Impacts | Foreign Currency Translation Reserve

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

(2,123)

3,282

(2,938)

Total Restatement Impacts | Retained Earnings/(Accumulated Losses)

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

296,861

314,234

277,130

As Previously Reported

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

471,206

280,255

$ (122,869)

(122,869)

As Previously Reported | Share Capital

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

As Previously Reported | Share Premium

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

1,261,454

708,306

3,908

As Previously Reported | Share-based Compensation Reserves

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

19,702

6,314

1,976

As Previously Reported | Foreign Currency Translation Reserve

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

6,987

(3,633)

(1,491)

As Previously Reported | Retained Earnings/(Accumulated Losses)

Restatement Of Previously Issued Consolidated Financial Statements [Line Items]

Total (deficit)/equity

$ (816,968)

$ (430,759)

$ (127,282)

[1]	These reserve accounts comprise the consolidated reserves of US$765.9 million, US$597.7 million and US$151.3 million in the consolidated statements of financial position as at December 31, 2021, 2020 and 2019, respectively.

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

Restatement of Previously Issued Consolidated Financial Statements - Restatement on Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax	$ (407,196)	$ (308,285)	$ (127,319)
Adjustments for:
Finance income	(971)	(2,930)	(4,581)
Finance costs	900	4,209	223
Depreciation of property, plant and equipment	8,139	6,234	3,163
Loss on disposal of property, plant and equipment	974	55
Amortization of intangible assets	1,379	192	63
Depreciation of right-of-use assets	4,399	3,507	2,036
Fair value loss of warrant liability	6,200
Fair value loss of convertible redeemable preferred shares		79,984
Fair value gains on financial assets measured at fair value change through profit or loss		(47)	(474)
Foreign currency exchange loss/(gain), net	4,867	(66)	(584)
Equity-settled share-based compensation expense	20,158	4,760	1,272
Deferred government grant	(295)	(114)
Cash flows from (used in) operations before changes in working capital	(361,446)	(212,501)	(126,201)
Decrease/(increase) in trade receivables	24,590	(45,000)	21,229
(Increase)/decrease in prepayments, other receivables and other assets	(2,966)	3,366	(5,178)
Increase in other non-current assets	(1,175)	(3,973)
Decrease/(increase) in inventories	51	(643)	(22)
Government grant received	80	2,452
Increase/(decrease) in trade and notes payables	1,805	(4,348)	2,011
Increase in other payables and accruals	140,747	26,932	31,727
(Decrease)/increase in other non-current liabilities	(158)	554
Increase in pledged deposits, net	(1,060)	(128)
Cash used in operations	(199,532)	(233,289)	(76,434)
Income tax paid		(278)	(15,432)
Finance income received	652	3,366	9,024
Income tax received	557	7,391
Interest on loan from related party			(24)
Interest on lease payments	(142)	(195)	(199)
Net cash flow used in operating activities	(198,465)	(223,005)	(83,065)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(42,197)	(26,254)	(26,773)
Purchase of intangible assets	(3,207)	(4,029)	(534)
Prepayment to collaborator for collaboration right- of-use assets	(1,708)	(19,493)	(11,863)
Purchase of financial assets measured at fair value through profit or loss	(50,000)	(22,682)	(314,840)
Cash received from withdrawal of financial assets measured at fair value through profit or loss	50,081	22,682	320,854
Cash receipts of investment income		47
Cash advances to related parties			(13,006)
Collection of cash advances to related parties			62,996
Proceeds from disposal of property, plant and equipment	4	1	74
Addition in time deposits	(298,107)	(50,000)	(75,559)
Decrease in time deposits	180,000	75,559
Purchase of financial assets measured at amortized cost	(29,849)
Addition in pledged deposits			(256)
Decrease in pledged deposits			255
Net cash flows used in investing activities	(194,983)	(24,169)	(58,652)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of cash advances from related parties		(4)	(19,223)
Proceeds from convertible redeemable preferred shares		160,450
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs	323,440
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor	300,000
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs		450,085
Proceeds from issuance of ordinary shares relating to private placement by GenScript		12,000
Proceeds from exercise of share options	4,642	1,464
Payments of expenses for issuance of convertible redeemable preferred shares		(2,514)
Proceeds from cash advances from related parties			38,945
Proceeds from loans from related parties			2,867
Repayments of loans from related parties			(2,867)
Principal portion of lease payments	(1,419)	(2,602)	(5,056)
Net cash flows from financing activities	626,663	618,879	14,666
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	233,215	371,705	(127,051)
Effect of foreign exchange rate changes, net	34	620	249
Cash and cash equivalents at beginning of year	455,689	83,364	210,166
CASH AND CASH EQUIVALENTS AT END OF YEAR	688,938	455,689	83,364
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances	858,607	506,073	159,179
Less: Pledged deposits	1,444	384	256
Time deposits	168,225	50,000	75,559
Cash and cash equivalents as stated in the statement of financial position	688,938	455,689	83,364
Cash and cash equivalents as stated in the statement of cash flows	688,938	455,689	83,364
As Previously Reported
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax	(386,208)	(307,622)	(130,370)
Adjustments for:
Finance income	(971)	(2,930)	(4,581)
Finance costs	900	4,209	223
(Reversal of)/provision for the impairment of trade receivables	(22)	13	1
Depreciation of property, plant and equipment	11,046	8,248	4,001
Loss on disposal of property, plant and equipment	974	55
Amortization of intangible assets	1,379	192	63
Depreciation of right-of-use assets	1,492	1,493	1,198
Fair value loss of warrant liability	6,200
Fair value loss of convertible redeemable preferred shares		79,984
Fair value gains on financial assets measured at fair value change through profit or loss		(47)	(474)
Foreign currency exchange loss/(gain), net	4,867	(66)	(250)
Equity-settled share-based compensation expense	20,158	4,760	1,272
Deferred government grant	(295)	(114)
Cash flows from (used in) operations before changes in working capital	(340,480)	(211,825)	(128,917)
Decrease/(increase) in trade receivables	24,590	(45,000)	(3,771)
(Increase)/decrease in prepayments, other receivables and other assets	(2,966)	3,366	(3,928)
Increase in other non-current assets	(1,175)	(3,973)
Decrease/(increase) in inventories	51	(643)	(22)
Government grant received	80	2,452
Increase/(decrease) in trade and notes payables	1,805	(4,348)	2,011
Increase in other payables and accruals	142,091	20,230	31,727
(Decrease)/increase in other non-current liabilities	(158)	554
(Decrease)/increase in contract liabilities	(22,310)	6,026	26,466
Increase in pledged deposits, net	(1,060)	(128)
Cash used in operations	(199,532)	(233,289)	(76,434)
Income tax paid		(278)	(15,432)
Finance income received	652	3,366	9,024
Income tax received	557	7,391
Interest on loan from related party			(24)
Interest on lease payments	(142)	(195)	(199)
Net cash flow used in operating activities	(198,465)	(223,005)	(83,065)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(43,905)	(45,747)	(38,636)
Purchase of intangible assets	(3,207)	(4,029)	(534)
Purchase of financial assets measured at fair value through profit or loss	(50,000)	(22,682)	(314,840)
Cash received from withdrawal of financial assets measured at fair value through profit or loss	50,081	22,682	320,854
Cash receipts of investment income		47
Cash advances to related parties			(13,006)
Collection of cash advances to related parties			62,996
Proceeds from disposal of property, plant and equipment	4	1	74
Addition in time deposits	(298,107)	(50,000)	(75,559)
Decrease in time deposits	180,000	75,559
Purchase of financial assets measured at amortized cost	(29,849)
Addition in pledged deposits			(256)
Decrease in pledged deposits			255
Net cash flows used in investing activities	(194,983)	(24,169)	(58,652)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of cash advances from related parties		(4)	(19,223)
Proceeds from convertible redeemable preferred shares		160,450
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs	323,440
Proceeds from issuance of ordinary shares and warrant relating to private placement for an institutional investor	300,000
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs		450,085
Proceeds from issuance of ordinary shares relating to private placement by GenScript		12,000
Proceeds from exercise of share options	4,642	1,464
Payments of expenses for issuance of convertible redeemable preferred shares		(2,514)
Proceeds from cash advances from related parties			38,945
Proceeds from loans from related parties			2,867
Repayments of loans from related parties			(2,867)
Principal portion of lease payments	(1,419)	(2,602)	(5,056)
Net cash flows from financing activities	626,663	618,879	14,666
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	233,215	371,705	(127,051)
Effect of foreign exchange rate changes, net	34	620	249
Cash and cash equivalents at beginning of year	455,689	83,364	210,166
CASH AND CASH EQUIVALENTS AT END OF YEAR	688,938	455,689	83,364
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances	858,607	506,073	159,179
Less: Pledged deposits	1,444	384	256
Time deposits	168,225	50,000	75,559
Cash and cash equivalents as stated in the statement of financial position	688,938	455,689	83,364
Cash and cash equivalents as stated in the statement of cash flows	688,938	455,689	83,364
Total Adjustments
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax	(20,988)	(663)	3,051
Adjustments for:
(Reversal of)/provision for the impairment of trade receivables	22	(13)	(1)
Depreciation of property, plant and equipment	(2,907)	(2,014)	(838)
Depreciation of right-of-use assets	2,907	2,014	838
Foreign currency exchange loss/(gain), net			(334)
Cash flows from (used in) operations before changes in working capital	(20,966)	(676)	2,716
Decrease/(increase) in trade receivables			25,000
(Increase)/decrease in prepayments, other receivables and other assets			(1,250)
Increase in other payables and accruals	(1,344)	6,702
(Decrease)/increase in contract liabilities	22,310	(6,026)	(26,466)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	1,708	19,493	11,863
Prepayment to collaborator for collaboration right- of-use assets	$ (1,708)	$ (19,493)	$ (11,863)

Summary of Significant Accounting Policies as Restated - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021 USD ($) Milestone	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Impairment loss	$ 0
Description of recognize a short-term leases	The Group applies the short-term lease recognition exemption to its short-term leases that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. Lease payments on short-term leases are recognized as an expense on a straight-line basis over the lease term.
Cash and cash equivalents maturity, months	3 months
Non-refundable upfront amount recognized as revenue	$ 350,000,000
Milestone payments	50,000,000
Estimated total transaction price	400,000,000
Upfront fees recognized as revenue	$ 350,000,000			$ 350,000,000
Number of milestone payments \| Milestone	2
Number of additional milestone payments \| Milestone	3
Additional milestone payment receivable	$ 65,000,000
Milestone payment not eligible to receive based on subsequent change in development plan	280,000,000
Equity-settled share-based compensation expense	20,158,000	$ 4,760,000	$ 1,272,000
Top of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Milestone payment receivable	$ 1,100,000,000
CARTITUDE-1 Clinical Trial
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Number of milestone payments \| Milestone	2
Milestone achievement, clinical milestone	$ 60,000,000
Cilta-cel
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Number of milestone payments \| Milestone	1
Milestone achievement, clinical milestone	$ 75,000,000
Stock Option and Restricted Stock Unit Scheme
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Upfront fees recognized as revenue	350,000,000			$ 350,000,000
Equity-settled share-based compensation expense	0
Specified manufacturing milestones
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Milestone payments	125,000,000
Milestone payment receivable	125,000,000
Specified development milestones
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Milestone payments	215,000,000
Specified regulatory milestones
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Milestone payments	800,000,000
Milestone payment receivable	705,000,000
Specified net trade sales milestones
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Milestone payments	210,000,000
Milestone payment receivable	210,000,000
Specified future development milestones
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Milestone payment receivable	$ 60,000,000

Summary of Significant Accounting Policies as Restated - Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Freehold Land
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	Not depreciated
Buildings
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	2.60%
Transportation Equipment
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	10.00%
Bottom of Range \| Leasehold Improvement
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	10.00%
Bottom of Range \| Machinery and Equipment
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	10.00%
Bottom of Range \| Computer, Fixtures and Office Equipment
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	20.00%
Top of Range \| Leasehold Improvement
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	20.00%
Top of Range \| Machinery and Equipment
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	20.00%
Top of Range \| Computer, Fixtures and Office Equipment
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Estimated useful lives of property, plant and equipment	33.30%

Summary of Significant Accounting Policies as Restated - Intangible Assets Amortised on Straight-line Basis over Useful Economic Lives (Details)	12 Months Ended
	Dec. 31, 2021
Software
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Software	3-10 years

Summary of Significant Accounting Policies as Restated - Right-of-use Assets Depreciated on Straight-line Basis over Lease Terms and Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2021
Leasehold Land
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	50 years
Building Improvement \| Bottom of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	2 years
Building Improvement \| Top of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	18 years
Machinery and Equipment \| Bottom of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	5 years
Machinery and Equipment \| Top of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	10 years
Office Equipment \| Bottom of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	3 years
Office Equipment \| Top of Range
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
Lease terms and estimated useful lives of right-of-use assets	5 years

Significant Accounting Judgements and Estimates as Restated - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Significant Accounting Judgements And Estimates [Abstract]
Gross deferred tax assets	$ 22,761	$ 30,801	$ 5,716
Unrecognized deferred tax assets for tax losses	609,200	200,523
Equity-settled share option expense	$ 2,400	$ 1,900	$ 1,300

Operating Segment Information as Restated - Summary of Revenue from External Customers as Restated (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Operating Segments [Line Items]
Revenue	$ 68,826	$ 75,000	$ 59,980
United States of America
Disclosure Of Operating Segments [Line Items]
Revenue	65,402	$ 75,000	59,977
China
Disclosure Of Operating Segments [Line Items]
Revenue	$ 3,424		$ 3

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

Operating Segment Information as Restated - Summary of Non-current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Operating Segments [Line Items]
Non-current assets	$ 164,910	$ 128,149
United States of America
Disclosure Of Operating Segments [Line Items]
Non-current assets	103,648	78,022
China
Disclosure Of Operating Segments [Line Items]
Non-current assets	50,800	43,953
Other
Disclosure Of Operating Segments [Line Items]
Non-current assets	$ 10,462	$ 6,174

Operating Segment Information as Restated - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Operating Segments [Line Items]
Revenue	$ 68,826	$ 75,000	$ 59,980
Nanjing Probio Biotech Co., Ltd.
Disclosure Of Operating Segments [Line Items]
Revenue	3,400
United States of America
Disclosure Of Operating Segments [Line Items]
Revenue	$ 65,402	$ 75,000	$ 59,977
Customer information	single customer	single customer	single customer

- Definition

+ References

+ Details

Revenue, Other Income and Gains as Restated - Summary of Analysis of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from contracts with customer
Sales of goods			$ 3
Licensing and Royalties	$ 3,424
Revenue from contracts with customer	68,826	$ 75,000	59,980
Licensing of intellectual property
Revenue from contracts with customer
License and collaboration revenue	$ 65,402	$ 75,000	$ 59,977

Revenue, Other Income and Gains as Restated - Additional Information (Details) - Licensing of intellectual property - USD ($) $ in Thousands		12 Months Ended
	May 27, 2015	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
License and collaboration revenue		$ 65,402	$ 75,000	$ 59,977
Janssen Agreement \| US and Non-US Territories
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
License and collaboration revenue	$ 400,000	$ 600,000

Revenue, Other Income and Gains as Restated - Other Income and Gains (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Other income and gains

Finance income

$ 971

$ 2,930

$ 4,581

Government grants

^[1]

1,736

3,072

1,682

Others

138

Other Income

2,742

6,006

6,401

Foreign currency exchange gain, net

584

Fair value gains on financial assets measured at fair value change through profit or loss

474

Others

^[2]

317

Other gains

317

113

1,058

Other Income And Gains

$ 3,059

$ 6,119

$ 7,459

[1]	The amount represents subsidies received from local government authorities to support the Group’s business. There were no unfulfilled conditions and other contingencies attached to these government grants.
[2]	The amount mainly represents reimbursement of depositary fees that are related to the establishment and maintenance of the American Depository Receipts (ADR) program.

Loss Before Tax as Restated - Summery of loss before tax is arrived at after charging (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee benefit expense (including directors’ remuneration):
Equity-settled share-based compensation expense	$ 20,158	$ 4,760	$ 1,272
Profit Loss Before Tax Arrived After Charging
Profit Loss Before Tax [Line Items]
Loss on disposal of assets	974	55
IPO expenses		1,439
Follow-on expenses	400
Employee benefit expense (including directors’ remuneration):
Wages and salaries	105,751	70,682	37,038
Pension scheme contributions (defined contribution schemes)	2,257	640	1,166
Equity-settled share-based compensation expense	$ 20,158	$ 4,760	$ 1,272

Finance Costs - Summary of Finance Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finance Costs [Abstract]
Interest on lease liabilities	$ 142	$ 195	$ 199
Interest on interest-bearing loans and borrowings (note 25)	758
Expenses for issuance of convertible redeemable preferred shares		4,014
Interest on an entrusted loan from a related party			24
Total	$ 900	$ 4,209	$ 223

Income Tax as Restated - Additional Information (Details) - HKD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Hong Kong
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 2,000,000	$ 2,000,000	$ 2,000,000
Income tax rate	8.25%	8.25%	8.25%
Income tax rate on remaining assessable profits	16.50%	16.50%	16.50%
United States of America
Major Components Of Tax Expense Income [Line Items]
Income tax rate	21.00%	21.00%	21.00%
Withholding tax rate	30.00%
New Jersey
Major Components Of Tax Expense Income [Line Items]
Income tax rate	9.00%	9.00%	9.00%
Surcharge rate	2.50%
Ireland
Major Components Of Tax Expense Income [Line Items]
Income tax rate	12.50%	12.50%	12.50%
Withholding tax rate	25.00%	25.00%	20.00%
Non trading income tax rate	25.00%	25.00%	25.00%
China
Major Components Of Tax Expense Income [Line Items]
Income tax rate	25.00%	25.00%	25.00%
Withholding tax rate	10.00%
Belgium
Major Components Of Tax Expense Income [Line Items]
Income tax rate	25.00%
Withholding tax rate	30.00%

Income Tax as Restated - Summary of Tax Credits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major Components Of Tax Expense Income [Line Items]
Deferred	$ (4,241)	$ (37,747)	$ (18,009)
Total tax credit for the year	(3,614)	(41,912)	(25,729)
United States of America
Major Components Of Tax Expense Income [Line Items]
Current - Tax credit	211	(4,548)	(2,933)
Elsewhere
Major Components Of Tax Expense Income [Line Items]
Current - Tax credit	$ 416	$ 383	$ (4,787)

Income Tax as Restated - Summary of Reconciliation of Tax Expense Applicable to Loss Before Tax at the Statutory Rates (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major Components Of Tax Expense Income [Abstract]
Loss before tax	$ (407,196)	$ (308,285)	$ (127,319)
At the statutory blended income tax rate of 28.1% (2020 and 2019: 28.1%)	(114,463)	(86,659)	(35,789)
Effect of tax rate differences in other countries and regions	15,027	35,062	5,528
Research and development credit	(954)	(15,643)	(3,324)
Effect of non-deductible expenses	2,298	383	1,532
Tax losses and deductible temporary differences not recognized	102,481	26,040	5,212
Option income tax benefit	(9,532)	(442)
Others	1,529	(653)	1,112
Tax credit at the Group’s effective rate	$ (3,614)	$ (41,912)	$ (25,729)
At the statutory blended income tax rate	28.10%	28.10%	28.10%
Effect of tax rate differences in other countries and regions	(3.70%)	(11.40%)	(4.30%)
Research and development credit, effective tax rate	0.20%	5.10%	2.60%
Effect of non-deductible expenses, effective tax rate	(0.60%)	(0.10%)	(1.20%)
Tax losses and deductible temporary differences not recognized, effective tax rate	(25.20%)	(8.40%)	(4.10%)
Option income tax benefit, effective tax rate	2.30%	0.10%
Others, effective tax rate	(0.40%)	0.20%	(0.90%)
Tax credit at the Group’s effective rate	0.90%	13.60%	20.20%

Income Tax as Restated - Summary of Income Tax Related to Uncertain Tax Position (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major Components Of Tax Expense Income [Abstract]
Balance as of December 31	$ 9,488	$ 8,795	$ 12,782

Loss per Share Attributable to Ordinary Equity Holders of the Parent as Restated - Additional Information (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basic Earnings Per Share [Abstract]
Weighted average number of ordinary shares issued	281,703,291	236,305,234	200,000,000

Loss per Share Attributable to Ordinary Equity Holders of the Parent as Restated - Summary of Calculations of Basic and Diluted Loss per Share (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Basic Earnings Per Share [Abstract]
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	$ (403,582)	$ (266,373)	$ (101,590)
Weighted average number of ordinary shares in issue during the year used in the basic earnings per share calculation	281,703,291	236,305,234	200,000,000

Property, Plant and Equipment as Restated - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	$ 72,342	$ 45,188
Additions	38,879	32,185
Disposals	(1,113)	(165)
Depreciation provided during the year	(8,139)	(6,234)
Exchange realignment	537	1,368
Property, plant and equipment, ending balance	102,506	72,342
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	82,963	49,171
Property, plant and equipment, ending balance	119,448	82,963
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	(10,621)	(3,983)
Property, plant and equipment, ending balance	(16,942)	(10,621)
Land
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	2,889	2,889
Property, plant and equipment, ending balance	2,889	2,889
Land \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	2,889	2,889
Property, plant and equipment, ending balance	2,889	2,889
Buildings
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	10,393	9,742
Depreciation provided during the year	(543)	(487)
Transfers	4,801	1,138
Property, plant and equipment, ending balance	14,651	10,393
Buildings \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	11,210	10,072
Property, plant and equipment, ending balance	16,011	11,210
Buildings \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	(817)	(330)
Property, plant and equipment, ending balance	(1,360)	(817)
Leasehold Improvement
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	10,033	9,612
Disposals	(859)
Depreciation provided during the year	(1,833)	(1,019)
Exchange realignment	123	375
Transfers	9,941	1,065
Property, plant and equipment, ending balance	17,405	10,033
Leasehold Improvement \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	11,887	10,382
Property, plant and equipment, ending balance	20,908	11,887
Leasehold Improvement \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	(1,854)	(770)
Property, plant and equipment, ending balance	(3,503)	(1,854)
Machinery and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	19,327	18,265
Additions	1,603
Disposals	(177)	(165)
Depreciation provided during the year	(4,967)	(3,638)
Exchange realignment	358	775
Transfers	8,675	4,090
Property, plant and equipment, ending balance	24,819	19,327
Machinery and Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	25,841	20,802
Property, plant and equipment, ending balance	35,251	25,841
Machinery and Equipment \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	(6,514)	(2,537)
Property, plant and equipment, ending balance	(10,432)	(6,514)
Computer, Fixtures and Office Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	1,855	957
Additions	7	560
Disposals	(77)
Depreciation provided during the year	(792)	(1,086)
Exchange realignment	10	12
Transfers	341	1,412
Property, plant and equipment, ending balance	1,344	1,855
Computer, Fixtures and Office Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	3,281	1,297
Property, plant and equipment, ending balance	2,977	3,281
Computer, Fixtures and Office Equipment \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	(1,426)	(340)
Property, plant and equipment, ending balance	(1,633)	(1,426)
Transportation Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	34	36
Depreciation provided during the year	(4)	(4)
Exchange realignment	1	2
Property, plant and equipment, ending balance	31	34
Transportation Equipment \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	44	42
Property, plant and equipment, ending balance	45	44
Transportation Equipment \| Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	(10)	(6)
Property, plant and equipment, ending balance	(14)	(10)
Construction in Progress
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	27,811	3,687
Additions	37,269	31,625
Exchange realignment	45	204
Transfers	(23,758)	(7,705)
Property, plant and equipment, ending balance	41,367	27,811
Construction in Progress \| Cost
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment, beginning balance	27,811	3,687
Property, plant and equipment, ending balance	$ 41,367	$ 27,811

Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Intangible Assets [Line Items]
Net carrying amount, beginning balance	$ 2,852
Net carrying amount, ending balance	4,684	$ 2,852
Software
Disclosure Of Intangible Assets [Line Items]
Net carrying amount, beginning balance	2,852	519
Additions	3,207	2,583
Amortization provided during the year	(1,379)	(192)
Exchange realignment	4	(58)
Net carrying amount, ending balance	4,684	2,852
Software \| Cost
Disclosure Of Intangible Assets [Line Items]
Net carrying amount, beginning balance	3,186	598
Net carrying amount, ending balance	6,402	3,186
Software \| Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Net carrying amount, beginning balance	(334)	(79)
Net carrying amount, ending balance	$ (1,718)	$ (334)

Other Non-Current Assets as Restated - Summary of Other Non-Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Categories Of Current Financial Assets [Abstract]
Value-added Tax (“VAT”) recoverable	$ 4,080	$ 3,542
Prepaid expenses	1,068	431
Collaboration Assets-Prepaid Lease	12,121	9,216
Other non-current assets	$ 17,269	$ 13,189

Leases as Restated - Additional Information (Details)	12 Months Ended
Leases as Restated - Additional Information (Details)	Dec. 31, 2021 USD ($) ParkingSpace	Dec. 31, 2020 USD ($)
Leases [Line Items]
Lessee, lease term description	12 months or less
Number of car parking spaces \| ParkingSpace	5
Lease term	12 months
Rental income recognised	$ 13,000	$ 4,000
Finance lease income	$ 0	$ 0
Buildings \| Bottom of Range
Leases [Line Items]
Lessee, lease terms	2 years
Buildings \| Top of Range
Leases [Line Items]
Lessee, lease terms	10 years
Land
Leases [Line Items]
Lessee, lease terms	50 years
Ongoing lease payments	$ 0

Leases as Restated - Summary of Right-of-use Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets	$ 38,283	$ 39,542	$ 27,790	$ 27,790
Land
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets	4,862	4,851
Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets	2,324	3,158
Collaboration Assets
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets	$ 31,097	$ 31,533

Leases as Restated - Summary of Carrying Amounts of The Right-of-use Assets and Movements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	$ 39,542	$ 27,790
Additions	3,202	15,596
Disposals	(112)
Lease modification		(928)
Exchange realignment	50	591
Depreciation of right-of-use assets	(4,399)	(3,507)
Right-of-use assets ending balance	38,283	39,542
Land
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	4,851
Right-of-use assets ending balance	4,862	4,851
Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	3,158
Right-of-use assets ending balance	2,324	3,158
Right-of-Use Assets Non Collaboration \| Land
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	4,851	4,630
Exchange realignment	112	318
Depreciation of right-of-use assets	(101)	(97)
Right-of-use assets ending balance	4,862	4,851
Right-of-Use Assets Non Collaboration \| Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	3,158	4,718
Additions	678	491
Disposals	(59)
Lease modification		(928)
Exchange realignment	(62)	273
Depreciation of right-of-use assets	(1,391)	(1,396)
Right-of-use assets ending balance	2,324	3,158
Collaboration Assets \| Machinery and Equipment
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	10,201	6,787
Additions	2,517	4,369
Disposals	(53)
Depreciation of right-of-use assets	(1,491)	(955)
Right-of-use assets ending balance	11,174	10,201
Collaboration Assets \| Buildings
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	21,311	11,639
Additions	7	10,726
Depreciation of right-of-use assets	(1,411)	(1,054)
Right-of-use assets ending balance	19,907	21,311
Collaboration Assets \| Computer and Office Equipment
Disclosure Of Quantitative Information About Rightofuse Assets [Line Items]
Right-of-use assets, beginning balance	21	16
Additions		10
Depreciation of right-of-use assets	(5)	(5)
Right-of-use assets ending balance	$ 16	$ 21

Leases as Restated - Summary of Lease Liabilities Measured at Present Value of Lease Payments to be Made Over Lease Term (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2020
Disclosure Of Detailed Information About Lease Liabilities [Line Items]
Payments	$ (1,743)	$ (2,866)	$ (5,527)
Analyzed into:
Current portion	911	1,464		$ 1,027
Non-current portion	1,593	1,909		$ 5,058
Lease liabilities [member]
Disclosure Of Detailed Information About Lease Liabilities [Line Items]
Carrying amount, lease liabilities	3,373	6,085
Additions	678	491
Lease modifications		(928)
Disposals	(68)
Accretion of interest recognized during the year	142	195
Payments	(1,561)	(2,797)
Exchange realignment	(60)	327	(16)
Carrying amount, lease liabilities	2,504	3,373	6,085
Analyzed into:
Current portion	911	1,464
Non-current portion	1,593	1,909
Carrying amount, lease liabilities	$ 2,504	$ 3,373	$ 6,085

Leases as Restated - Summary of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Presentation Of Leases For Lessee [Abstract]
Interest on lease liabilities	$ 142	$ 195	$ 199
Depreciation charge of right-of-use assets	4,399	3,507
Expense relating to short-term leases	182	69
Total amount recognized in profit or loss	$ 4,723	$ 3,771

Leases as Restated - Summary of Undiscounted Minimum Lease Payments Receivables in Future Periods under Non-cancellable Finance Leases and Operating Leases (Details) - Within One Year - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finance leases:
Undiscounted minimum lease payments receivables in future periods under non-cancellable finance leases	$ 94	$ 619
Operating leases:
Undiscounted minimum lease payments receivables in future periods under non-cancellable operating leases	$ 13	$ 4

Convertible Redeemable Preferred Shares - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	May 13, 2021
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued		20,809,850
Price per share		$ 0.0001
Series A Preference Shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued	20,591,629
Price per share	$ 7.792
Issuance of ordinary shares	$ 160.5
Percentage of dividends	8.00%
Automatic conversion, description	Each Series A Preference Share will be automatically converted upon the closing of a Qualified IPO into a number of ordinary shares as is determined by dividing the Series A original issue price by a conversion price is equal to the lower of (i) the conversion price at the time in effect for such Series A Preference Share and (ii) the price per share that equals 90% of the lowest net price per ordinary share received by the Company in the Qualified IPO.
Redemption rights, description	At any time on or after the occurrence of a Trigger Event (as defined below), each investor may require the Company to redeem the Series A Preference Shares issued to the investor and require the Company to immediately pay the investor an amount equal to the redemption price, plus 8% annualized.
Fair value loss	$ 80.0

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Classes Of Inventories [Abstract]
Raw materials and consumables	$ 1,749	$ 1,800

Trade Receivables as Restated - Summary of Trade Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Disclosure Of Financial Assets [Line Items]
Trade receivables	$ 50,410	$ 75,000	$ 30,000
Gross Carrying Amount
Disclosure Of Financial Assets [Line Items]
Trade receivables	$ 50,410	$ 75,000

Trade Receivables as Restated - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Assets [Line Items]
Percentage of concentration of credit risk of trade receivables due from one single customer under a license and collaboration agreement	99.20%	100.00%
License And Collaboration Agreement
Disclosure Of Financial Assets [Line Items]
Trade receivables due from related parties	$ 50.0	$ 75.0
Nanjing Probio Biotech Co., Ltd.
Disclosure Of Financial Assets [Line Items]
Trade receivables due from related parties	$ 0.4
Bottom of Range
Disclosure Of Financial Assets [Line Items]
Credit period of trade receivables	45 days
Top of Range
Disclosure Of Financial Assets [Line Items]
Credit period of trade receivables	60 days

Prepayments, Other Receivables and Other Assets as Restated - Summary of Prepayments, Other Receivables and Other Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]
VAT recoverable	$ 4,080	$ 3,542
Prepayments	1,068	431
Prepayments Other Receivable and Other Assets
Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]
Interest receivable	230	80
Other receivables	837	264
Income tax refund	4,712	4,712
VAT recoverable	2,264	1,941
Prepayments	5,715	3,455
Total	$ 13,758	$ 10,452

Prepayments, Other Receivables and Other Assets as Restated - Additional Information (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Other Receivables
Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]
Other receivables due from related parties	$ 262,000	$ 20,000
Prepayment
Disclosure Of Prepayments Other Receivables And Other Assets [Line Items]
Other receivables due from related parties	$ 1,199,000	$ 0

Financial Assets Measured At Amortized Cost - Summary of Financial Assets Measured at Amortized Cost (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Assets [Line Items]
Financial assets measured at amortized cost	$ 940,115	$ 582,036
Financial Assets Measured at Amortized Cost
Disclosure Of Financial Assets [Line Items]
Financial assets measured at amortized cost	$ 29,937

Financial Assets Measured At Amortized Cost - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Assets [Line Items]
Financial assets measured at amortized cost	$ 940,115	$ 582,036
Commercial Paper Issued by Financial Institution
Disclosure Of Financial Assets [Line Items]
Financial assets measured at amortized cost	$ 30,000
Discounted bid yield percentage	0.50%
Financial assets measured at amortized cost maturity date	Jun. 01, 2022

Cash and Cash Equivalents, Time Deposits and Pledged Deposits - Summary of Cash and Cash Equivalents, Time Deposits and Pledged Deposits (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Cash and bank balances	$ 858,607	$ 506,073
Less: Pledged deposits	(1,444)	(384)
Time deposits	(168,225)	(50,000)
Cash and cash equivalents	688,938	455,689	$ 83,364	$ 83,364	$ 210,166
Denominated in USD
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Cash and cash equivalents	681,025	451,165
Denominated in RMB
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Cash and bank balances	5,900	4,300
Cash and cash equivalents	5,875	4,335
Denominated in EUR
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Cash and cash equivalents	$ 2,038	$ 189

Cash and Cash Equivalents, Time Deposits and Pledged Deposits - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Cash and bank balances	$ 858,607	$ 506,073
Denominated in RMB
Disclosure Of Cash And Cash Equivalents Time Deposits And Pledged Deposits [Line Items]
Cash and bank balances	$ 5,900	$ 4,300

Trade and Notes Payables - Summary of Trade and Notes Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Trade And Other Payables [Abstract]
Trade payables	$ 7,043	$ 4,911
Notes payable		327
Trade and notes payables	$ 7,043	$ 5,238	$ 9,586

Trade and Notes Payables - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Trade And Notes Payables [Line Items]
Trade payables, term	30 days
Trade payables	$ 7,043	$ 4,911
Related Parties
Trade And Notes Payables [Line Items]
Trade payables	$ 2,400	$ 2,100

Other Payables and Accruals as Restated - Summary of Other Payables and Accruals (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Disclosure Of Other Payables And Accruals [Abstract]
Accrued payroll	$ 19,207	$ 13,609
Accrued expense	81,364	56,863
Other payables	16,867	25,760
Payable for Collaboration Assets	5,605	3,399
Other tax payables	515	156
Other payables and accruals	$ 123,558	$ 99,787	$ 70,854

Other Payables and Accruals as Restated - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Other Payables And Accruals [Abstract]
Other payables due to related parties	$ 3.3	$ 3.7

Deferred Tax as Restated - Schedule of Movements in Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	$ (35,042)	$ (47,704)
Deferred tax charged/(credited) to the statement of profit or loss during the year	12,281	12,662
Ending balance	(22,761)	(35,042)
Right of Use Assets
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	(159)
Deferred tax charged/(credited) to the statement of profit or loss during the year	159	(159)
Ending balance		(159)
Collaboration Revenue
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	(28,211)	(42,317)
Deferred tax charged/(credited) to the statement of profit or loss during the year	14,086	14,106
Ending balance	(14,125)	(28,211)
Difference Allowance in Excess of Related Depreciation
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	(6,672)	(5,387)
Deferred tax charged/(credited) to the statement of profit or loss during the year	(1,964)	(1,285)
Ending balance	$ (8,636)	$ (6,672)

Deferred Tax as Restated - Schedule of Movements in Deferred Tax Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	$ 30,801	$ 5,716
Deferred tax charged to the statement of profit or loss during the year	(8,040)	25,085
Ending balance	22,761	30,801
Lease liabilities [member]
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	165
Deferred tax charged to the statement of profit or loss during the year	(165)	165
Ending balance		165
Losses Available for Offsetting Against Future Taxable Profits
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	15,081	216
Deferred tax charged to the statement of profit or loss during the year	5,367	14,865
Ending balance	20,448	15,081
Difference in Intangible Assets Amortization
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	5,342	4,845
Deferred tax charged to the statement of profit or loss during the year	(4,286)	497
Ending balance	1,056	5,342
Accrued Expense
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	608
Deferred tax charged to the statement of profit or loss during the year	649	608
Ending balance	1,257	608
R&D Credit
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Beginning balance	9,605	655
Deferred tax charged to the statement of profit or loss during the year	$ (9,605)	8,950
Ending balance		$ 9,605

Deferred Tax as Restated - Schedule of Deferred Tax Assets and Liabilities (Details) $ in Thousands	Dec. 31, 2020 USD ($)
Deferred Tax Assets And Liabilities [Abstract]
Net deferred tax liabilities recognised in the consolidated statement of financial position	$ 4,241

Deferred Tax as Restated - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Hong Kong
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Tax losses	$ (38,000)	$ (25,000)
China
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Tax losses	$ (91,800,000)	$ (60,000,000.0)
Deferred tax carry forward period	5 years	5 years
Income tax rate	10.00%
Withholding tax percentage	10.00%
China \| Subsidiaries
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Retained Earnings	$ 0	$ 0
Ireland
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Tax losses	$ (82,900,000)	$ (71,300,000)
Deferred tax carry back period	1 year	1 year
United States of America
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Tax losses	$ (226,600,000)
Income tax rate	5.00%
Withholding tax percentage	30.00%
United States of America \| Subsidiaries
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Retained Earnings	$ 0	0
Belgium
Reconciliation Of Changes In Deferred Tax Assets [Line Items]
Tax losses	$ (500,000)

Deferred Tax as Restated - Summary of Items with Respect to, Deferred Tax Assets have not been Recognized (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Major Components Of Tax Expense Income [Abstract]
Deductible temporary differences	$ 15,420	$ 12,842
Tax losses	609,200	200,523
Deferred tax asset not yet recognized	$ 624,620	$ 213,365

Warrant Liability - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	May 13, 2021	Dec. 31, 2021
Number of shares issued	20,809,850
Price per share	$ 0.0001
Private placement purchase price per share	$ 14.41625
Proceeds from exercise of warrants	$ 300,000
Warrant liability assessed		$ 81,700
Fair value of warrant liability assessed		87,900
Warrant liability fair value loss recorded in profit or loss		$ 6,200
Warrant
Number of shares issued	10,000,000
Private placement purchase price per share	$ 20.00

Warrant Liability - Schedule of Movement of Warrant Liability (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement Of Changes In Equity [Abstract]
Issuance of the warrant liability	$ 81,700
Fair value loss of the warrant liability	6,200
At December 31, 2021	$ 87,900

Government Grants - Summary of Deferred Government Grants (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Government Grants [Abstract]
Deferred government grants	$ 2,170	$ 2,334
Current	304	283
Non-current	$ 1,866	$ 2,051

Government Grants - Additional Information (Details)	12 Months Ended
Government Grants - Additional Information (Details)	Dec. 31, 2021
Government Grants [Abstract]
Explanation of unfulfilled conditions and other contingencies attaching to government assistance	The grants were related to the subsidies received from local government authorities for the purpose of compensation for the expenditure on certain facilities and were credited to a deferred income account. The grants were released to other income and gains over the expected useful lives of the relevant assets. The group also received certain financial subsidies from local government authorities to support local business. There were no unfulfilled conditions and other contingencies attached to these government grants. These government grants were recognized in other income and gains upon receipt.

Interest-Bearing Loans and Borrowings - Summary of Interest-Bearing Loans and Borrowings (Details) - 3.03% Interest-Bearing Loans $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Effective interest rate (%)	3.03%
Maturity	No specific maturity date
Loans from a collaborator	$ 120,462

Interest-Bearing Loans and Borrowings - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 17, 2021	Sep. 17, 2021	Jun. 18, 2021
Disclosure Of Detailed Information About Borrowings [Abstract]
Funding advances from collaborator principal amount	$ 119.7	$ 49.3	$ 53.1	$ 17.3
Borrowings, adjustment to interest rate basis	2.50%
Borrowings, interest rate basis	The respective interest rate of each borrowing is based on the average annual London Interbank Offered Rate (LIBOR) for U.S. Dollars as reported in the Wall Street Journal on the due date of the quarterly invoice or the next business date should the due date fall on a weekend or holiday, plus 250 basis points, calculated on the number of days from the date on which the Company applied such borrowings.
Interest bearing borrowings funded interests accrued	$ 0.8

Share Capital and Share Premium - Summary of Shares (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Issued and fully paid:
308,456,852 (2020: 266,010,256) ordinary shares of US$0.0001 each	$ 31,000	$ 27,000	$ 20,000
Ordinary Shares
Authorized:
2,000,000,000 shares of US$0.0001 each	200,000	200,000
Issued and fully paid:
308,456,852 (2020: 266,010,256) ordinary shares of US$0.0001 each	$ 31,000	$ 27,000

Share Capital and Share Premium - Summary of Shares (Parenthetical) (Details) - $ / shares	Dec. 31, 2021	Dec. 20, 2021	May 13, 2021	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Price per share			$ 0.0001
Ordinary Shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares authorized	2,000,000,000			2,000,000,000
Number of shares issued and fully paid	308,456,852			266,010,256
Price per share	$ 0.0001	$ 20.00		$ 0.0001

Share Capital and Share Premium - Summary of Movements in the Company's Share Capital and Share Premium (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	$ 708,333	$ 3,928
Issuance of ordinary shares relating to private placement for an institutional investor	218,300
Issuance of ordinary shares for conversion of preferred shares		240,434
Issuance of ordinary shares for initial public offering, net of issuance cost	323,440	450,085
Issuance of ordinary shares for private placement by GenScript		12,000
Exercise of share options	6,089	1,886
Reclassification of vesting of restricted stockunits	5,323
Ending balance	$ 1,261,485	$ 708,333
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	266,010,256	200,000,000
Issuance of ordinary shares relating to private placement for an institutional investor (note 24)	20,809,850
Issuance of ordinary shares for conversion of preferred shares		20,907,282
Issuance of ordinary shares for initial public offering, net of issuance cost		42,377,500
Issuance of ordinary shares for follow-on public offering,net of issuance cost (note)	17,231,150
Issuance of ordinary shares for private placement by GenScript		1,043,478
Exercise of share options	4,056,380	1,681,996
Reclassification of vesting of restricted stock units	349,216
Ending balance	308,456,852	266,010,256
Issuance of ordinary shares relating to private placement for an institutional investor	$ 2
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	27	$ 20
Issuance of ordinary shares relating to private placement for an institutional investor	2
Issuance of ordinary shares for conversion of preferred shares		2
Issuance of ordinary shares for initial public offering, net of issuance cost	2	4
Exercise of share options		1
Ending balance	31	27
Share Premium
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	708,306	3,908
Issuance of ordinary shares relating to private placement for an institutional investor	218,298
Issuance of ordinary shares for conversion of preferred shares		240,432
Issuance of ordinary shares for initial public offering, net of issuance cost	323,438	450,081
Issuance of ordinary shares for private placement by GenScript		12,000
Exercise of share options	6,089	1,885
Reclassification of vesting of restricted stockunits	5,323
Ending balance	$ 1,261,454	$ 708,306

Share Capital and Share Premium - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Dec. 20, 2021	Dec. 31, 2020	Dec. 31, 2021	May 13, 2021
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued				20,809,850
Price per share				$ 0.0001
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs		$ 450,085
Ordinary Shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued	17,231,150
Price per share	$ 20.00	$ 0.0001	$ 0.0001
Proceeds from issuance of ordinary shares for initial public offering, net of issuance costs	$ 323,400
Issuance costs	$ 21,200

Share Option Scheme - Additional Information (Details)	12 Months Ended
Share Option Scheme - Additional Information (Details)	Dec. 31, 2021 USD ($) shares $ / shares	Dec. 31, 2020 USD ($) shares $ / shares	Dec. 31, 2019 USD ($) shares $ / shares	Dec. 20, 2021 shares	May 13, 2021 shares	Dec. 31, 2018 shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Effective date of share option scheme	December 21, 2017
Period of share option scheme remain in force	10 years
Weighted average share price for share options in share-based payment arrangement exercised during period \| $ / shares	$ 18.4846	$ 14.9131
Fair value of share options granted \| $	$ 5,700,000	$ 6,700,000	$ 1,100,000
Fair value per share of options granted \| $ / shares	$ 9.497	$ 9.817	$ 0.294
Share option expense \| $	$ 2,400,000	$ 1,900,000	$ 1,300,000
Weighted average share price used in share option fair value valuation model (US$ per share) \| $ / shares	$ 15.4774
Number of share options outstanding	9,529	14,241	18,013			14,311
Number of shares issued					20,809,850
Binomial Model
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of share options outstanding	9,529,158
Additional share capital amount \| $	$ 953
Share premium before issue expenses \| $	$ 27,600,000
Percentage of options outstanding	3.10%
Ordinary Shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of shares issued				17,231,150
Ordinary Shares \| Binomial Model
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of shares issued	9,529,158

Share Option Scheme - Summary of Share Options Outstanding Under the Scheme (Details)	12 Months Ended
	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares	Dec. 31, 2019 shares $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
At January 1, weighted average exercise price \| $ / shares	$ 1.9353	$ 0.9273	$ 0.7782
Granted during the year, weighted average exercise price \| $ / shares	15.4774	15.6128	1.4973
Forfeited during the year, weighted average exercise price \| $ / shares	2.9987	0.9963	1.0909
Exercised during the year, weighted average exercise price \| $ / shares	1.3346	1.0131
At December 31, weighted average exercise price \| $ / shares	2.8970	1.9353	0.9273
Exercisable at December 31, weighted average exercise price \| $ / shares	$ 1.4334	$ 1.0703	$ 0.7852
At January 1,Number of options \| shares	14,241	18,013	14,311
Granted during the year, Number of options \| shares	595	679	3,757
Forfeited during the year, Number of options \| shares	(1,251)	(2,769)	(55)
Exercised during the year, Number of options \| shares	(4,056)	(1,682)
At December 31, Number of options \| shares	9,529	14,241	18,013
Exercisable at December 31, Number of options \| shares	2,828	4,619	2,484

Share Option Scheme - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares	Dec. 31, 2019 shares $ / shares	Dec. 31, 2018 shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	9,529	14,241	18,013	14,311
2019/12/25 - 2027/12/25
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	4,054	5,393	6,347
Exercise price per share \| $ / shares	$ 0.5	$ 0.5	$ 0.5
2019/07/01 - 2028/08/29
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	1,849	4,317	7,283
Exercise price per share \| $ / shares	$ 1.0	$ 1.0	$ 1.0
2019/12/31 - 2028/12/30
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	382	540	656
Exercise price per share \| $ / shares	$ 1.0	$ 1.0	$ 1.0
2020/07/02 - 2029/07/01
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	1,822	2,868	3,225
Exercise price per share \| $ / shares	$ 1.5	$ 1.5	$ 1.5
2020/11/29 - 2029/11/28
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	332	444	502
Exercise price per share \| $ / shares	$ 11.5	$ 11.5	$ 1.5
2021/06/05 - 2030/06/04
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	90	90
Exercise price per share \| $ / shares	$ 11.5	$ 11.5
2021/09/01 - 2030/08/31
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	385	569
Exercise price per share \| $ / shares	$ 16.3	$ 16.3
2021/11/19 - 2030/11/18
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	20	20
Exercise price per share \| $ / shares	$ 13.6	$ 13.6
2022/03/29 – 2031/03/28
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	430
Exercise price per share \| $ / shares	$ 14.1
2022/08/27 – 2031/08/26
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of options	165
Exercise price per share \| $ / shares	$ 19.0
Top of Range \| 2019/12/25 - 2027/12/25
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Dec. 25, 2027	Dec. 25, 2027	Dec. 25, 2027
Top of Range \| 2019/07/01 - 2028/08/29
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Aug. 29, 2028	Aug. 29, 2028	Aug. 29, 2028
Top of Range \| 2019/12/31 - 2028/12/30
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Dec. 30, 2028	Dec. 30, 2028	Dec. 30, 2028
Top of Range \| 2020/07/02 - 2029/07/01
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Jul. 01, 2029	Jul. 01, 2029	Jul. 01, 2029
Top of Range \| 2020/11/29 - 2029/11/28
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Nov. 28, 2029	Nov. 28, 2029	Nov. 28, 2029
Top of Range \| 2021/06/05 - 2030/06/04
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Jun. 04, 2030	Jun. 04, 2030
Top of Range \| 2021/09/01 - 2030/08/31
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Aug. 31, 2030	Aug. 31, 2030
Top of Range \| 2021/11/19 - 2030/11/18
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Nov. 18, 2030	Nov. 18, 2030
Top of Range \| 2022/03/29 – 2031/03/28
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Mar. 28, 2031
Top of Range \| 2022/08/27 – 2031/08/26
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Aug. 26, 2031
Bottom of Range \| 2019/12/25 - 2027/12/25
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Dec. 25, 2019	Dec. 25, 2019	Dec. 25, 2019
Bottom of Range \| 2019/07/01 - 2028/08/29
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Jul. 01, 2019	Jul. 01, 2019	Jul. 01, 2019
Bottom of Range \| 2019/12/31 - 2028/12/30
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2019
Bottom of Range \| 2020/07/02 - 2029/07/01
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Jul. 02, 2020	Jul. 02, 2020	Jul. 02, 2020
Bottom of Range \| 2020/11/29 - 2029/11/28
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Nov. 29, 2020	Nov. 29, 2020	Nov. 29, 2020
Bottom of Range \| 2021/06/05 - 2030/06/04
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Jun. 05, 2021	Jun. 05, 2021
Bottom of Range \| 2021/09/01 - 2030/08/31
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Sep. 01, 2021	Sep. 01, 2021
Bottom of Range \| 2021/11/19 - 2030/11/18
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Nov. 19, 2021	Nov. 19, 2021
Bottom of Range \| 2022/03/29 – 2031/03/28
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Mar. 29, 2022
Bottom of Range \| 2022/08/27 – 2031/08/26
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise period	Aug. 27, 2022

Share Option Scheme - Summary of Exercise Prices and Exercise Periods of Share Options Outstanding (Parenthetical) (Details)	Dec. 31, 2021 $ / shares
November 29, 2019 through December 9, 2019 \| Genscript Group
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Exercise price per share	$ 11.50

Share Option Scheme - Summary of Fair Value of Equity Settled Share Options Granted (Details) - Year	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Expected life of options (year)	10	10	10
Bottom of Range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Expected volatility (%)	73.20%	73.00%	66.40%
Risk-free interest rate (%)	0.03%	0.07%	1.98%
Top of Range
Disclosure Of Number And Weighted Average Remaining Contractual Life Of Outstanding Share Options [Line Items]
Expected volatility (%)	76.40%	87.20%	80.30%
Risk-free interest rate (%)	1.72%	0.91%	2.69%

Restricted Stock Units - Additional Information (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	May 26, 2020	Dec. 31, 2021 USD ($) shares $ / shares	Dec. 31, 2020 USD ($) shares $ / shares	Dec. 31, 2019 USD ($) $ / shares
Restricted Stock Units [Line Items]
Restricted stock units scheme term	10 years
Fair value per share of options granted \| $ / shares		$ 9.497	$ 9.817	$ 0.294
Equity-settled share-based compensation expense		$ 20,158	$ 4,760	$ 1,272
RSU
Restricted Stock Units [Line Items]
Weighted-average remaining contractual life for outstanding RSUs granted		8 years 1 month 28 days	8 years 10 months 2 days
Fair value of share options granted		$ 32,000	$ 17,500
Fair value per share of options granted \| $ / shares		$ 15.012	$ 15.364
Equity-settled share-based compensation expense		$ 17,800	$ 2,900
Number of RSU, outstanding \| shares		2,601,000	1,113,000
Restricted Share Plan
Restricted Stock Units [Line Items]
Number of RSU, outstanding \| shares		2,601,187
Percentage of number of number shares issued		0.80%

Restricted Stock Units - Summary of Movement in Number of RSU Outstanding (Details) - RSU shares in Thousands	12 Months Ended
	Dec. 31, 2021 shares $ / shares	Dec. 31, 2020 shares $ / shares
Restricted Stock Units [Line Items]
Number of RSU, Outstanding at January 1 \| shares	1,113
Number of RSU, Granted during the year \| shares	2,133	1,139
Number of RSU, Vested during the year \| shares	(349)
Number of RSU, Forfeited during the year \| shares	(296)	(26)
Number of RSU, Outstanding at December 31 \| shares	2,601	1,113
Weighted average grant date fair value, Outstanding at January 1 \| $ / shares	$ 15.3409
Weighted average grant date fair value, Granted during the year \| $ / shares	15.0120	$ 15.3639
Weighted average grant date fair value, Vested during the year \| $ / shares	15.2420
Weighted average grant date fair value, Forfeited during the year \| $ / shares	14.4913	16.3350
Weighted average grant date fair value, Outstanding at December 31 \| $ / shares	$ 15.1808	$ 15.3409

Reserves as Restated - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Reserves Within Equity [Abstract]
Paid in capital and reserve funds	$ 71.9	$ 31.9

Notes to the Consolidated Statement of Cash Flows as Restated - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]
Non cash additions to interest-bearing loans and borrowings	$ 119.7
Non cash fair value loss of warrant liability	6.2
Non-cash additions to right-of-use assets	0.7	$ 0.5	$ 2.2
Non-cash additions to lease liabilities	0.7	0.5	2.2
Non cash additions to lease receivables	0.3	0.6	0.7
Settled lease receivables	0.2		0.7
Convertible Redeemable Preferred Shares
Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]
Non-cash additions to finance costs		1.5
Non-cash other payable		1.5
Fair value loss of convertible redeemable preferred shares		80.0
Other Payables and Accruals
Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]
Assets leased from the collaboration partner	7.6	5.2	6.8
Non-cash additions to property, plant and equipment	6.7	$ 8.6	2.2
Nanjing Probio Biotech Co., Ltd. and Jiangsu GenScript Probio Biotech Co., Ltd.
Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]
Non-cash prepayment in exchange of research and development service	$ 1.5
Genscript USA Incorporated
Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]
Settlement of balance due to related party			4.4
Outstanding due from related party			5.5
Genscript Biotech Corporation
Disclosure of Notes to Consolidated Statement of Cash Flows [Line Items]
Outstanding due from related party			$ 19.5

Notes to the Consolidated Statement of Cash Flows as Restated - Summary of Changes in Liabilities Arising from Financing Activities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Interest on lease liabilities	$ 142	$ 195	$ 199
Fair value loss of the convertible redeemable preferred shares		79,984
Conversion to ordinary shares		(240,434)
Convertible Redeemable Preferred Shares
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Changes from financing cash flows		160,450
Fair value loss of the convertible redeemable preferred shares		79,984
Conversion to ordinary shares		(240,434)
Other Payables to Related Parties
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance		4	4,688
Changes from financing cash flows		(4)	19,722
Non-cash transaction			(24,374)
Foreign exchange movement			(32)
Ending balance			4
Lease liabilities [member]
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	3,373	6,085	4,317
Additions of lease liabilities	678	(437)	6,840
Changes from financing cash flows	(1,419)	(2,602)	(5,056)
Disposal	(68)
Interest on lease liabilities	142	195	199
Interest paid classified as operating cash flows	(142)	(195)	(199)
Foreign exchange movement	(60)	327	(16)
Ending balance	$ 2,504	$ 3,373	$ 6,085

Notes to the Consolidated Statement of Cash Flows as Restated - Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Right-of-use assets
Within operating activities	$ 142	$ 195	$ 199
Within financing activities	1,419	2,602	5,056
Short-term leases	182	69	272
Cash outflow for leases	$ 1,743	$ 2,866	$ 5,527

Commitments and Contingencies as Restated - Summary of Capital Commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Capital Commitments [Abstract]
Construction in progress	$ 25,897	$ 33,637	$ 2,844

Commitments and Contingencies as Restated - Additional Information (Details) $ in Millions	1 Months Ended
	Sep. 30, 2021 USD ($)	Dec. 31, 2021 ft²
Capital Commitments [Abstract]
Former employee damages demand \| $	$ 3.0
Area of lease manufacturing facility in Raritan, New Jersey \| ft²		106,000

Related Party Transactions - Summary of Nature of Related Party Relationship (Details)	12 Months Ended
	Dec. 31, 2021
Nanjing GenScript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Nanjing Bestzyme Bioengineering Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Jiangsu GenScript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript (HongKong) Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript USA Incorporated
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript USA Holdings Inc
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Nanjing Probio Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript Biotech (Netherlands) B.V.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Jiangsu GenScript Probio Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript Netherlands
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript Biotech Corporation
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript (Nanjing) Co., Ltd. (formerly named as Jinsikang Technology (Nanjing) Co., Ltd.)
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company

Related Party Transactions - Summary of Transactions with Related Parties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	$ 10,908	$ 4,634	$ 4,978
Management fee		154	198
Proceeds from cash advances from related parties			38,945
Repayment of cash advances from related parties		4	19,223
Cash advances to related parties			13,006
Collection of cash advances to related parties			62,996
Nanjing Probio Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Licensing of patents to related parties	3,019
Sales-based royalties from related parties	405
Purchases from related parties	21
Nanjing GenScript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Sales of materials to related parties			3
Other income to related parties	12		265
Purchases from related parties	9,615	4,162	4,480
Proceeds from cash advances from related parties			2,168
Repayment of cash advances from related parties			6,310
Purchase of equipment		54	7
Sale of equipment			13
Genscript USA Incorporated
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	786	424	296
Management fee		95	198
Proceeds from cash advances from related parties			8,000
Repayment of cash advances from related parties			8,000
Collection of cash advances to related parties			14,500
Jiangsu GenScript Probio Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	334
Jiangsu GenScript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	146	41	198
Compensation fee for termination of service agreement	2,666
Genscript USA Holdings Inc
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties			4
Genscript Netherlands
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	6
Genscript Biotech (Netherlands) B.V.
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties		7
Genscript (HongKong) Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Management fee		59
Repayment of cash advances from related parties		$ 4
Genscript Biotech Corporation
Disclosure Of Transactions Between Related Parties [Line Items]
Proceeds from cash advances from related parties			28,199
Repayment of cash advances from related parties			4,335
Cash advances to related parties			13,006
Collection of cash advances to related parties			48,496
Genscript Biotech Corporation \| Follow-On Public Offering
Disclosure Of Transactions Between Related Parties [Line Items]
Financing from follow-on public offering, net of issuance cost	$ 84,600
Genscript (Nanjing) Co., Ltd. (formerly named as Jinsikang Technology (Nanjing) Co., Ltd.)
Disclosure Of Transactions Between Related Parties [Line Items]
Proceeds from cash advances from related parties			578
Repayment of cash advances from related parties			578
Entrusted loan from a related party			2,867
Repayments of entrusted loan from a related party			$ 2,867

Related Party Transactions - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 20, 2021	May 13, 2021
Disclosure Of Transactions Between Related Parties [Line Items]
Interest expense on borrowings	$ 758,000
Ordinary shares, purchased					20,809,850
Bottom of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Lessee's incremental borrowing rate applied to lease liabilities	2.00%
Lease liabilities, repayment term	5 years
Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Lessee's incremental borrowing rate applied to lease liabilities	8.89%
Nanjing GenScript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Consideration paid for shared services	$ 1,600,000	$ 3,300,000	$ 2,100,000
Genscript USA Incorporated
Disclosure Of Transactions Between Related Parties [Line Items]
Consideration paid for shared services	$ 3,000
Jinsikang Technology Nanjing Co Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Borrowings, interest rate			4.35%
Borrowings, repayment date			2019-12
Interest expense on borrowings			$ 24,000
Genscript Biotech Corporation \| Follow-On Public Offering
Disclosure Of Transactions Between Related Parties [Line Items]
Ordinary shares, purchased				4,500,000

Related Party Transactions - Summary of Outstanding Balances with Related Parties (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Lease liabilities [member]
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	$ 286,000	$ 933,000
Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	262,000	20,000
Prepayment
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	1,199,000	0
Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	2,370,000	2,103,000
Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	3,343,000	3,736,000
Nanjing Probio Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	400,000
Nanjing Probio Biotech Co., Ltd. \| Trade Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	409,000
Nanjing Probio Biotech Co., Ltd. \| Prepayment
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	274,000
Nanjing Probio Biotech Co., Ltd. \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	22,000
Nanjing GenScript Biotech Co., Ltd \| Lease liabilities [member]
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	286,000	351,000
Nanjing GenScript Biotech Co., Ltd \| Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	243,000	14,000
Nanjing GenScript Biotech Co., Ltd \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	2,301,000	1,547,000
Nanjing GenScript Biotech Co., Ltd \| Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	3,293,000	3,736,000
Genscript USA Incorporated \| Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	19,000	6,000
Genscript USA Incorporated \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	46,000	555,000
Genscript USA Incorporated \| Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	50,000
Jiangsu GenScript Probio Biotech Co., Ltd. \| Prepayment
Disclosure Of Transactions Between Related Parties [Line Items]
Other receivables due from related parties	925,000
Jiangsu GenScript Biotech Co., Ltd \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	$ 1,000	1,000
Genscript USA Holdings Inc \| Lease liabilities [member]
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties		$ 582,000

Related Party Transactions - Summary of Compensation of Key Management Personnel (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Transactions Between Related Parties [Abstract]
Short-term employee benefits	$ 1,942	$ 1,733	$ 1,036
Equity-settled share-based compensation expense	2,907	529	590
Termination payment		774
Total compensation paid to key management personnel	$ 4,849	$ 3,036	$ 1,626

Financial Instruments by Category as Restated - Summary of Financial Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	$ 940,115	$ 582,036
Trade Receivables
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	50,410	75,000
Financial Assets Included in Prepayments, Other Receivables and Other Assets
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	1,067	344
Financial Assets Measured at Amortized Cost
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	29,937
Time Deposits
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	168,225	50,000
Lease Receivables
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	94	619
Pledged Deposits
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	1,444	384
Cash and Cash Equivalents
Disclosure Of Financial Assets [Line Items]
Financial assets at amortized cost	$ 688,938	$ 455,689

Financial Instruments by Category as Restated - Summary of Financial Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortized cost	$ 146,876	$ 34,371
Financial liabilities at fair value through profit and loss	87,900
Trade And Notes Payables
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortized cost	7,043	5,238
Warrant Liability
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at fair value through profit and loss	87,900
Financial Liabilities included in Other Payables and Accruals
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortized cost	16,867	25,760
Lease liabilities [member]
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortized cost	2,504	$ 3,373
Interest Bearing Loan And Borrowings
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortized cost	$ 120,462

Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Measurement Hierarchy of Financial Instruments (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Disclosure Fair Value Measurement Hierarchy Of Financial Instrument [Line Items]
Financial liabilities at fair value through profit and loss	$ 87,900
Significant Observable Inputs (Level 2) \| Warrant Liability
Disclosure Fair Value Measurement Hierarchy Of Financial Instrument [Line Items]
Financial liabilities at fair value through profit and loss	$ 87,900

Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Valuation of Warrant Liability (Details) - Warrant Liability	12 Months Ended
	Dec. 31, 2021
Disclosure Of Fair Value Valuation Of Warrants Liability [Line Items]
Expected volatility (%)	70.50%
Risk-free interest rate (%)	0.58%
Dividend yield (%)	0.00%

Fair Value and Fair Value Hierarchy of Financial Instruments - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Abstract]
Fair value, assets, level 1 to level 2 transfers	$ 0	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers	0	0	0
Fair value, liabilities, level 1 to level 2 transfers	0	0	0
Fair value, liabilities, level 2 to level 1 transfers	0	0	0
Fair value, measurement asset transfers into level 3	0	0	0
Fair value, measurement asset transfers out of level 3	0	0	0
Fair value, measurement liability, transfers into level 3	0	0	0
Fair value, measurement liability, transfers out of level 3	$ 0	$ 0	$ 0

Financial Risk Management Objectives and Policies as Restated - Additional Information (Details) - Foreign Currency Risk - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Financial Instruments [Line Items]
Percentage of foreign currency forward exchange contract	54.00%		15.00%
Outstanding foreign currency forward exchange contracts	$ 0	$ 0	$ 0

Financial Risk Management Objectives and Policies as Restated - Summary of Sensitivity to Reasonably Possible Change in Exchange Rates (Details) - Foreign Currency Risk - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
US$ Strengthens Against RMB
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	5.00%	5.00%	5.00%
Decrease/ (increase) in loss before tax	$ 1,215	$ 678	$ 329
US$ Weakens Against RMB
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	(5.00%)	(5.00%)	(5.00%)
Decrease/ (increase) in loss before tax	$ (1,215)	$ (678)	$ (329)
US$ Strengthens Against EUR
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	5.00%	5.00%	5.00%
Decrease/ (increase) in loss before tax	$ (3,086)	$ (817)	$ 3,310
US$ Weakens Against EUR
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	(5.00%)	(5.00%)	(5.00%)
Decrease/ (increase) in loss before tax	$ 3,086	$ 817	$ (3,310)

Financial Risk Management Objectives and Policies as Restated - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Disclosure Of Financial Instruments [Line Items]
Other payables and accruals	$ 123,558	$ 99,787	$ 70,854
Warrant liability	87,900
Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Trade and notes payables	7,043	5,238
Other payables and accruals	16,867	25,760
Warrant liability	87,900
Interest-bearing loans and borrowings (note)	120,462
Lease liabilities	2,619	3,563
Financial liabilities	234,891	34,561
Less than 1 years \| Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Trade and notes payables	7,043	5,238
Other payables and accruals	16,867	25,760
Warrant liability	87,900
Lease liabilities	911	1,464
Financial liabilities	112,721	32,462
Over 1 years \| Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Interest-bearing loans and borrowings (note)	120,462
Lease liabilities	1,708	2,099
Financial liabilities	$ 122,170	$ 2,099

Financial Risk Management Objectives and Policies as Restated - Summary of Monitoring Capital Using Gearing Ratio (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2020
Disclosure Of Financial Instruments [Line Items]
Total liabilities	$ 353,521	$ 124,322	$ 141,295
Total assets	1,119,465	722,093	$ 292,618
Capital Management
Disclosure Of Financial Instruments [Line Items]
Total liabilities	353,521	124,322
Total assets	$ 1,119,465	$ 722,093
Gearing ratio	32.00%	17.00%